<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Centene Corporation (CNC) Q4 2025 Earnings Call February 6, 2026 9:00 AM EST<br><br>Company Participants<br><br>Jennifer Gilligan - Senior Vice President of Investor Relations<br>Sarah London - CEO & Director<br>Andrew Asher - Chief Financial Officer<br><br>Conference Call Participants<br><br>Ann Hynes - Mizuho Securities USA LLC, Research Division<br>Justin Lake - Wolfe Research, LLC<br>Kevin Fischbeck - BofA Securities, Research Division<br>Stephen Baxter - Wells Fargo Securities, LLC, Research Division<br>Sarah James - Cantor Fitzgerald & Co., Research Division<br>Joshua Raskin - Nephron Research LLC<br>Albert Rice - UBS Investment Bank, Research Division<br>Scott Fidel - Goldman Sachs Group, Inc., Research Division<br>Lance Wilkes - Bernstein Institutional Services LLC, Research Division<br>Andrew Mok - Barclays Bank PLC, Research Division<br>David Windley - Jefferies LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Good day, and welcome to the Centene Corporation Fourth Quarter and Full Year 2025 Earnings Conference Call.</td><td>ì„¼í‹°ë‹ˆ ì½”í¼ë ˆì´ì…˜ (CNC) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 6ì¼ ì˜¤ì „ 9ì‹œ (ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ì œë‹ˆí¼ ê¸¸ë¦¬ê±´ - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>ì‚¬ë¼ ëŸ°ë˜ - CEO ê²¸ ì´ì‚¬<br>ì•¤ë“œë¥˜ ì• ì…” - ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ì•¤ í•˜ì¸ì¦ˆ - ë¯¸ì¦ˆí˜¸ ì¦ê¶Œ USA LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì €ìŠ¤í‹´ ë ˆì´í¬ - ìš¸í”„ ë¦¬ì„œì¹˜ LLC<br>ì¼€ë¹ˆ í”¼ì‰¬ë²¡ - BofA ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìŠ¤í‹°ë¸ ë°±ìŠ¤í„° - ì›°ìŠ¤íŒŒê³  ì¦ê¶Œ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì‚¬ë¼ ì œì„ìŠ¤ - ìº”í„° í”¼ì¸ ì œëŸ´ë“œ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì¡°ìŠˆì•„ ë¼ìŠ¤í‚¨ - ë„¤í”„ë¡  ë¦¬ì„œì¹˜ LLC<br>ì•¨ë²„íŠ¸ ë¼ì´ìŠ¤ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìŠ¤ì½§ í”¼ë¸ - ê³¨ë“œë§Œì‚­ìŠ¤ ê·¸ë£¹ Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ëœìŠ¤ ìœŒí¬ìŠ¤ - ë²ˆìŠ¤íƒ€ì¸ ì¸ìŠ¤í‹°íŠœì…”ë„ ì„œë¹„ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì•¤ë“œë¥˜ ëª© - ë°”í´ë ˆì´ì¦ˆ ë±…í¬ PLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë°ì´ë¹„ë“œ ìœˆë“¤ë¦¬ - ì œí”„ë¦¬ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì„¼í‹°ë‹ˆ ì½”í¼ë ˆì´ì…˜ 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>[Operator Instructions] Please note today's event is being recorded. I would now like to turn the conference over to Jennifer Gilligan, Senior Vice President, Investor Relations. Please go ahead. Jennifer Gilligan<br>Senior Vice President of Investor Relations<br><br>Thank you, Rocco, and good morning, everyone. Thank you for joining us on our fourth quarter and year-end 2025 Earnings Results Conference Call. Sarah London, Chief Executive Officer; and Drew Asher, Executive Vice President and Chief Financial Officer of Centene, will host this morning's call, which also can be accessed through our website at centene.com. Also, guidance slides can be found on our website alongside the webcast.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, Rocco. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. 2025ë…„ 4ë¶„ê¸° ë° ì—°ë§ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Centeneì˜ ìµœê³ ê²½ì˜ì(CEO)ì¸ Sarah Londonê³¼ ìˆ˜ì„ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)ì¸ Drew Asherê°€ ì˜¤ëŠ˜ ì•„ì¹¨ ì½œì„ ì§„í–‰í•  ì˜ˆì •ì´ë©°, ì´ ì½œì€ ì €í¬ ì›¹ì‚¬ì´íŠ¸ centene.comì„ í†µí•´ì„œë„ ì ‘ì†í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ê°€ì´ë˜ìŠ¤ ìŠ¬ë¼ì´ë“œëŠ” ì›¹ìºìŠ¤íŠ¸ì™€ í•¨ê»˜ ì €í¬ ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>[ì°¸ê³ : ì´ ë²ˆì—­ì€ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ë„ì…ë¶€ë¡œ, íšŒì‚¬ì˜ ì£¼ìš” ê²½ì˜ì§„ì´ 2025ë…„ 4ë¶„ê¸° ë° ì—°ë§ ì‹¤ì ì„ ë°œí‘œí•˜ëŠ” ìë¦¬ì„ì„ ì•ˆë‚´í•˜ê³  ìˆìŠµë‹ˆë‹¤.]</td></tr>
<tr><td>Any remarks that Centene may make about future expectations, plans and prospects constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Specifically, our commentary on 2026, including drivers of adjusted diluted earnings per share for 2026 are forward-looking statements.</td><td>ì„¼í‹°ë‹ˆê°€ ë¯¸ë˜ ì „ë§, ê³„íš ë° ì˜ˆìƒì— ëŒ€í•´ ì–¸ê¸‰í•˜ëŠ” ëª¨ë“  ë‚´ìš©ì€ 1995ë…„ ì¦ê¶Œì†Œì†¡ê°œí˜ë²•(Private Securities Litigation Reform Act of 1995)ì˜ ì„¸ì´í”„í•˜ë²„ ì¡°í•­ì— ë”°ë¥¸ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì— í•´ë‹¹í•©ë‹ˆë‹¤. íŠ¹íˆ, 2026ë…„ ì£¼ë‹¹ìˆœì´ìµ ì¡°ì •ì¹˜(adjusted diluted earnings per share)ì˜ ë™ì¸(drivers)ì„ í¬í•¨í•œ 2026ë…„ì— ëŒ€í•œ ìš°ë¦¬ì˜ ë…¼í‰ì€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our fourth quarter and year-end 2025 press release and 2026 guidance presentation filed this morning and other public SEC filings, which are available on the company's website under the Investors section. Centene anticipates that subsequent events and developments may cause its estimates to change. While the company may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. The call will also refer to certain non-GAAP measures.</td><td>ì‹¤ì œ ê²°ê³¼ëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ ë‚˜íƒ€ë‚´ëŠ” ë°”ì™€ ì¤‘ëŒ€í•˜ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìœ¼ë©°, ì´ëŠ” ì˜¤ëŠ˜ ì•„ì¹¨ ì œì¶œëœ 2025ë…„ 4ë¶„ê¸° ë° ì—°ë§ ì‹¤ì  ë³´ë„ìë£Œì™€ 2026ë…„ ê°€ì´ë˜ìŠ¤ í”„ë ˆì  í…Œì´ì…˜, ê·¸ë¦¬ê³  íšŒì‚¬ ì›¹ì‚¬ì´íŠ¸ íˆ¬ìì ì„¹ì…˜ì—ì„œ í™•ì¸ ê°€ëŠ¥í•œ ê¸°íƒ€ ê³µê°œ SEC ì œì¶œ ì„œë¥˜ì—ì„œ ë…¼ì˜ëœ ë‹¤ì–‘í•œ ì¤‘ìš” ìš”ì¸ë“¤ì„ í¬í•¨í•œ ì—¬ëŸ¬ ìš”ì¸ì˜ ê²°ê³¼ì…ë‹ˆë‹¤. Centeneì€ í›„ì† ì‚¬ê±´ ë° ìƒí™© ì „ê°œë¡œ ì¸í•´ ì¶”ì •ì¹˜ê°€ ë³€ê²½ë  ìˆ˜ ìˆìŒì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. íšŒì‚¬ëŠ” í–¥í›„ íŠ¹ì • ì‹œì ì— ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ìˆ˜ ìˆìœ¼ë‚˜, ê·¸ëŸ¬í•œ ì—…ë°ì´íŠ¸ ì˜ë¬´ëŠ” ëª…ì‹œì ìœ¼ë¡œ ë¶€ì¸í•©ë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ì½œì€ ë˜í•œ íŠ¹ì • ë¹„-GAAP ì§€í‘œë¥¼ ì–¸ê¸‰í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>A reconciliation of these measures with the most directly comparable GAAP measures can be found in our fourth quarter and year-end 2025 press release and 2026 guidance presentation. With that, I would like to turn the call over to our CEO, Sarah London. Sarah? Sarah London<br>CEO & Director<br><br>Thank you, Jen, and thanks, everyone, for joining us. This morning, we reported a fourth quarter adjusted diluted loss per share of $1.19, contributing to our full year 2025 adjusted diluted EPS of $2.08. While 2025 was undeniably challenging, disciplined execution enabled us to close the year slightly ahead of the expectations we outlined on our third quarter call.</td><td>ì´ëŸ¬í•œ ì§€í‘œë“¤ê³¼ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œë“¤ ê°„ì˜ ì¡°ì •ë‚´ì—­ì€ ë‹¹ì‚¬ì˜ 2025ë…„ 4ë¶„ê¸° ë° ì—°ë§ ë³´ë„ìë£Œì™€ 2026ë…„ ê°€ì´ë˜ìŠ¤ í”„ë ˆì  í…Œì´ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ CEOì¸ Sarah Londonì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. Sarah?<br><br>Sarah London<br>CEO ê²¸ ì´ì‚¬<br><br>Jen, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ì½œì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ë‹¹ì‚¬ëŠ” 4ë¶„ê¸° ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì†ì‹¤ 1.19ë‹¬ëŸ¬ë¥¼ ë³´ê³ í–ˆìœ¼ë©°, ì´ëŠ” 2025ë…„ ì „ì²´ ì—°ë„ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ 2.08ë‹¬ëŸ¬ì— ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. 2025ë…„ì´ ë¶€ì¸í•  ìˆ˜ ì—†ì´ ì–´ë ¤ìš´ í•œ í•´ì˜€ì§€ë§Œ, ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ì„ í†µí•´ 3ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ì œì‹œí–ˆë˜ ì „ë§ì¹˜ë¥¼ ì†Œí­ ìƒíšŒí•˜ë©° í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Medicaid profitability improved, strengthening the trajectory of our largest business. Underlying medical cost trend within marketplace and across the Medicare segment was in line to slightly favorable as we closed out Q4 and both segments delivered 2026 enrollment results consistent with our expectations, creating a solid foundation for next year's earnings power. As we looked at 2026, we are positioned to deliver meaningful margin improvement and renewed adjusted EPS growth. We expect full year 2026 adjusted EPS to be greater than $3, representing more than 40% year-over-year growth and marking important progress toward restoring the enterprise's embedded earnings power.</td><td>ë©”ë””ì¼€ì´ë“œ ìˆ˜ìµì„±ì´ ê°œì„ ë˜ì–´ ìš°ë¦¬ì˜ ìµœëŒ€ ì‚¬ì—…ë¶€ë¬¸ì˜ ì„±ì¥ ê¶¤ë„ê°€ ê°•í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ë§ˆì¼“í”Œë ˆì´ìŠ¤ì™€ ë©”ë””ì¼€ì–´ ë¶€ë¬¸ ì „ë°˜ì˜ ê¸°ì € ì˜ë£Œë¹„ ì¶”ì„¸ëŠ” 4ë¶„ê¸°ë¥¼ ë§ˆê°í•˜ë©´ì„œ ì˜ˆìƒê³¼ ì¼ì¹˜í•˜ê±°ë‚˜ ì•½ê°„ ì–‘í˜¸í–ˆìœ¼ë©°, ë‘ ë¶€ë¬¸ ëª¨ë‘ ìš°ë¦¬ì˜ ê¸°ëŒ€ì— ë¶€í•©í•˜ëŠ” 2026ë…„ ê°€ì…ì ì‹¤ì ì„ ë‹¬ì„±í•˜ì—¬ ë‚´ë…„ ìˆ˜ìµë ¥ì„ ìœ„í•œ ê²¬ê³ í•œ ê¸°ë°˜ì„ ë§ˆë ¨í–ˆìŠµë‹ˆë‹¤. 2026ë…„ì„ ì „ë§í•  ë•Œ, ìš°ë¦¬ëŠ” ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„ ê³¼ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì˜ ì¬ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. 2026ë…„ ì „ì²´ ì—°ë„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 3ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ì „ë…„ ëŒ€ë¹„ 40% ì´ìƒì˜ ì„±ì¥ì„ ë‚˜íƒ€ë‚´ê³  ê¸°ì—…ì˜ ë‚´ì¬ëœ ìˆ˜ìµë ¥ì„ íšŒë³µí•˜ëŠ” ë° ìˆì–´ ì¤‘ìš”í•œ ì§„ì „ì„ ì˜ë¯¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>This outlook incorporates Medicaid margin stability, significant margin recovery within our marketplace business, and continued progress towards our goal of breakeven in Medicare Advantage. Now let's take a look at our business lines, beginning with Medicaid. As an organization, we have been laser-focused on restoring our Medicaid business to sustainable profitability while maintaining our focus on quality outcomes for our members and the communities we serve. As a result of strong cross-enterprise execution, we demonstrated significant progress on this mission in the back half of 2025 with continued momentum through Q4.</td><td>ì´ ì „ë§ì—ëŠ” ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ ì•ˆì •ì„±, ë§ˆì¼“í”Œë ˆì´ìŠ¤ ì‚¬ì—… ë‚´ ìƒë‹¹í•œ ë§ˆì§„ íšŒë³µ, ê·¸ë¦¬ê³  ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì˜ ì†ìµë¶„ê¸°ì  ë‹¬ì„± ëª©í‘œë¥¼ í–¥í•œ ì§€ì†ì ì¸ ì§„ì „ì´ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ì œ ë©”ë””ì¼€ì´ë“œë¶€í„° ì‹œì‘í•˜ì—¬ ê° ì‚¬ì—… ë¶€ë¬¸ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ì¡°ì§ ì°¨ì›ì—ì„œ ìš°ë¦¬ëŠ” íšŒì›ë“¤ê³¼ ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ì§€ì—­ì‚¬íšŒì˜ ì–‘ì§ˆì˜ ì„±ê³¼ì— ëŒ€í•œ ì§‘ì¤‘ì„ ìœ ì§€í•˜ë©´ì„œ ë©”ë””ì¼€ì´ë“œ ì‚¬ì—…ì„ ì§€ì† ê°€ëŠ¥í•œ ìˆ˜ìµì„±ìœ¼ë¡œ íšŒë³µì‹œí‚¤ëŠ” ë° ì „ë ¥ì„ ê¸°ìš¸ì—¬ ì™”ìŠµë‹ˆë‹¤. ê°•ë ¥í•œ ì „ì‚¬ì  ì‹¤í–‰ì˜ ê²°ê³¼ë¡œ, ìš°ë¦¬ëŠ” 2025ë…„ í•˜ë°˜ê¸°ì— ì´ ëª©í‘œì— ëŒ€í•œ ìƒë‹¹í•œ ì§„ì „ì„ ë³´ì—¬ì£¼ì—ˆìœ¼ë©° 4ë¶„ê¸°ê¹Œì§€ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì„ ì´ì–´ê°”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our fourth quarter health benefits ratio of 93.0% was consistent with expectations we set for investors in October, representing 40 basis points of sequential improvement and 190 basis points of improvement from Q2 levels. While flu drove significant national media coverage, flu and influenza-related illness cost within Medicaid were consistent with the elevated expectations we had incorporated into our financial outlook. Trend patterns remained largely consistent in Q4 compared to Q3 with behavioral health still driving roughly half of excess trends in both home health and high-cost drugs as secondary pressure points.</td><td>4ë¶„ê¸° ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨(HBR)ì€ 93.0%ë¡œ 10ì›”ì— íˆ¬ììë“¤ì—ê²Œ ì œì‹œí–ˆë˜ ì „ë§ê³¼ ì¼ì¹˜í–ˆìœ¼ë©°, ì „ë¶„ê¸° ëŒ€ë¹„ 40bp ê°œì„ , 2ë¶„ê¸° ëŒ€ë¹„ 190bp ê°œì„ ì„ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. ë…ê°ì´ ì „êµ­ì ì¸ ì–¸ë¡  ë³´ë„ë¥¼ ì´ëŒì—ˆì§€ë§Œ, ë©”ë””ì¼€ì´ë“œ ë‚´ ë…ê° ë° ì¸í”Œë£¨ì—”ì ê´€ë ¨ ì§ˆí™˜ ë¹„ìš©ì€ ìš°ë¦¬ê°€ ì¬ë¬´ ì „ë§ì— ë°˜ì˜í–ˆë˜ ë†’ì€ ìˆ˜ì¤€ì˜ ì˜ˆìƒì¹˜ì™€ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì¶”ì„¸ íŒ¨í„´ì€ 4ë¶„ê¸°ê°€ 3ë¶„ê¸°ì™€ ëŒ€ì²´ë¡œ ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ì—ˆìœ¼ë©°, í–‰ë™ê±´ê°•ì´ ì—¬ì „íˆ ì´ˆê³¼ ì¶”ì„¸ì˜ ì•½ ì ˆë°˜ì„ ì°¨ì§€í–ˆê³ , ì¬ê°€ì˜ë£Œì™€ ê³ ë¹„ìš© ì˜ì•½í’ˆì´ ë¶€ì°¨ì ì¸ ì••ë°• ìš”ì¸ìœ¼ë¡œ ì‘ìš©í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As we head into 2026, we continue to organize around the key levers that will drive improvement in the Medicaid business, including optimizing our networks for cost and quality performance, thoughtful implementation of new and enhanced clinical programs, rate advocacy and collaboration with our state partners on program reform, increasing vigilance in our detection and reduction of unnecessary utilization and a more aggressive approach to fraud within the provider ecosystem in service of our mandate to protect Medicaid program integrity.</td><td>2026ë…„ì„ ë§ì´í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” ë©”ë””ì¼€ì´ë“œ ì‚¬ì—…ì˜ ê°œì„ ì„ ê²¬ì¸í•  í•µì‹¬ ë™ë ¥ë“¤ì„ ì¤‘ì‹¬ìœ¼ë¡œ ê³„ì†í•´ì„œ ì¡°ì§ì„ ì •ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¹„ìš© ë° í’ˆì§ˆ ì„±ê³¼ë¥¼ ìœ„í•œ ë„¤íŠ¸ì›Œí¬ ìµœì í™”, ì‹ ê·œ ë° ê°•í™”ëœ ì„ìƒ í”„ë¡œê·¸ë¨ì˜ ì‹ ì¤‘í•œ ë„ì…, ìš”ìœ¨ ì˜¹í˜¸ ë° í”„ë¡œê·¸ë¨ ê°œí˜ì— ëŒ€í•œ ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆì™€ì˜ í˜‘ë ¥, ë¶ˆí•„ìš”í•œ ì˜ë£Œ ì´ìš©ì˜ íƒì§€ ë° ê°ì†Œì— ëŒ€í•œ ê°ì‹œ ê°•í™”, ê·¸ë¦¬ê³  ë©”ë””ì¼€ì´ë“œ í”„ë¡œê·¸ë¨ ë¬´ê²°ì„± ë³´í˜¸ë¼ëŠ” ìš°ë¦¬ì˜ ì‚¬ëª…ì— ì…ê°í•œ ì˜ë£Œ ê³µê¸‰ì ìƒíƒœê³„ ë‚´ ì‚¬ê¸°ì— ëŒ€í•œ ë³´ë‹¤ ì ê·¹ì ì¸ ì ‘ê·¼ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Our applied behavioral analytics or ABA task force established in Q2 of 2025 is a perfect example of how we have pulled critical levers to manage costs on behalf of our state partners while improving the quality of member care at the same time. Leveraging Centene's scale and reach, the team analyzed our ABA data across our 29-state footprint. What we found were consistent patterns of outlier providers with volume versus outcomes-driven care patterns, where the maximum number of hours are prescribed for every patient instead of an individualized care plan.</td><td>ìš°ë¦¬ê°€ 2025ë…„ 2ë¶„ê¸°ì— ì„¤ë¦½í•œ ì‘ìš©í–‰ë™ë¶„ì„(ABA) íƒœìŠ¤í¬í¬ìŠ¤ëŠ” íšŒì› ì¹˜ë£Œì˜ ì§ˆì„ í–¥ìƒì‹œí‚¤ëŠ” ë™ì‹œì— ì£¼ ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ì„ ëŒ€ì‹ í•˜ì—¬ ë¹„ìš©ì„ ê´€ë¦¬í•˜ê¸° ìœ„í•´ ì¤‘ìš”í•œ ë ˆë²„ë“¤ì„ ì–´ë–»ê²Œ í™œìš©í–ˆëŠ”ì§€ ë³´ì—¬ì£¼ëŠ” ì™„ë²½í•œ ì‚¬ë¡€ì…ë‹ˆë‹¤. Centeneì˜ ê·œëª¨ì™€ ë„ë‹¬ ë²”ìœ„ë¥¼ í™œìš©í•˜ì—¬, íŒ€ì€ 29ê°œ ì£¼ì— ê±¸ì¹œ ìš°ë¦¬ì˜ ABA ë°ì´í„°ë¥¼ ë¶„ì„í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ë°œê²¬í•œ ê²ƒì€ ê°œë³„í™”ëœ ì¹˜ë£Œ ê³„íš ëŒ€ì‹  ëª¨ë“  í™˜ìì—ê²Œ ìµœëŒ€ ì‹œê°„ì„ ì²˜ë°©í•˜ëŠ”, ì„±ê³¼ ì¤‘ì‹¬ì´ ì•„ë‹Œ ì§„ë£ŒëŸ‰ ì¤‘ì‹¬ì˜ ì¹˜ë£Œ íŒ¨í„´ì„ ë³´ì´ëŠ” ì´ìƒì¹˜ ì œê³µìë“¤ì˜ ì¼ê´€ëœ íŒ¨í„´ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We found children who had been in therapy for 5 to 10 years, where clinical evidence suggests the optimal duration is 2 to 3 years as well as those enrolled in 40 hours per week of therapy instead of balanced school integrated care. And we saw a lack of appropriate board-certified oversight of registered behavior technicians. These dynamics drive cost in the system, but far more importantly, they are red flags relative to the quality of patient care for a very vulnerable population. Centene's approach has been data-driven and multipronged. We engage directly with providers on gaps we see and focus our networks on providers who follow evidence-based best practices.</td><td>ìš°ë¦¬ëŠ” 5ë…„ì—ì„œ 10ë…„ ë™ì•ˆ ì¹˜ë£Œë¥¼ ë°›ì•„ì˜¨ ì•„ë™ë“¤ì„ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. ì„ìƒì  ê·¼ê±°ì— ë”°ë¥´ë©´ ìµœì  ì¹˜ë£Œ ê¸°ê°„ì€ 2~3ë…„ì¸ë°ë„ ë§ì…ë‹ˆë‹¤. ë˜í•œ í•™êµ í†µí•© ëŒë´„ê³¼ì˜ ê· í˜• ì¡íŒ ì ‘ê·¼ ëŒ€ì‹  ì£¼ë‹¹ 40ì‹œê°„ì˜ ì¹˜ë£Œì— ë“±ë¡ëœ ì•„ë™ë“¤ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë“±ë¡ í–‰ë™ ê¸°ìˆ ì(registered behavior technicians)ì— ëŒ€í•œ ì ì ˆí•œ ìê²©ì¦ ë³´ìœ  ì „ë¬¸ê°€ì˜ ê°ë…ì´ ë¶€ì¡±í•œ ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ê´€ê³„ëŠ” ì‹œìŠ¤í…œ ë‚´ ë¹„ìš©ì„ ì¦ê°€ì‹œí‚¤ì§€ë§Œ, í›¨ì”¬ ë” ì¤‘ìš”í•œ ê²ƒì€ ì´ê²ƒì´ ë§¤ìš° ì·¨ì•½í•œ ì§‘ë‹¨ì— ëŒ€í•œ í™˜ì ì¹˜ë£Œ í’ˆì§ˆê³¼ ê´€ë ¨ëœ ìœ„í—˜ ì‹ í˜¸ë¼ëŠ” ì ì…ë‹ˆë‹¤. Centeneì˜ ì ‘ê·¼ ë°©ì‹ì€ ë°ì´í„° ê¸°ë°˜ì´ë©° ë‹¤ê°ì ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë°œê²¬í•œ ê²©ì°¨ì— ëŒ€í•´ ì˜ë£Œ ì œê³µìë“¤ê³¼ ì§ì ‘ ì†Œí†µí•˜ê³ , ê·¼ê±° ê¸°ë°˜ ëª¨ë²” ì‚¬ë¡€ë¥¼ ë”°ë¥´ëŠ” ì˜ë£Œ ì œê³µìë“¤ì„ ì¤‘ì‹¬ìœ¼ë¡œ ë„¤íŠ¸ì›Œí¬ë¥¼ êµ¬ì¶•í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We meet directly with our state partners to share data, inform program design and reduce outlier payments. And we launched an ABA specific engagement program to support members, their parents and their providers. These programs are developed and led by PhD-level Board-certified behavioral analysts who are still practicing so this is not algorithmic or theoretical for us. It is about being responsible stewards of taxpayer dollars and transforming the health of the communities we serve one kiddo at a time in this case. Rates continued to be another powerful and important tool to ensure program sustainability.</td><td>ìš°ë¦¬ëŠ” ì£¼ ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ ì§ì ‘ ë§Œë‚˜ ë°ì´í„°ë¥¼ ê³µìœ í•˜ê³ , í”„ë¡œê·¸ë¨ ì„¤ê³„ì— ë°˜ì˜í•˜ë©°, ì´ìƒì¹˜ ì§€ê¸‰ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  íšŒì›, ë¶€ëª¨, ê·¸ë¦¬ê³  ì œê³µìë“¤ì„ ì§€ì›í•˜ê¸° ìœ„í•œ ABA íŠ¹í™” ì°¸ì—¬ í”„ë¡œê·¸ë¨ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í”„ë¡œê·¸ë¨ë“¤ì€ í˜„ì¬ë„ ì§„ë£Œ ì¤‘ì¸ ë°•ì‚¬ í•™ìœ„ ì†Œì§€ ê³µì¸ í–‰ë™ ë¶„ì„ê°€ë“¤ì´ ê°œë°œí•˜ê³  ì£¼ë„í•˜ê³  ìˆì–´, ì´ê²ƒì€ ìš°ë¦¬ì—ê²Œ ì•Œê³ ë¦¬ì¦˜ì ì´ê±°ë‚˜ ì´ë¡ ì ì¸ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì´ëŠ” ë‚©ì„¸ì ìê¸ˆì˜ ì±…ì„ ìˆëŠ” ê´€ë¦¬ìê°€ ë˜ê³ , ì´ ê²½ìš° í•œ ë²ˆì— í•œ ì•„ì´ì”© ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ì§€ì—­ì‚¬íšŒì˜ ê±´ê°•ì„ ë³€í™”ì‹œí‚¤ëŠ” ê²ƒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ìš”ìœ¨(rates)ì€ í”„ë¡œê·¸ë¨ ì§€ì†ê°€ëŠ¥ì„±ì„ ë³´ì¥í•˜ê¸° ìœ„í•œ ë˜ ë‹¤ë¥¸ ê°•ë ¥í•˜ê³  ì¤‘ìš”í•œ ë„êµ¬ë¡œ ê³„ì† ì‘ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>On this front, we closed 2025 with a composite rate adjustment of approximately 5.5% above 2024 levels, consistent with our prior commentary. 1/1 final rates were in line with our expectation and as the underlying data naturally rolls forward, we believe rate decisions will increasingly be made on data that reflects the acuity and trend dynamics we have experienced in Medicaid over the last 2 years. We will continue to be proactive in our engagement and data sharing as we move through 2026 and prepare for 2027 program changes.</td><td>ì´ëŸ¬í•œ ì¸¡ë©´ì—ì„œ, ë‹¹ì‚¬ëŠ” 2025ë…„ì„ 2024ë…„ ëŒ€ë¹„ ì•½ 5.5%ì˜ ì¢…í•© ìš”ìœ¨ ì¡°ì •ìœ¼ë¡œ ë§ˆê°í–ˆìœ¼ë©°, ì´ëŠ” ê¸°ì¡´ ë…¼í‰ê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤. 1ì›” 1ì¼ ìµœì¢… ìš”ìœ¨ì€ ë‹¹ì‚¬ì˜ ì˜ˆìƒê³¼ ë¶€í•©í–ˆìœ¼ë©°, ê¸°ì´ˆ ë°ì´í„°ê°€ ìì—°ìŠ¤ëŸ½ê²Œ ê°±ì‹ ë¨ì— ë”°ë¼, ìš”ìœ¨ ê²°ì •ì€ ì§€ë‚œ 2ë…„ê°„ ë©”ë””ì¼€ì´ë“œì—ì„œ ê²½í—˜í•œ ì¤‘ì¦ë„ ë° ì¶”ì„¸ ì—­í•™ì„ ë°˜ì˜í•˜ëŠ” ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì ì°¨ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2026ë…„ì„ ì§„í–‰í•˜ê³  2027ë…„ í”„ë¡œê·¸ë¨ ë³€ê²½ì„ ì¤€ë¹„í•˜ë©´ì„œ ì ê·¹ì ì¸ ì°¸ì—¬ì™€ ë°ì´í„° ê³µìœ ë¥¼ ì§€ì†í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Standing here today, we have greater visibility into the drivers of our core business and command of the levers needed to drive earnings recovery in Medicaid over the next few years, while maintaining and improving the quality of our care our members receive. Turning to Marketplace. Fundamental medical cost trend for our marketplace business came in slightly better than expectations in Q4. In December, we also received an updated view of the 2025 Wakely data, which showed favorable development relative to our reserve. We experienced 2 out-of-period items in the quarter, including a 2023 CMS reconciliation and costs related to no surprises at disputes.</td><td>ì˜¤ëŠ˜ ì´ ìë¦¬ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” í•µì‹¬ ì‚¬ì—…ì˜ ë™ì¸ë“¤ì— ëŒ€í•œ ê°€ì‹œì„±ì´ ë”ìš± ë†’ì•„ì¡Œìœ¼ë©°, íšŒì›ë“¤ì´ ë°›ëŠ” ì¼€ì–´ì˜ ì§ˆì„ ìœ ì§€í•˜ê³  ê°œì„ í•˜ë©´ì„œ í–¥í›„ ëª‡ ë…„ê°„ Medicaid ì‚¬ì—…ì˜ ìˆ˜ìµ íšŒë³µì„ ê²¬ì¸í•˜ëŠ” ë° í•„ìš”í•œ ë ˆë²„ë“¤ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. Marketplace ì‚¬ì—…ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ Marketplace ì‚¬ì—…ì˜ ê·¼ë³¸ì ì¸ ì˜ë£Œë¹„ ì¶”ì„¸ëŠ” 4ë¶„ê¸°ì— ì˜ˆìƒë³´ë‹¤ ì•½ê°„ ì–‘í˜¸í•˜ê²Œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. 12ì›”ì—ëŠ” ë˜í•œ 2025ë…„ Wakely ë°ì´í„°ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ëœ ì „ë§ì„ ë°›ì•˜ëŠ”ë°, ì´ëŠ” ìš°ë¦¬ì˜ ì¤€ë¹„ê¸ˆ ëŒ€ë¹„ ìœ ë¦¬í•œ ì „ê°œë¥¼ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¶„ê¸° ì¤‘ 2ê±´ì˜ ê¸°ê°„ ì™¸ í•­ëª©ì„ ê²½í—˜í–ˆëŠ”ë°, ì—¬ê¸°ì—ëŠ” 2023ë…„ CMS ì¡°ì •ê³¼ No Surprises Act ë¶„ìŸ ê´€ë ¨ ë¹„ìš©ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>This prompted us to add an accrual for further NSA development related to 2025 dates of service, which ultimately pushed the segment HBR up by roughly 100 basis points versus our original expectations. We have accounted for estimated 2026 NSA costs in our guidance. While the No Surprises Act was designed to protect consumers, it has increasingly become weaponized by market participants looking to extract profits from the system through the independent dispute resolutions or IDR process. We are vocal in advocating for NSA reform. And in the meantime, we'll be taking a more proactive litigious posture as necessary.</td><td>ì´ë¡œ ì¸í•´ 2025ë…„ ì„œë¹„ìŠ¤ ì œê³µì¼ê³¼ ê´€ë ¨ëœ ì¶”ê°€ NSA ê°œë°œ ë¹„ìš©ì„ ë°œìƒì‹œì¼œì•¼ í–ˆìœ¼ë©°, ì´ëŠ” ê¶ê·¹ì ìœ¼ë¡œ ë‹¹ì´ˆ ì˜ˆìƒ ëŒ€ë¹„ í•´ë‹¹ ë¶€ë¬¸ì˜ HBRì„ ì•½ 100bp ìƒìŠ¹ì‹œì¼°ìŠµë‹ˆë‹¤. 2026ë…„ ì¶”ì • NSA ë¹„ìš©ì€ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. No Surprises Act(ì˜ˆìƒì™¸ ì˜ë£Œë¹„ ë°©ì§€ë²•)ëŠ” ì†Œë¹„ì ë³´í˜¸ë¥¼ ìœ„í•´ ì„¤ê³„ë˜ì—ˆì§€ë§Œ, ì ì°¨ ë…ë¦½ ë¶„ìŸ í•´ê²°(IDR) í”„ë¡œì„¸ìŠ¤ë¥¼ í†µí•´ ì‹œìŠ¤í…œì—ì„œ ì´ìµì„ ì¶”êµ¬í•˜ë ¤ëŠ” ì‹œì¥ ì°¸ì—¬ìë“¤ì— ì˜í•´ ì•…ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” NSA ê°œí˜ì„ ì ê·¹ì ìœ¼ë¡œ ì£¼ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ì‚¬ì´ì— í•„ìš”ì‹œ ë³´ë‹¤ ì ê·¹ì ì¸ ì†Œì†¡ ëŒ€ì‘ ìì„¸ë¥¼ ì·¨í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As an example, earlier this week, we filed a multimillion-dollar lawsuit against the New York provider alleging fraudulent manipulation of in-network and out-of-network claims. We will continue to take aggressive action to protect the system from fraudulent and abusive exploitation of NSA loopholes. Turning to 2026. The Marketplace team executed incredibly well over the last few months in a dynamic open enrollment period, investing in additional operational support to care for a customer base navigating significant change and uncertainty. In the absence of congressional intervention enhanced advanced premium tax credits expired at the end of 2025.</td><td>ì˜ˆë¥¼ ë“¤ì–´, ì´ë²ˆ ì£¼ ì´ˆì— ìš°ë¦¬ëŠ” ë„¤íŠ¸ì›Œí¬ ë‚´ ë° ë„¤íŠ¸ì›Œí¬ ì™¸ ì²­êµ¬ì˜ ì‚¬ê¸°ì  ì¡°ì‘ í˜ì˜ë¡œ ë‰´ìš• ì˜ë£Œ ì œê³µìë¥¼ ìƒëŒ€ë¡œ ìˆ˜ë°±ë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì†Œì†¡ì„ ì œê¸°í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” NSA í—ˆì ì˜ ì‚¬ê¸°ì ì´ê³  ì•…ì˜ì ì¸ ì•…ìš©ìœ¼ë¡œë¶€í„° ì‹œìŠ¤í…œì„ ë³´í˜¸í•˜ê¸° ìœ„í•´ ê³„ì†í•´ì„œ ì ê·¹ì ì¸ ì¡°ì¹˜ë¥¼ ì·¨í•  ê²ƒì…ë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ë§ˆì¼“í”Œë ˆì´ìŠ¤ íŒ€ì€ ì—­ë™ì ì¸ ê³µê°œ ë“±ë¡ ê¸°ê°„ ë™ì•ˆ ì§€ë‚œ ëª‡ ë‹¬ê°„ ë§¤ìš° í›Œë¥­í•˜ê²Œ ì—…ë¬´ë¥¼ ìˆ˜í–‰í–ˆìœ¼ë©°, ìƒë‹¹í•œ ë³€í™”ì™€ ë¶ˆí™•ì‹¤ì„±ì„ ê²ªê³  ìˆëŠ” ê³ ê° ê¸°ë°˜ì„ ëŒë³´ê¸° ìœ„í•´ ì¶”ê°€ì ì¸ ìš´ì˜ ì§€ì›ì— íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì˜íšŒì˜ ê°œì…ì´ ì—†ëŠ” ìƒí™©ì—ì„œ ê°•í™”ëœ ì„ ê¸‰ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œê°€ 2025ë…„ ë§ì— ë§Œë£Œë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As a reminder, we accounted for this assumption and the impact it would have on the market risk pool and cost in our 2026 pricing. Ambetter membership developed in line with expectations, and we are on track for first quarter ending membership of roughly 3.5 million members as compared to our December membership of $5.5 million. While market sign-ups are being reported publicly, this isn't the most helpful indicator of true market dynamics. Now that we are into February, paid membership is the most important metric for planning and forecasting. Through the end of January, Ambetter paid rates while below historical levels are right in line with our expectations in a post-eAPTC environment.</td><td>ì°¸ê³ ë¡œ ì €í¬ëŠ” ì´ëŸ¬í•œ ê°€ì •ê³¼ ê·¸ê²ƒì´ ì‹œì¥ ìœ„í—˜ í’€ ë° ë¹„ìš©ì— ë¯¸ì¹  ì˜í–¥ì„ 2026ë…„ ê°€ê²© ì±…ì •ì— ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. Ambetter íšŒì› ìˆ˜ëŠ” ì˜ˆìƒëŒ€ë¡œ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, 12ì›” íšŒì› ìˆ˜ 550ë§Œ ëª…ê³¼ ë¹„êµí•˜ì—¬ 1ë¶„ê¸° ë§ íšŒì› ìˆ˜ëŠ” ì•½ 350ë§Œ ëª…ì— ì´ë¥¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì‹œì¥ ê°€ì…ì ìˆ˜ê°€ ê³µê°œì ìœ¼ë¡œ ë³´ê³ ë˜ê³  ìˆì§€ë§Œ, ì´ëŠ” ì‹¤ì œ ì‹œì¥ ì—­í•™ì„ ë‚˜íƒ€ë‚´ëŠ” ê°€ì¥ ìœ ìš©í•œ ì§€í‘œëŠ” ì•„ë‹™ë‹ˆë‹¤. ì´ì œ 2ì›”ì— ì ‘ì–´ë“¤ë©´ì„œ ìœ ë£Œ íšŒì› ìˆ˜ê°€ ê³„íš ë° ì˜ˆì¸¡ì„ ìœ„í•œ ê°€ì¥ ì¤‘ìš”í•œ ì§€í‘œì…ë‹ˆë‹¤. 1ì›” ë§ê¹Œì§€ Ambetterì˜ ìœ ë£Œ íšŒì› ë¹„ìœ¨ì€ ê³¼ê±° ìˆ˜ì¤€ë³´ë‹¤ëŠ” ë‚®ì§€ë§Œ, eAPTC(í–¥ìƒëœ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ) ì´í›„ í™˜ê²½ì—ì„œ ì €í¬ ì˜ˆìƒê³¼ ì •í™•íˆ ì¼ì¹˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Relative to member demographics, our membership is more notably enrolled in Bronze plans for 2026 compared to prior years, with many of those members still able to access 0 premium products. Bronze membership will represent a little over 30% of our marketplace enrollment this year compared to a range of 19% to 24% over the past 4 years. Age and gender demographics remain consistent with recent years. Risk adjustment was obviously a source of significant deviation from our financial plans last year. As you think about the expectations incorporated into our 2026 plan, we anticipate being in a meaningful payable position for the 2026 plan year at this time.</td><td>íšŒì› ì¸êµ¬í†µê³„ì™€ ê´€ë ¨í•˜ì—¬, 2026ë…„ ë‹¹ì‚¬ íšŒì›ë“¤ì€ ì´ì „ ì—°ë„ë“¤ì— ë¹„í•´ ë¸Œë¡ ì¦ˆ í”Œëœì— ë” ë§ì´ ê°€ì…ë˜ì–´ ìˆìœ¼ë©°, ì´ë“¤ íšŒì› ì¤‘ ìƒë‹¹ìˆ˜ëŠ” ì—¬ì „íˆ ë¬´ë³´í—˜ë£Œ ìƒí’ˆì„ ì´ìš©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë¸Œë¡ ì¦ˆ íšŒì›ì€ ë§ˆì¼“í”Œë ˆì´ìŠ¤ ê°€ì…ìì˜ 30%ë¥¼ ì•½ê°„ ìƒíšŒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ì§€ë‚œ 4ë…„ê°„ 19%ì—ì„œ 24% ë²”ìœ„ì˜€ë˜ ê²ƒê³¼ ë¹„êµë©ë‹ˆë‹¤. ì—°ë ¹ ë° ì„±ë³„ ì¸êµ¬í†µê³„ëŠ” ìµœê·¼ ëª‡ ë…„ê³¼ ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìœ„í—˜ë„ ì¡°ì •(risk adjustment)ì€ ëª…ë°±íˆ ì‘ë…„ ì¬ë¬´ ê³„íšì—ì„œ ì¤‘ëŒ€í•œ í¸ì°¨ì˜ ì›ì¸ì´ì—ˆìŠµë‹ˆë‹¤. 2026ë…„ ê³„íšì— ë°˜ì˜ëœ ê¸°ëŒ€ì¹˜ë¥¼ ê³ ë ¤í•˜ì‹¤ ë•Œ, í˜„ ì‹œì ì—ì„œ ë‹¹ì‚¬ëŠ” 2026 ì‚¬ì—…ì—°ë„ì— ìƒë‹¹í•œ ì§€ê¸‰ í¬ì§€ì…˜(payable position)ì— ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Consistent with other years, we will reassess our risk adjustment position and assumptions as we move through the year and receive additional data. To that end, in an effort to drive additional visibility at an industry level, we are pleased to have worked closely with Wakely, the independent actuarial firm to support publication of a new report reflecting market-wide paid membership metallic tier distribution and statewide average premium set to be released towards the end of Q1 in order to help market participants better inform risk adjustment assumptions going forward.</td><td>ë‹¤ë¥¸ ì—°ë„ë“¤ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ, ìš°ë¦¬ëŠ” ì—°ì¤‘ ì¶”ê°€ ë°ì´í„°ë¥¼ í™•ë³´í•˜ë©´ì„œ ìœ„í—˜ ì¡°ì • í¬ì§€ì…˜ê³¼ ê°€ì •ë“¤ì„ ì¬í‰ê°€í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë§¥ë½ì—ì„œ, ì—…ê³„ ì°¨ì›ì˜ ê°€ì‹œì„±ì„ ë†’ì´ê¸° ìœ„í•œ ë…¸ë ¥ì˜ ì¼í™˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ë…ë¦½ ë³´í—˜ê³„ë¦¬ ë²•ì¸ì¸ Wakelyì™€ ê¸´ë°€íˆ í˜‘ë ¥í•˜ì—¬ ì‹œì¥ ì „ì²´ì˜ ìœ ë£Œ íšŒì› ë©”íƒˆë¦­ í‹°ì–´ ë¶„í¬ì™€ ì£¼ ì „ì²´ í‰ê·  ë³´í—˜ë£Œë¥¼ ë°˜ì˜í•œ ìƒˆë¡œìš´ ë³´ê³ ì„œ ë°œí–‰ì„ ì§€ì›í•˜ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ ë³´ê³ ì„œëŠ” 1ë¶„ê¸° ë§ê²½ ë°œí‘œë  ì˜ˆì •ì´ë©°, ì‹œì¥ ì°¸ì—¬ìë“¤ì´ í–¥í›„ ìœ„í—˜ ì¡°ì • ê°€ì •ì„ ë³´ë‹¤ ì •í™•í•˜ê²Œ ìˆ˜ë¦½í•˜ëŠ” ë° ë„ì›€ì„ ì¤„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>While 2025 was a difficult year for the Marketplace business, we believe the actions we took in the back half of 2025 set us up to navigate 2026 with increased visibility and confidence. We continue to advocate for program reform that will drive affordability and further stabilize the individual marketplace overall as an alternative to employer-sponsored insurance and a solution for small business owners and other hard-working Americans and their families. Finally, Medicare. Our Medicare segment delivered strong results throughout 2025. Fourth quarter fundamental Medicare Advantage performance was in line with our expectations, setting us up with a solid jump-off point for 2026.</td><td>2025ë…„ì€ ë§ˆì¼“í”Œë ˆì´ìŠ¤(Marketplace) ì‚¬ì—…ì— ì–´ë ¤ìš´ í•œ í•´ì˜€ì§€ë§Œ, 2025ë…„ í•˜ë°˜ê¸°ì— ì·¨í•œ ì¡°ì¹˜ë“¤ì´ 2026ë…„ì„ ë” ëª…í™•í•œ ê°€ì‹œì„±ê³¼ í™•ì‹ ì„ ê°€ì§€ê³  í—¤ì³ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ê¸°ë°˜ì„ ë§ˆë ¨í–ˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³ ìš©ì£¼ ì œê³µ ë³´í—˜ì˜ ëŒ€ì•ˆì´ì ì†Œê·œëª¨ ì‚¬ì—…ì£¼ì™€ ì—¬íƒ€ ê·¼ë©´í•œ ë¯¸êµ­ì¸ë“¤ê³¼ ê·¸ ê°€ì¡±ë“¤ì„ ìœ„í•œ ì†”ë£¨ì…˜ìœ¼ë¡œì„œ ê°œì¸ ë§ˆì¼“í”Œë ˆì´ìŠ¤ ì „ë°˜ì˜ ê²½ì œì„±ì„ ë†’ì´ê³  ì•ˆì •ì„±ì„ ë”ìš± ê°•í™”í•  í”„ë¡œê·¸ë¨ ê°œí˜ì„ ì§€ì†ì ìœ¼ë¡œ ì§€ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ë©”ë””ì¼€ì–´ì…ë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì€ 2025ë…„ ë‚´ë‚´ ê²¬ì¡°í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage) ê¸°ì´ˆ ì„±ê³¼ëŠ” ìš°ë¦¬ì˜ ì˜ˆìƒì— ë¶€í•©í–ˆìœ¼ë©°, ì´ëŠ” 2026ë…„ì„ ìœ„í•œ íƒ„íƒ„í•œ ì¶œë°œì ì„ ë§ˆë ¨í•´ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We completed a review of our provider contract portfolio in the quarter and adjusted certain receivables accordingly, which drove the slightly elevated HBR compared to expectations. Overall, we continue to look for opportunities to position the business for improved profitability in 2026 on the way to our goal of breakeven Medicare Advantage results in 2027, an important enterprise milestone. Our Medicare Advantage product positioning yielded the intended results for 2026 membership and we expect to end the first quarter with a decline in MA membership consistent with our strategy to refine our footprint and fine-tune our value proposition for Medicaid beneficiaries.</td><td>ë¶„ê¸° ì¤‘ ìš°ë¦¬ëŠ” ì˜ë£Œ ê³µê¸‰ì ê³„ì•½ í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ ê²€í† ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì´ì— ë”°ë¼ íŠ¹ì • ë¯¸ìˆ˜ê¸ˆì„ ì¡°ì •í–ˆìŠµë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ì˜ˆìƒë³´ë‹¤ HBR(ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì´ ë‹¤ì†Œ ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” 2027ë…„ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ ì†ìµë¶„ê¸° ë‹¬ì„±ì´ë¼ëŠ” ì¤‘ìš”í•œ ê¸°ì—… ëª©í‘œë¥¼ í–¥í•´ ë‚˜ì•„ê°€ëŠ” ê³¼ì •ì—ì„œ, 2026ë…„ ìˆ˜ìµì„± ê°œì„ ì„ ìœ„í•´ ì‚¬ì—…ì„ í¬ì§€ì…”ë‹í•  ê¸°íšŒë¥¼ ì§€ì†ì ìœ¼ë¡œ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ê°€ì…ì ìˆ˜ë¥¼ ìœ„í•œ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ ìƒí’ˆ í¬ì§€ì…”ë‹ì€ ì˜ë„í•œ ê²°ê³¼ë¥¼ ê°€ì ¸ì™”ìœ¼ë©°, ìš°ë¦¬ì˜ ì‚¬ì—… ì˜ì—­ì„ ì •ì œí•˜ê³  ë©”ë””ì¼€ì´ë“œ ìˆ˜í˜œìë“¤ì„ ìœ„í•œ ê°€ì¹˜ ì œì•ˆì„ ë¯¸ì„¸ ì¡°ì •í•˜ë ¤ëŠ” ì „ëµì— ë¶€í•©í•˜ê²Œ 1ë¶„ê¸° ë§ MA ê°€ì…ì ìˆ˜ê°€ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>PDP ended Q4 with some additional favorability, thanks to slightly moderating trend, and that team deserves a well-earned shout out for having managed the business expertly through significant program changes. As we look ahead to 2026, Part D enrollment is tracking to high single-digit percentage growth at the end of the first quarter compared to year-end 2025, with member mix across the products aligning well with program and formulary design. This year provides an important opportunity to build on the meaningful progress we've made in Medicare Advantage and further strengthen the platform that will most effectively serve Medicare beneficiaries as well as dual eligible membership.</td><td>PDPëŠ” ì•½ê°„ ì™„í™”ë˜ëŠ” ì¶”ì„¸ ë•ë¶„ì— 4ë¶„ê¸°ë¥¼ ì¶”ê°€ì ì¸ í˜¸ì¡°ë¡œ ë§ˆê°í–ˆìœ¼ë©°, ì¤‘ëŒ€í•œ í”„ë¡œê·¸ë¨ ë³€ê²½ ê³¼ì •ì—ì„œ ì‚¬ì—…ì„ ì „ë¬¸ì ìœ¼ë¡œ ê´€ë¦¬í•´ì˜¨ íŒ€ì€ ë§ˆë•…í•œ ì°¬ì‚¬ë¥¼ ë°›ì„ ìê²©ì´ ìˆìŠµë‹ˆë‹¤. 2026ë…„ì„ ì „ë§í•  ë•Œ, Part D ê°€ì…ì ìˆ˜ëŠ” 2025ë…„ ë§ ëŒ€ë¹„ 1ë¶„ê¸° ë§ ê¸°ì¤€ìœ¼ë¡œ í•œ ìë¦¿ìˆ˜ í›„ë°˜ëŒ€ ì„±ì¥ë¥ ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì œí’ˆ ì „ë°˜ì˜ íšŒì› êµ¬ì„±ì€ í”„ë¡œê·¸ë¨ ë° ì²˜ë°©ì§‘ ì„¤ê³„ì™€ ì˜ ë¶€í•©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ëŠ” ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì—ì„œ ì´ë£¬ ì˜ë¯¸ ìˆëŠ” ì§„ì „ì„ ê¸°ë°˜ìœ¼ë¡œ ë©”ë””ì¼€ì–´ ìˆ˜í˜œìì™€ ì´ì¤‘ ìê²© íšŒì› ëª¨ë‘ë¥¼ ê°€ì¥ íš¨ê³¼ì ìœ¼ë¡œ ì„œë¹„ìŠ¤í•  ìˆ˜ ìˆëŠ” í”Œë«í¼ì„ ë”ìš± ê°•í™”í•  ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>We continue to focus on STARS improvement, clinical engagement and overall SG&A efficiencies. At the same time, we launched a redesigned duals operating model, leveraging insights from our deep experience managing complex populations to enhance our service and member experience for a decent member base that now accounts for roughly 40% of our Medicare Advantage business.</td><td>ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ STARS ê°œì„ , ì„ìƒ ì°¸ì—¬ í™•ëŒ€, ê·¸ë¦¬ê³  ì „ë°˜ì ì¸ íŒë§¤ê´€ë¦¬ë¹„ íš¨ìœ¨ì„±ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë™ì‹œì— ë³µì¡í•œ ì¸êµ¬ì§‘ë‹¨ ê´€ë¦¬ì— ëŒ€í•œ í’ë¶€í•œ ê²½í—˜ì—ì„œ ì–»ì€ í†µì°°ë ¥ì„ í™œìš©í•˜ì—¬ ì¬ì„¤ê³„ëœ ì´ì¤‘ìê²©ì ìš´ì˜ ëª¨ë¸ì„ ì¶œì‹œí–ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ í˜„ì¬ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ ì‚¬ì—…ì˜ ì•½ 40%ë¥¼ ì°¨ì§€í•˜ëŠ” ì´ì¤‘ìê²©ì íšŒì› ê¸°ë°˜ì— ëŒ€í•œ ì„œë¹„ìŠ¤ì™€ íšŒì› ê²½í—˜ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Last week's 2027 advanced notice, at least initially suggests a more pressured view of rates than industry expectations, but it does not change our focus on returning our Medicare book to profitability, aligning closely with our key Medicaid markets, and continuing to invest in quality programs and benefits that support our core member base. We expect rates to be finalized in early April, consistent with prior years. Taking a step back, our long-term goal across our businesses is to deliver industry-leading outcomes at an industry-leading cost structure.</td><td>ì§€ë‚œì£¼ ë°œí‘œëœ 2027ë…„ ì‚¬ì „ ê³ ì§€ëŠ” ìµœì†Œí•œ ì´ˆê¸°ì—ëŠ” ì—…ê³„ ì˜ˆìƒë³´ë‹¤ ë” ì••ë°•ì ì¸ ìˆ˜ê°€ ì „ë§ì„ ì‹œì‚¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ë©”ë””ì¼€ì–´ ì‚¬ì—…ë¶€ë¥¼ ìˆ˜ìµì„±ìœ¼ë¡œ ë³µê·€ì‹œí‚¤ê³ , í•µì‹¬ ë©”ë””ì¼€ì´ë“œ ì‹œì¥ê³¼ ê¸´ë°€íˆ ì—°ê³„í•˜ë©°, í•µì‹¬ íšŒì› ê¸°ë°˜ì„ ì§€ì›í•˜ëŠ” í’ˆì§ˆ í”„ë¡œê·¸ë¨ê³¼ í˜œíƒì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ëŠ” ìš°ë¦¬ì˜ ì´ˆì ì„ ë³€í™”ì‹œí‚¤ì§€ ì•ŠìŠµë‹ˆë‹¤. ìˆ˜ê°€ëŠ” ì˜ˆë…„ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ 4ì›” ì´ˆì— ìµœì¢… í™•ì •ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í•œ ê±¸ìŒ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, ìš°ë¦¬ ì‚¬ì—… ì „ë°˜ì— ê±¸ì¹œ ì¥ê¸° ëª©í‘œëŠ” ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ë¹„ìš© êµ¬ì¡°ë¡œ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì„±ê³¼ë¥¼ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As we create the road map to harvest Centene's full potential earnings power, there is no question that data, technology and artificial intelligence will be a critical lever and accelerant to this work. Over the last few years, we have been building the necessary data foundation and systematically integrating AI into our operations, resulting in proof points around accelerated prior authorization approvals, improved call center operations enhanced member navigation and engagement experiences and advanced analytics capabilities that support our medical economics work and our payment integrity operations.</td><td>ì„¼í‹°ë‹ˆì˜ ì ì¬ì  ìˆ˜ìµ ì°½ì¶œë ¥ì„ ìµœëŒ€í•œ ì‹¤í˜„í•˜ê¸° ìœ„í•œ ë¡œë“œë§µì„ ìˆ˜ë¦½í•˜ëŠ” ê³¼ì •ì—ì„œ, ë°ì´í„°, ê¸°ìˆ , ê·¸ë¦¬ê³  ì¸ê³µì§€ëŠ¥ì´ ì´ëŸ¬í•œ ì‘ì—…ì˜ í•µì‹¬ ë ˆë²„ì´ì ê°€ì†í™” ìš”ì¸ì´ ë  ê²ƒì„ì€ ì˜ì‹¬ì˜ ì—¬ì§€ê°€ ì—†ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ìš°ë¦¬ëŠ” í•„ìš”í•œ ë°ì´í„° ê¸°ë°˜ì„ êµ¬ì¶•í•´ì™”ìœ¼ë©°, AIë¥¼ ìš´ì˜ì— ì²´ê³„ì ìœ¼ë¡œ í†µí•©í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì‚¬ì „ìŠ¹ì¸ ì²˜ë¦¬ ê°€ì†í™”, ì½œì„¼í„° ìš´ì˜ ê°œì„ , íšŒì› ì•ˆë‚´ ë° ì°¸ì—¬ ê²½í—˜ í–¥ìƒ, ê·¸ë¦¬ê³  ì˜ë£Œ ê²½ì œì„± ì—…ë¬´ì™€ ì§€ê¸‰ ë¬´ê²°ì„± ìš´ì˜ì„ ì§€ì›í•˜ëŠ” ê³ ë„í™”ëœ ë¶„ì„ ì—­ëŸ‰ ë“±ì—ì„œ ì‹¤ì§ˆì ì¸ ì„±ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As an example of the latter, we currently score our claims data against 75 different algorithms designed to triangulate potential fraud. Alerts are triggered and sent to a group of cross-functional experts for immediate review and intervention. As we step into 2026, we are closely tracking the inflection of Gen AI and accelerating our integration of Agentic capabilities into our core operations to drive automation and efficiency and using it as a catalyst to reimagine and elevate the experience we deliver to our members, partners and other stakeholders. You should expect to hear more on this in the quarters ahead. 2025 challenged us but it also made us stronger.</td><td>í›„ìì˜ ì˜ˆë¡œ, ìš°ë¦¬ëŠ” í˜„ì¬ ì ì¬ì  ì‚¬ê¸°ë¥¼ ì‚¼ê°ì¸¡ëŸ‰í•˜ë„ë¡ ì„¤ê³„ëœ 75ê°€ì§€ ì•Œê³ ë¦¬ì¦˜ì„ ê¸°ë°˜ìœ¼ë¡œ ì²­êµ¬ ë°ì´í„°ë¥¼ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ë³´ê°€ ë°œë™ë˜ë©´ ì¦‰ê°ì ì¸ ê²€í† ì™€ ê°œì…ì„ ìœ„í•´ êµì°¨ ê¸°ëŠ¥ ì „ë¬¸ê°€ ê·¸ë£¹ì— ì „ì†¡ë©ë‹ˆë‹¤. 2026ë…„ì„ ë§ì´í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” ìƒì„±í˜• AIì˜ ë³€ê³¡ì ì„ ë©´ë°€íˆ ì¶”ì í•˜ê³  ìˆìœ¼ë©°, ìë™í™”ì™€ íš¨ìœ¨ì„±ì„ ì´‰ì§„í•˜ê¸° ìœ„í•´ ì—ì´ì „í‹±(Agentic) ì—­ëŸ‰ì„ í•µì‹¬ ìš´ì˜ì— í†µí•©í•˜ëŠ” ê²ƒì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ë¥¼ ì´‰ë§¤ì œë¡œ í™œìš©í•˜ì—¬ íšŒì›, íŒŒíŠ¸ë„ˆ ë° ê¸°íƒ€ ì´í•´ê´€ê³„ìë“¤ì—ê²Œ ì œê³µí•˜ëŠ” ê²½í—˜ì„ ì¬êµ¬ìƒí•˜ê³  í–¥ìƒì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì´ì— ëŒ€í•´ ë” ë§ì€ ì†Œì‹ì„ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. 2025ë…„ì€ ìš°ë¦¬ì—ê²Œ ë„ì „ì´ì—ˆì§€ë§Œ ë™ì‹œì— ìš°ë¦¬ë¥¼ ë” ê°•í•˜ê²Œ ë§Œë“¤ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Amid continued landscape volatility and with the benefit of enhanced visibility across lines of business as we move through the back half of the year, we took the opportunity as an organization to reassess and refresh our views of both existing and emerging headwinds and tailwinds. We have prudently positioned our 2026 outlook, incorporating an expectation that policy-related variability will continue to influence our core business lines. We are confident in our ability to execute against the outlook we have provided today building on the positive momentum we have generated in recent months.</td><td>ì§€ì†ë˜ëŠ” ì‹œì¥ ë³€ë™ì„± ì†ì—ì„œ, ê·¸ë¦¬ê³  í•˜ë°˜ê¸°ë¡œ ì ‘ì–´ë“¤ë©´ì„œ ì‚¬ì—…ë¶€ë¬¸ ì „ë°˜ì— ê±¸ì³ ê°€ì‹œì„±ì´ ê°œì„ ë¨ì— ë”°ë¼, ìš°ë¦¬ëŠ” ì¡°ì§ ì°¨ì›ì—ì„œ ê¸°ì¡´ ë° ìƒˆë¡­ê²Œ ë¶€ìƒí•˜ëŠ” ì—­í’ê³¼ ìˆœí’ ìš”ì¸ë“¤ì— ëŒ€í•œ ê´€ì ì„ ì¬í‰ê°€í•˜ê³  ì¬ì •ë¦½í•˜ëŠ” ê¸°íšŒë¥¼ ê°€ì¡ŒìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì •ì±… ê´€ë ¨ ë³€ë™ì„±ì´ í•µì‹¬ ì‚¬ì—…ë¶€ë¬¸ì— ì§€ì†ì ìœ¼ë¡œ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë¼ëŠ” ì˜ˆìƒì„ ë°˜ì˜í•˜ì—¬ 2026ë…„ ì „ë§ì„ ì‹ ì¤‘í•˜ê²Œ ì„¤ì •í–ˆìŠµë‹ˆë‹¤. ìµœê·¼ ëª‡ ê°œì›”ê°„ ìš°ë¦¬ê°€ ë§Œë“¤ì–´ë‚¸ ê¸ì •ì ì¸ ëª¨ë©˜í…€ì„ ë°”íƒ•ìœ¼ë¡œ ì˜¤ëŠ˜ ì œì‹œí•œ ì „ë§ì„ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we see continued opportunity for margin expansion in the months and years ahead, while keeping our members at the center of everything we do. As I have said before and feel only more strongly after the year we have navigated the [ Cen team ] is an incredibly powerful engine. They are fired up and focused on the opportunity ahead and committed to the hard work necessary to deliver margin that will power our mission. With that, I will turn it over to Drew to provide more details about the quarter and our view of 2026. Andrew Asher<br>Chief Financial Officer<br><br>Thank you, Sarah.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” íšŒì›ë“¤ì„ ëª¨ë“  ì—…ë¬´ì˜ ì¤‘ì‹¬ì— ë‘ë©´ì„œë„ í–¥í›„ ëª‡ ê°œì›”ê³¼ ëª‡ ë…„ê°„ ë§ˆì§„ í™•ëŒ€ì˜ ì§€ì†ì ì¸ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ì´ì „ì—ë„ ë§ì”€ë“œë ¸ê³ , ìš°ë¦¬ê°€ í—¤ì³ì˜¨ í•œ í•´ë¥¼ ê²ªì€ í›„ ë”ìš± ê°•í•˜ê²Œ ëŠë¼ëŠ” ê²ƒì€, [Cen íŒ€]ì´ ë¯¿ì„ ìˆ˜ ì—†ì„ ë§Œí¼ ê°•ë ¥í•œ ì—”ì§„ì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë“¤ì€ ì•ìœ¼ë¡œì˜ ê¸°íšŒì— ëŒ€í•´ ì—´ì •ì ì´ê³  ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, ìš°ë¦¬ì˜ ë¯¸ì…˜ì„ ë’·ë°›ì¹¨í•  ë§ˆì§„ì„ ë‹¬ì„±í•˜ëŠ” ë° í•„ìš”í•œ ì–´ë ¤ìš´ ì‘ì—…ì— ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Drewì—ê²Œ ë„˜ê²¨ ë¶„ê¸° ì‹¤ì ê³¼ 2026ë…„ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì „ë§ì— ëŒ€í•´ ë” ìì„¸íˆ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Andrew Asher<br>ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Sarah.</td></tr>
<tr><td>Today, we reported fourth quarter and full year 2025 results, including $174.6 billion in premium and service revenue and adjusted diluted earnings per share of $2.08. The fourth quarter GAAP diluted loss per share of $2.24 includes a $389 million net loss prompted by a Q4 definitive agreement to divest the remaining Magellan business. Recall, we previously divested the Magellan pharmacy and specialty businesses at gains over the past few years.</td><td>ì˜¤ëŠ˜ ìš°ë¦¬ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ë°œí‘œí–ˆìœ¼ë©°, ë³´í—˜ë£Œ ë° ì„œë¹„ìŠ¤ ë§¤ì¶œ 1,746ì–µ ë‹¬ëŸ¬ì™€ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ 2.08ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° GAAP í¬ì„ ì£¼ë‹¹ìˆœì†ì‹¤ 2.24ë‹¬ëŸ¬ì—ëŠ” 4ë¶„ê¸°ì— ì²´ê²°ëœ ì”ì—¬ Magellan ì‚¬ì—… ë§¤ê° í™•ì • ê³„ì•½ìœ¼ë¡œ ì¸í•œ 3ì–µ 8,900ë§Œ ë‹¬ëŸ¬ì˜ ìˆœì†ì‹¤ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ, ìš°ë¦¬ëŠ” ì§€ë‚œ ëª‡ ë…„ê°„ Magellan ì•½êµ­ ë° ì „ë¬¸ì˜ì•½í’ˆ ì‚¬ì—…ì„ ì´ìµì„ ë‚´ê³  ë§¤ê°í•œ ë°” ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>From an adjusted earnings standpoint, we are pleased that the underlying fundamentals in Q4 are tracking our prior forecasted full year adjusted diluted EPS of greater than $2 and this sets us up well for our 2026 guidance that we'll cover in a minute. Starting with Medicaid. We saw continued progress and improvement in the HBR with Q4 improving to 93.0% while we have a lot further to go in Medicaid to achieve a reasonable HBR and margin, the back half of 2025 was a good start with 2 consecutive quarters of HBR improvement.</td><td>ì¡°ì • ì‹¤ì  ê´€ì ì—ì„œ, 4ë¶„ê¸° ê¸°ì € í€ë”ë©˜í„¸ì´ ì´ì „ì— ì˜ˆì¸¡í–ˆë˜ ì—°ê°„ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ 2ë‹¬ëŸ¬ ì´ìƒì„ ë‹¬ì„±í•˜ê³  ìˆì–´ ë§Œì¡±ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ì´ëŠ” ì ì‹œ í›„ ë‹¤ë£° 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ì¢‹ì€ ê¸°ë°˜ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° HBR(ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì´ 93.0%ë¡œ ê°œì„ ë˜ë©´ì„œ ì§€ì†ì ì¸ ì§„ì „ê³¼ ê°œì„ ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œì—ì„œ í•©ë¦¬ì ì¸ HBRê³¼ ë§ˆì§„ì„ ë‹¬ì„±í•˜ê¸°ê¹Œì§€ëŠ” ì•„ì§ ê°ˆ ê¸¸ì´ ë©€ì§€ë§Œ, 2025ë…„ í•˜ë°˜ê¸°ëŠ” 2ê°œ ë¶„ê¸° ì—°ì† HBR ê°œì„ ì„ ë³´ì´ë©° ì¢‹ì€ ì¶œë°œì„ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our 1/1 net rates are supportive of our 2026 guidance of a stable Medicaid HBR with an assumed full year 2026 net rate impact of mid-4s and the corresponding mid-4s 2026 net trend expectation. As expected, we continue to see slight attrition in membership closing out 2025 at 12.5 million members. We continue to drive quality and affordability health care initiatives and work with our state partners on the optimal program structures and associated rates. While certain areas are still elevated, behavioral, home health and high-cost drugs, we can see tangible progress in the business. Overall, this is another quarter of good progress in Medicaid.</td><td>1ì›” 1ì¼ ìˆœìš”ìœ¨ì€ ì•ˆì •ì ì¸ ë©”ë””ì¼€ì´ë“œ HBR(ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì— ëŒ€í•œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ë’·ë°›ì¹¨í•˜ë©°, 2026ë…„ ì—°ê°„ ìˆœìš”ìœ¨ ì˜í–¥ì€ 4% ì¤‘ë°˜ëŒ€ë¡œ ê°€ì •í•˜ê³  ìˆê³ , ì´ì— ìƒì‘í•˜ëŠ” 2026ë…„ ìˆœíŠ¸ë Œë“œ ì „ë§ë„ 4% ì¤‘ë°˜ëŒ€ì…ë‹ˆë‹¤. ì˜ˆìƒëŒ€ë¡œ íšŒì› ìˆ˜ëŠ” ì†Œí­ ê°ì†Œí•˜ì—¬ 2025ë…„ ë§ 1,250ë§Œ ëª…ìœ¼ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê³„ì†í•´ì„œ ì–‘ì§ˆì˜ ì˜ë£Œì„œë¹„ìŠ¤ì™€ ë¹„ìš© íš¨ìœ¨ì„± ì œê³  ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì¶”ì§„í•˜ê³  ìˆìœ¼ë©°, ìµœì ì˜ í”„ë¡œê·¸ë¨ êµ¬ì¡°ì™€ ê´€ë ¨ ìš”ìœ¨ì— ëŒ€í•´ ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. í–‰ë™ê±´ê°•, ì¬íƒì˜ë£Œ, ê³ ê°€ ì˜ì•½í’ˆ ë“± ì¼ë¶€ ì˜ì—­ì€ ì—¬ì „íˆ ë†’ì€ ìˆ˜ì¤€ì´ì§€ë§Œ, ì‚¬ì—… ì „ë°˜ì—ì„œ ê°€ì‹œì ì¸ ì§„ì „ì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë©”ë””ì¼€ì´ë“œ ë¶€ë¬¸ì—ì„œ ë˜ í•œ ë¶„ê¸° ë™ì•ˆ ì–‘í˜¸í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our Commercial segment HBR in Q4 was about 1 point higher than our forecast with a few items moving in both directions, but the elements that matter most for 2026 were positive. Importantly, the current period medical costs and trends were slightly better than our expectations in the fourth quarter. So we feel good about Q4 fundamentals as we turn the calendar into 2026. Another positive sign in the quarter was a favorable change in our view of 2025 relative morbidity or risk adjustment based upon the third round of Wakely data. This was a couple of hundred million worth of net P&L outperformance in the quarter, which also bodes well for our 2026 pricing assumptions.</td><td>ë‹¹ì‚¬ì˜ ìƒì—… ë¶€ë¬¸ HBR(Health Benefit Ratio, ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì€ 4ë¶„ê¸°ì— ì˜ˆìƒì¹˜ë³´ë‹¤ ì•½ 1í¬ì¸íŠ¸ ë†’ì•˜ìœ¼ë©°, ëª‡ ê°€ì§€ í•­ëª©ë“¤ì´ ì–‘ë°©í–¥ìœ¼ë¡œ ì›€ì§ì˜€ì§€ë§Œ 2026ë…„ì— ê°€ì¥ ì¤‘ìš”í•œ ìš”ì†Œë“¤ì€ ê¸ì •ì ì´ì—ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, ë‹¹ê¸° ì˜ë£Œë¹„ìš©ê³¼ ì¶”ì„¸ê°€ 4ë¶„ê¸° ì˜ˆìƒì¹˜ë³´ë‹¤ ì†Œí­ ì–‘í˜¸í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ìœ¼ë¡œ ì ‘ì–´ë“¤ë©´ì„œ 4ë¶„ê¸° í€ë”ë©˜í„¸ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë¶„ê¸° ì¤‘ ë˜ ë‹¤ë¥¸ ê¸ì •ì ì¸ ì‹ í˜¸ëŠ” Wakely ë°ì´í„° 3ì°¨ ë¼ìš´ë“œë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•œ 2025ë…„ ìƒëŒ€ì  ì´í™˜ìœ¨(relative morbidity) ë˜ëŠ” ìœ„í—˜ë„ ì¡°ì •(risk adjustment)ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì „ë§ì´ í˜¸ì˜ì ìœ¼ë¡œ ë³€í™”í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ë¶„ê¸° ì¤‘ ì•½ ìˆ˜ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ìˆœ ì†ìµ ì´ˆê³¼ ë‹¬ì„±ì„ ì˜ë¯¸í•˜ë©°, ì´ëŠ” 2026ë…„ ê°€ê²© ì±…ì • ê°€ì •ì—ë„ ê¸ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So what more than offset this good news, 2 items. A 2023 revenue reconciliation with CMS that has no bearing on 2026 and increases in cost and accruals related to the No Surprises Act that Sarah covered. Those 2 items drove the net 1% higher than planned HBR in Q4, which otherwise would have been quite favorable. Consistent with our Q3 commentary and now bolstered by Q4 insights, we expect our marketplace pricing actions to adequately capture the 2025 and 2026 market shifts 2026 trends and policy changes in place during the open enrollment period, all of which support meaningful pretax margin expansion in 2026 compared to losing approximately 1% in 2025.</td><td>ì´ëŸ¬í•œ ì¢‹ì€ ì†Œì‹ë³´ë‹¤ ë” í° ì˜í–¥ì„ ë¯¸ì¹œ ë‘ ê°€ì§€ í•­ëª©ì´ ìˆìŠµë‹ˆë‹¤. 2026ë…„ê³¼ëŠ” ë¬´ê´€í•œ CMSì™€ì˜ 2023ë…„ ìˆ˜ìµ ì¡°ì •, ê·¸ë¦¬ê³  Sarahê°€ ì„¤ëª…í•œ No Surprises Act(ì˜ˆìƒì™¸ ì˜ë£Œë¹„ ì²­êµ¬ ê¸ˆì§€ë²•)ì™€ ê´€ë ¨ëœ ë¹„ìš© ë° ì¶©ë‹¹ê¸ˆ ì¦ê°€ì…ë‹ˆë‹¤. ì´ ë‘ í•­ëª©ìœ¼ë¡œ ì¸í•´ 4ë¶„ê¸° HBR(ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì´ ê³„íš ëŒ€ë¹„ ìˆœ 1% ë†’ì•„ì¡Œìœ¼ë©°, ì´ê²ƒì´ ì•„ë‹ˆì—ˆë‹¤ë©´ ìƒë‹¹íˆ ì–‘í˜¸í–ˆì„ ê²ƒì…ë‹ˆë‹¤. 3ë¶„ê¸° ë…¼í‰ê³¼ ì¼ê´€ë˜ê²Œ, ê·¸ë¦¬ê³  ì´ì œ 4ë¶„ê¸° ì¸ì‚¬ì´íŠ¸ë¡œ ë’·ë°›ì¹¨ë˜ì–´, ë‹¹ì‚¬ì˜ ë§ˆì¼“í”Œë ˆì´ìŠ¤ ê°€ê²© ì¡°ì¹˜ê°€ 2025ë…„ê³¼ 2026ë…„ ì‹œì¥ ë³€í™”, 2026ë…„ ì¶”ì„¸, ê·¸ë¦¬ê³  ê³µê°œ ë“±ë¡ ê¸°ê°„ ì¤‘ ì‹œí–‰ëœ ì •ì±… ë³€í™”ë¥¼ ì ì ˆíˆ ë°˜ì˜í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì´ 2025ë…„ ì•½ 1% ì†ì‹¤ ëŒ€ë¹„ 2026ë…„ ì˜ë¯¸ ìˆëŠ” ì„¸ì „ ë§ˆì§„ í™•ëŒ€ë¥¼ ë’·ë°›ì¹¨í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In our Medicare segment, we executed well in 2025, including the fourth quarter. In our growing PDP business, we delivered strong 2025 performance, including Q4 despite the headwinds and uncertainties created by the Inflation Reduction Act. This is a testament to our experience, cost structure and market positioning in PDP. In our Medicare Advantage business in 2025, we progressed nicely toward our goal of breakeven in 2027. Q4 fundamentals were on track and the reported results include a write-off of some older provider receivables. As Sarah covered, we like our 2026 positioning as we wrapped up the annual enrollment period.</td><td>ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì—ì„œ ìš°ë¦¬ëŠ” 4ë¶„ê¸°ë¥¼ í¬í•¨í•˜ì—¬ 2025ë…„ í•œ í•´ ë™ì•ˆ ì„±ê³µì ìœ¼ë¡œ ì‚¬ì—…ì„ ìˆ˜í–‰í–ˆìŠµë‹ˆë‹¤. ì„±ì¥í•˜ê³  ìˆëŠ” PDP(ì²˜ë°©ì•½ í”Œëœ) ì‚¬ì—…ì—ì„œëŠ” ì¸í”Œë ˆì´ì…˜ ê°ì¶•ë²•(Inflation Reduction Act)ìœ¼ë¡œ ì¸í•œ ì—­í’ê³¼ ë¶ˆí™•ì‹¤ì„±ì—ë„ ë¶ˆêµ¬í•˜ê³  4ë¶„ê¸°ë¥¼ í¬í•¨í•œ 2025ë…„ ì „ë°˜ì— ê±¸ì³ ê°•ë ¥í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” PDP ë¶„ì•¼ì—ì„œ ìš°ë¦¬ì˜ ê²½í—˜, ë¹„ìš© êµ¬ì¡° ë° ì‹œì¥ í¬ì§€ì…”ë‹ì„ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage) ì‚¬ì—…ì—ì„œëŠ” 2025ë…„ ë™ì•ˆ 2027ë…„ ì†ìµë¶„ê¸°ì  ë‹¬ì„±ì´ë¼ëŠ” ëª©í‘œë¥¼ í–¥í•´ ìˆœì¡°ë¡­ê²Œ ì§„ì „í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° í€ë”ë©˜í„¸ì€ ê³„íšëŒ€ë¡œ ì§„í–‰ë˜ì—ˆìœ¼ë©°, ë³´ê³ ëœ ì‹¤ì ì—ëŠ” ì¼ë¶€ ì˜¤ë˜ëœ ì˜ë£Œê¸°ê´€ ë¯¸ìˆ˜ê¸ˆì— ëŒ€í•œ ìƒê°ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. Sarahê°€ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´, ì—°ê°„ ê°€ì… ê¸°ê°„ì„ ë§ˆë¬´ë¦¬í•˜ë©´ì„œ ìš°ë¦¬ëŠ” 2026ë…„ í¬ì§€ì…”ë‹ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We will provide CMS comments on the disappointing 2027 advanced notice Medicare rate, which will likely cut into seniors benefits and product selection. And as we construct the 2027 bids over the next few months, we will do so with the same goal to solve for breakeven performance in 2027. Our Q4 adjusted SG&A expense ratio of 7.5% brings our full year to 7.4% which is 110 basis points lower than 2024, reflecting continued discipline and scale. We ended the year with about $400 million of cash available for general corporate use. We reduced debt by $189 million in the quarter and ended up with a debt-to-cap ratio of 46.5%.</td><td>ìš°ë¦¬ëŠ” ì‹¤ë§ìŠ¤ëŸ¬ìš´ 2027ë…„ ì‚¬ì „ ê³µì§€ ë©”ë””ì¼€ì–´ ìš”ìœ¨ì— ëŒ€í•´ CMSì— ì˜ê²¬ì„ ì œì¶œí•  ì˜ˆì •ì´ë©°, ì´ëŠ” ê³ ë ¹ì í˜œíƒê³¼ ìƒí’ˆ ì„ íƒê¶Œì„ ì¶•ì†Œì‹œí‚¬ ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. í–¥í›„ ëª‡ ê°œì›”ê°„ 2027ë…„ ì…ì°°ì„ êµ¬ì„±í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” 2027ë…„ ì†ìµë¶„ê¸°ì  ë‹¬ì„±ì´ë¼ëŠ” ë™ì¼í•œ ëª©í‘œë¥¼ ê°€ì§€ê³  ì§„í–‰í•  ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸° ì¡°ì • íŒê´€ë¹„ìœ¨ì€ 7.5%ë¡œ, ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” 7.4%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 2024ë…„ ëŒ€ë¹„ 110bp ë‚®ì€ ìˆ˜ì¹˜ë¡œ ì§€ì†ì ì¸ ë¹„ìš© ê´€ë¦¬ì™€ ê·œëª¨ì˜ ê²½ì œë¥¼ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ë§ ê¸°ì¤€ ì¼ë°˜ ê¸°ì—…ìš©ë„ë¡œ ì‚¬ìš© ê°€ëŠ¥í•œ í˜„ê¸ˆì€ ì•½ 4ì–µ ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ë‹¹ ë¶„ê¸°ì— ë¶€ì±„ë¥¼ 1ì–µ 8,900ë§Œ ë‹¬ëŸ¬ ê°ì¶•í–ˆìœ¼ë©°, ë¶€ì±„ë¹„ìœ¨ì€ 46.5%ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our medical claims liability totaled $20.5 billion and represents 46 days in claims payable, a decrease of 2 days as compared to the third quarter of 2025 driven by payouts of state-directed payments and the elimination of the Medicare premium deficiency reserve in Q4, which is corroboration of the progress we are making in Medicare Advantage for 2026. That's a wrap on 2025, a strong finish to a rough year. Let's move to 2026 and associated guidance elements, including a few slides we posted on our website. We expect premium and service revenue of $170 million to $174 billion.</td><td>ì˜ë£Œ ì²­êµ¬ ë¶€ì±„ëŠ” 205ì–µ ë‹¬ëŸ¬ë¡œ ë¯¸ì§€ê¸‰ ì²­êµ¬ì¼ìˆ˜ ê¸°ì¤€ 46ì¼ì— í•´ë‹¹í•˜ë©°, ì´ëŠ” 2025ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 2ì¼ ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°ì†ŒëŠ” ì£¼ì •ë¶€ ì§€ì‹œ ì§€ê¸‰ê¸ˆì˜ ì§€ê¸‰ê³¼ 4ë¶„ê¸° ë©”ë””ì¼€ì–´ ë³´í—˜ë£Œ ê²°ì†ì¶©ë‹¹ê¸ˆ ì œê±°ì— ê¸°ì¸í•˜ë©°, ì´ëŠ” 2026ë…„ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì—ì„œ ìš°ë¦¬ê°€ ì´ë£¨ê³  ìˆëŠ” ì§„ì „ì„ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ 2025ë…„ì„ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. í˜ë“  í•œ í•´ë¥¼ ê°•í•˜ê²Œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ì´ì œ 2026ë…„ê³¼ ê´€ë ¨ ê°€ì´ë˜ìŠ¤ í•­ëª©ë“¤ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì €í¬ ì›¹ì‚¬ì´íŠ¸ì— ê²Œì‹œí•œ ëª‡ ê°€ì§€ ìŠ¬ë¼ì´ë“œê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë³´í—˜ë£Œ ë° ì„œë¹„ìŠ¤ ìˆ˜ìµì€ 1,700ì–µ ë‹¬ëŸ¬ì—ì„œ 1,740ì–µ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>As you can see in the bridge, Medicaid premium revenue is down a couple of billion including some member attrition in 2026, partially offset by rate increases. We expect Medicaid member months down 5% to 6% in 2026. We expect Marketplace revenue to be down about $8 billion, driven by policy and market impacts, including the expiration of the enhanced APTCs net of rate increases designed to increase yield and improve margin. To give you some membership magnitude, as Sarah outlined, we expect around 3.5 million marketplace members as of the end of Q1 and slight attrition thereafter, though we are still in the payment grace periods, which could swing membership somewhat during Q1.</td><td>ë¸Œë¦¬ì§€ì—ì„œ ë³´ì‹œë‹¤ì‹œí”¼, ë©”ë””ì¼€ì´ë“œ ë³´í—˜ë£Œ ìˆ˜ìµì€ 2026ë…„ì— ìš”ìœ¨ ì¸ìƒìœ¼ë¡œ ì¼ë¶€ ìƒì‡„ë˜ê¸°ëŠ” í•˜ì§€ë§Œ ì¼ë¶€ íšŒì› ì´íƒˆì„ í¬í•¨í•˜ì—¬ ì•½ 20ì–µ ë‹¬ëŸ¬ ê°ì†Œí•  ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ë©”ë””ì¼€ì´ë“œ íšŒì› ì›”ìˆ˜ëŠ” 5%ì—ì„œ 6% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë§ˆì¼“í”Œë ˆì´ìŠ¤ ìˆ˜ìµì€ ì•½ 80ì–µ ë‹¬ëŸ¬ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ìˆ˜ìµë¥  ì œê³ ì™€ ë§ˆì§„ ê°œì„ ì„ ìœ„í•´ ì„¤ê³„ëœ ìš”ìœ¨ ì¸ìƒì„ ê°ì•ˆí•œ ê°•í™”ëœ APTC(ì„ ì§€ê¸‰ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ)ì˜ ë§Œë£Œë¥¼ í¬í•¨í•œ ì •ì±… ë° ì‹œì¥ ì˜í–¥ì— ê¸°ì¸í•©ë‹ˆë‹¤. íšŒì› ê·œëª¨ë¥¼ ë§ì”€ë“œë¦¬ë©´, Sarahê°€ ì„¤ëª…í•œ ëŒ€ë¡œ 1ë¶„ê¸° ë§ ê¸°ì¤€ ì•½ 350ë§Œ ëª…ì˜ ë§ˆì¼“í”Œë ˆì´ìŠ¤ íšŒì›ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ê·¸ ì´í›„ ì†Œí­ì˜ ì´íƒˆì´ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë‹¤ë§Œ í˜„ì¬ ë‚©ë¶€ ìœ ì˜ˆ ê¸°ê°„ ì¤‘ì´ë¯€ë¡œ 1ë¶„ê¸° ë™ì•ˆ íšŒì› ìˆ˜ê°€ ë‹¤ì†Œ ë³€ë™ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect the Medicare segment to grow premium revenue approximately $7.5 billion, driven by our Medicare PDP business, the majority of which is from the premium yield increase, which we'll touch on in a moment, coupled with growth in membership, which sits at about $8.7 million coming out of open enrollment. Medicare Advantage revenue is projected to be essentially flat from '25 to '26 with membership down intentionally and yields up. The forecasted 2026 revenue split in the Medicare segment is approximately 41% Medicare Advantage and 59% PDP. We expect the consolidated HBR of 90.9% to 91.7% in 2026 at the midpoint, down 60 basis points from 2025.</td><td>ìš°ë¦¬ëŠ” ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì˜ ë³´í—˜ë£Œ ìˆ˜ìµì´ ì•½ 75ì–µ ë‹¬ëŸ¬ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ë°, ì´ëŠ” ë©”ë””ì¼€ì–´ PDP ì‚¬ì—…ì— ì˜í•´ ì£¼ë„ë˜ë©°, ê·¸ ëŒ€ë¶€ë¶„ì€ ê³§ ë‹¤ë£¨ê²Œ ë  ë³´í—˜ë£Œ ìˆ˜ìµë¥  ì¦ê°€ì—ì„œ ë¹„ë¡¯ë˜ê³ , ê³µê°œ ê°€ì… ê¸°ê°„ì„ ë§ˆì¹˜ê³  ì•½ 870ë§Œ ëª… ìˆ˜ì¤€ì— ìˆëŠ” ê°€ì…ì ì¦ê°€ì™€ ê²°í•©ëœ ê²ƒì…ë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ ìˆ˜ìµì€ '25ë…„ì—ì„œ '26ë…„ê¹Œì§€ ë³¸ì§ˆì ìœ¼ë¡œ ë³´í•©ì„¸ë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ê°€ì…ì ìˆ˜ëŠ” ì˜ë„ì ìœ¼ë¡œ ê°ì†Œí•˜ê³  ìˆ˜ìµë¥ ì€ ì¦ê°€í•  ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì˜ ì˜ˆìƒ ìˆ˜ìµ êµ¬ì„±ì€ ì•½ 41%ê°€ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì´ê³  59%ê°€ PDPì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026ë…„ ì—°ê²° HBRì´ ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ 90.9%ì—ì„œ 91.7%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” 2025ë…„ ëŒ€ë¹„ 60bp ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>That's driven by an expected recovery in marketplace, as you can see in the bridge. Consistent with previous commentary, we initially expect a flat Medicaid segment HBR in 2026 compared to 2025's 93.7%. In the Medicare segment, we expect improvement in the Medicare Advantage and a higher PDP HBR driven by 2 things: one, we are initially assuming a 2026 pretax margin around 2%, down from a good year in the 3s and two, there was a meaningful increase in the direct subsidy from $143 to $200 reflecting industry pricing for higher pharmacy trends due to the IRA. So think about a rise in premium and pharmacy expense without any need to increase SG&A. This drives a higher mathematical HBR.</td><td>ì´ëŠ” ë¸Œë¦¬ì§€ì—ì„œ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´ ë§ˆì¼“í”Œë ˆì´ìŠ¤ì˜ íšŒë³µì´ ì˜ˆìƒë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ì „ ì„¤ëª…ê³¼ ì¼ê´€ë˜ê²Œ, 2026ë…„ ë©”ë””ì¼€ì´ë“œ ë¶€ë¬¸ HBR(ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨)ì€ 2025ë…„ì˜ 93.7%ì™€ ë¹„êµí•´ ë³´í•©ì„ ì´ˆê¸° ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì—ì„œëŠ” ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì˜ ê°œì„ ê³¼ PDP(ì²˜ë°©ì•½ í”Œëœ) HBR ìƒìŠ¹ì„ ì˜ˆìƒí•˜ëŠ”ë°, ì´ëŠ” ë‘ ê°€ì§€ ìš”ì¸ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì²«ì§¸, 2026ë…„ ì„¸ì „ ë§ˆì§„ì„ ì•½ 2%ë¡œ ì´ˆê¸° ê°€ì •í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 3%ëŒ€ì˜ ì–‘í˜¸í–ˆë˜ ì „ë…„ë„ì—ì„œ í•˜ë½í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë‘˜ì§¸, IRA(ì¸í”Œë ˆì´ì…˜ ê°ì¶•ë²•)ë¡œ ì¸í•œ ë†’ì€ ì•½ì œë¹„ ì¶”ì„¸ë¥¼ ë°˜ì˜í•œ ì—…ê³„ ê°€ê²© ì±…ì •ìœ¼ë¡œ ì¸í•´ ì§ì ‘ ë³´ì¡°ê¸ˆì´ 143ë‹¬ëŸ¬ì—ì„œ 200ë‹¬ëŸ¬ë¡œ ì˜ë¯¸ ìˆê²Œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ SG&A(íŒë§¤ê´€ë¦¬ë¹„)ë¥¼ ì¦ê°€ì‹œí‚¬ í•„ìš” ì—†ì´ ë³´í—˜ë£Œì™€ ì•½ì œë¹„ê°€ ìƒìŠ¹í•˜ëŠ” ê²ƒìœ¼ë¡œ ìƒê°í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì´ëŠ” ìˆ˜í•™ì ìœ¼ë¡œ ë” ë†’ì€ HBRì„ ìœ ë°œí•©ë‹ˆë‹¤.</td></tr>
<tr><td>That's factored into our initial 2% pretax margin forecast for PDP. You can see the other guidance elements, including stability in the SG&A rate, continued pay down of debt and associated impact on interest expense, reduced investment income from assumed Fed fund rate cuts an adjusted tax rate of 26% to 27%, slightly higher than a normal statutory rate given the mix and level of earnings forecasted for 2026. No share buyback reflected in guidance. We will continue to assess the field of capital deployment opportunities as we generate excess cash.</td><td>ì´ëŠ” PDPì˜ ì´ˆê¸° ì„¸ì „ì´ìµë¥  2% ì „ë§ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. íŒë§¤ê´€ë¦¬ë¹„ìœ¨ì˜ ì•ˆì •ì„±, ì§€ì†ì ì¸ ë¶€ì±„ ìƒí™˜ ë° ì´ìë¹„ìš©ì— ë¯¸ì¹˜ëŠ” ì˜í–¥, ì—°ì¤€ ê¸°ì¤€ê¸ˆë¦¬ ì¸í•˜ ê°€ì •ì— ë”°ë¥¸ íˆ¬ììˆ˜ìµ ê°ì†Œ, 2026ë…„ ì˜ˆìƒ ìˆ˜ìµ êµ¬ì„±ê³¼ ìˆ˜ì¤€ì„ ê³ ë ¤í•œ 26~27%ì˜ ì¡°ì • ì„¸ìœ¨(ì¼ë°˜ ë²•ì •ì„¸ìœ¨ë³´ë‹¤ ë‹¤ì†Œ ë†’ì€ ìˆ˜ì¤€) ë“± ê¸°íƒ€ ê°€ì´ë˜ìŠ¤ ìš”ì†Œë“¤ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ì—ëŠ” ìì‚¬ì£¼ ë§¤ì…ì´ ë°˜ì˜ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì´ˆê³¼ í˜„ê¸ˆì„ ì°½ì¶œí•¨ì— ë”°ë¼ ìë³¸ ë°°ë¶„ ê¸°íšŒ ë¶„ì•¼ë¥¼ ì§€ì†ì ìœ¼ë¡œ í‰ê°€í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>With respect to seasonality of earnings, as we sit here today, we expect the majority of 2026 adjusted EPS in Q1, stepping down in Q2 and further to around breakeven in Q3 with a loss in Q4. This is driven by the seasonality and benefit design of marketplace and PDP products, both with lower HBRs in the beginning of the year and higher at the end of the year. Our EPS outlook of greater than $3 reflects a meaningful forecasted turnaround of marketplace margins, Medicaid stabilization, continued Medicare Advantage progress, a prudent PDP margin assumption and lower interest expense from continued deleveraging.</td><td>ìˆ˜ìµì˜ ê³„ì ˆì„±ê³¼ ê´€ë ¨í•˜ì—¬, í˜„ì¬ ì‹œì ì—ì„œ 2026ë…„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS)ì˜ ëŒ€ë¶€ë¶„ì´ 1ë¶„ê¸°ì— ë°œìƒí•˜ê³ , 2ë¶„ê¸°ì— ê°ì†Œí•˜ë©°, 3ë¶„ê¸°ì—ëŠ” ì†ìµë¶„ê¸°ì  ìˆ˜ì¤€ìœ¼ë¡œ ë”ìš± í•˜ë½í•˜ê³  4ë¶„ê¸°ì—ëŠ” ì†ì‹¤ì´ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” ë§ˆì¼“í”Œë ˆì´ìŠ¤ì™€ PDP ìƒí’ˆì˜ ê³„ì ˆì„±ê³¼ ê¸‰ì—¬ ì„¤ê³„ì— ê¸°ì¸í•˜ëŠ”ë°, ë‘ ìƒí’ˆ ëª¨ë‘ ì—°ì´ˆì—ëŠ” ì˜ë£Œê¸‰ì—¬ë¹„ìœ¨(HBR)ì´ ë‚®ê³  ì—°ë§ì—ëŠ” ë†’ì•„ì§€ëŠ” íŠ¹ì„±ì´ ìˆìŠµë‹ˆë‹¤. 3ë‹¬ëŸ¬ ì´ìƒì˜ ì£¼ë‹¹ìˆœì´ìµ ì „ë§ì€ ë§ˆì¼“í”Œë ˆì´ìŠ¤ ë§ˆì§„ì˜ ì˜ë¯¸ ìˆëŠ” í„´ì–´ë¼ìš´ë“œ ì˜ˆìƒ, ë©”ë””ì¼€ì´ë“œ ì•ˆì •í™”, ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì˜ ì§€ì†ì ì¸ ê°œì„ , ì‹ ì¤‘í•œ PDP ë§ˆì§„ ê°€ì •, ê·¸ë¦¬ê³  ì§€ì†ì ì¸ ë¶€ì±„ ê°ì¶•ì„ í†µí•œ ì´ìë¹„ìš© ê°ì†Œë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>I'm sure you are too, but we are pleased to turn the page on 2025 with 2026 one step towards restoration of earnings for Centene. Thank you for your interest in Centene and Rocco, please open it up for questions.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ë„ ê·¸ëŸ¬ì‹œê² ì§€ë§Œ, ì €í¬ëŠ” 2025ë…„ì„ ë§ˆë¬´ë¦¬í•˜ê³  2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì´ëŠ” Centeneì˜ ì‹¤ì  íšŒë³µì„ í–¥í•œ í•œ ê±¸ìŒì…ë‹ˆë‹¤. Centeneì— ëŒ€í•œ ê´€ì‹¬ì— ê°ì‚¬ë“œë¦¬ë©°, Rocco, ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Centene Corporation Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼ ë° ê°€ì´ë˜ìŠ¤<br>- **2025ë…„ ì‹¤ì **: ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(EPS) $2.08, 4ë¶„ê¸° ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì†ì‹¤ $1.19 ê¸°ë¡. ë§¤ì¶œ $174.6B ë‹¬ì„±<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ì¡°ì • EPS $3 ì´ìƒ ì „ë§ìœ¼ë¡œ ì „ë…„ ëŒ€ë¹„ 40% ì´ìƒ ì„±ì¥ ì˜ˆìƒ. ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ $170B~$174B<br>- **ìˆ˜ìµì„± ê°œì„  ê²½ë¡œ**: ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ ì•ˆì •í™”, ë§ˆì¼“í”Œë ˆì´ìŠ¤ ì‚¬ì—… ëŒ€í­ íšŒë³µ, ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ 2027ë…„ ì†ìµë¶„ê¸° ëª©í‘œ ì§„í–‰ ì¤‘<br><br>## ì‚¬ì—…ë¶€ë¬¸ë³„ ì£¼ìš” ë™í–¥<br>- **ë©”ë””ì¼€ì´ë“œ**: 4ë¶„ê¸° HBR 93.0%ë¡œ 3ë¶„ê¸° ëŒ€ë¹„ 40bp ê°œì„ . 2026ë…„ ìˆœìš”ìœ¨ ì¸ìƒ mid-4% ë°˜ì˜í•˜ì—¬ HBR ì•ˆì •í™” ì „ë§. íšŒì›ìˆ˜ëŠ” 1,250ë§Œëª…ìœ¼ë¡œ ì†Œí­ ê°ì†Œ<br>- **ë§ˆì¼“í”Œë ˆì´ìŠ¤**: ê°•í™”ëœ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ(eAPTC) ì¢…ë£Œì—ë„ ë¶ˆêµ¬í•˜ê³  1ë¶„ê¸° ë§ íšŒì›ìˆ˜ 350ë§Œëª… ì˜ˆìƒ. 2026ë…„ ì˜ë¯¸ìˆëŠ” ì„¸ì „ ë§ˆì§„ í™•ëŒ€ ì „ë§. No Surprises Act ê´€ë ¨ ë¹„ìš© ì¦ê°€ë¡œ 4ë¶„ê¸° HBR 100bp ìƒìŠ¹<br>- **ë©”ë””ì¼€ì–´**: PDP ì‚¬ì—… ê°•ì„¸ ì§€ì†, íšŒì›ìˆ˜ 870ë§Œëª…. MA ì‚¬ì—…ì€ ì˜ë„ì  íšŒì›ìˆ˜ ê°ì†Œ</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] And today's first question comes from Ann Hynes at Mizuho.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì˜¤ëŠ˜ ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ë¯¸ì¦ˆí˜¸ì˜ Ann Hynesë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Ann Hynes: Mizuho Securities USA LLC, Research Division On your great expectation from Medicaid or 4.5%, I would think that would be higher just given trend has been so elevated over the past couple of years. Can you just give us more details what's happening on the state level and you view that as conservative? Would you be able to get the midyear rate increases? Any color would be great.</td><td>**Ann Hynes:** ë©”ë””ì¼€ì´ë“œì—ì„œ 4.5%ì˜ ê¸°ëŒ€ì¹˜ë¥¼ ë§ì”€í•˜ì…¨ëŠ”ë°, ì§€ë‚œ ëª‡ ë…„ê°„ ì¶”ì„¸ê°€ ìƒë‹¹íˆ ë†’ì•˜ë˜ ê²ƒì„ ê°ì•ˆí•˜ë©´ ë” ë†’ì„ ê²ƒìœ¼ë¡œ ìƒê°ë©ë‹ˆë‹¤. ì£¼ ì •ë¶€ ì°¨ì›ì—ì„œ ì–´ë–¤ ì¼ì´ ì¼ì–´ë‚˜ê³  ìˆëŠ”ì§€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì´ë¥¼ ë³´ìˆ˜ì ì¸ ì „ë§ìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ìš”? ì—°ì¤‘ ìš”ìœ¨ ì¸ìƒì„ ë°›ì„ ìˆ˜ ìˆì„ê¹Œìš”? ì–´ë–¤ ì„¤ëª…ì´ë“  ì¢‹ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Sure. Thanks, Ann, for the question. So a couple of things. One, as we said, throughout 2025, the conversation with our state partners continue to be constructive. I think we also have the benefit of the fact that as we step into this rate cycle we have a full 2 years of both the acuity dynamics and the step-up in trend encapsulated in the data. And so we think that is important and helpful to inform rate decisions. . So again, we're starting with a prudent assumption around that 4.5% for 2026. I would point to the fact that our 2025 rates matured favorably from where we started at the beginning of 2025 and ended with that composite rate at roughly 5.5%. And then balanced against that obviously is all of the work that we've done over the back half of '25 to really bend trend, which is what's driving the assumption of the flat HBR year-over-year.</td><td>**CEO & Director:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì €, ë§ì”€ë“œë¦° ëŒ€ë¡œ 2025ë…„ ë‚´ë‚´ ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ì˜ ë…¼ì˜ëŠ” ê±´ì„¤ì ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ë²ˆ ìš”ìœ¨ ì‚¬ì´í´ì— ì ‘ì–´ë“¤ë©´ì„œ ì¤‘ì¦ë„ ë³€í™”ì™€ ì¶”ì„¸ ìƒìŠ¹ ëª¨ë‘ë¥¼ í¬í•¨í•œ 2ë…„ ì „ì²´ ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ìˆë‹¤ëŠ” ì´ì ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš”ìœ¨ ê²°ì •ì— ìˆì–´ ì¤‘ìš”í•˜ê³  ìœ ìš©í•œ ì •ë³´ê°€ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, 2026ë…„ì— ëŒ€í•´ì„œëŠ” 4.5%ë¼ëŠ” ì‹ ì¤‘í•œ ê°€ì •ì—ì„œ ì¶œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ ìš”ìœ¨ì˜ ê²½ìš°, ì—°ì´ˆ ì‹œì‘ ì‹œì ë³´ë‹¤ ìš°í˜¸ì ìœ¼ë¡œ ì„±ìˆ™í•´ì ¸ì„œ ìµœì¢…ì ìœ¼ë¡œ ì•½ 5.5%ì˜ ì¢…í•© ìš”ìœ¨ë¡œ ë§ˆë¬´ë¦¬ë˜ì—ˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ ê· í˜•ì„ ë§ì¶”ëŠ” ê²ƒì€ 25ë…„ í•˜ë°˜ê¸°ì— ìš°ë¦¬ê°€ ì¶”ì„¸ë¥¼ ì „í™˜í•˜ê¸° ìœ„í•´ ì‹¤ì œë¡œ ìˆ˜í–‰í•œ ëª¨ë“  ì‘ì—…ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì „ë…„ ëŒ€ë¹„ HBR(ë³‘ì› ì…ì›ìœ¨) ë³´í•© ê°€ì •ì„ ë’·ë°›ì¹¨í•˜ëŠ” ìš”ì¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today come from Justin Lake with Wolfe Research.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Wolfe Researchì˜ Justin Lakeë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: I wanted to kind of follow up on Ann's question here. First, you talked about trend in 4.5% in 2026 for Medicaid. Curious what that trend was in 2025? And maybe you can help us understand first half versus second half, just to get the run rate kind of coming out of the year versus that 4.5% assumption next year. And then to Ann's question on the rates, your rates were 5.5% last year, your rates are 4.5% this year. I'm just curious how the states justify that, given when you have your conversations with them given what's going on in the market, what's going on with trend and acuity, et cetera? And maybe you could just tell us how 1/1 looks versus the 4.5% full year?</td><td>**Wolfe Research, LLC:** 2025ë…„ ë©”ë””ì¼€ì´ë“œ íŠ¸ë Œë“œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì—°ì´ˆì—ëŠ” ì•½ê°„ ë†’ê²Œ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ìƒë°˜ê¸°ì—ëŠ” 5% ì´ˆë°˜ëŒ€ì˜€ê³ , í•˜ë°˜ê¸°ë¡œ ê°€ë©´ì„œ 4%ëŒ€ ì¤‘ë°˜ìœ¼ë¡œ ë‚®ì•„ì§ˆ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì—°ë§ ëŸ°ë ˆì´íŠ¸(run rate)ëŠ” 2026ë…„ 4.5% ê°€ì •ì¹˜ì™€ ìƒë‹¹íˆ ê·¼ì ‘í•˜ê²Œ ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤.<br><br>ì£¼ì •ë¶€ë“¤ê³¼ì˜ ìš”ìœ¨ í˜‘ìƒ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì‘ë…„ 5.5%ì—ì„œ ì˜¬í•´ 4.5%ë¡œ ë‚®ì•„ì§„ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ”, ì£¼ì •ë¶€ ì…ì¥ì—ì„œëŠ” ì¬ë“±ë¡(redetermination) ê³¼ì •ì´ ë§ˆë¬´ë¦¬ë˜ë©´ì„œ íšŒì› ë¯¹ìŠ¤ê°€ ì•ˆì •í™”ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë§ì€ ì£¼ì—ì„œ íŒ¬ë°ë¯¹ ê¸°ê°„ ë™ì•ˆ ì¶•ì ëœ ì¬ì • ì—¬ë ¥ì„ í™œìš©í•˜ê³  ìˆê³ , ì „ë°˜ì ì¸ ì˜ë£Œë¹„ íŠ¸ë Œë“œê°€ ì˜ˆìƒë³´ë‹¤ ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆë‹¤ëŠ” ì ë„ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ë¬¼ë¡  ìš°ë¦¬ëŠ” ì‹œì¥ ìƒí™©, ì¤‘ì¦ë„(acuity) ë³€í™”, ì‹¤ì œ ë¹„ìš© íŠ¸ë Œë“œì— ëŒ€í•´ ì§€ì†ì ìœ¼ë¡œ ëŒ€í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì£¼ì •ë¶€ë“¤ë„ ì˜ˆì‚° ì œì•½ì´ ìˆê³ , ìš°ë¦¬ì˜ íš¨ìœ¨ì ì¸ ìš´ì˜ê³¼ ë„¤íŠ¸ì›Œí¬ ê´€ë¦¬ ëŠ¥ë ¥ì„ ì‹ ë¢°í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>1ì›” 1ì¼ ê¸°ì¤€ ìš”ìœ¨ì€ ì „ì²´ ì—°ê°„ 4.5%ì™€ ëŒ€ì²´ë¡œ ì¼ì¹˜í•˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì¼ë¶€ ì£¼ì—ì„œëŠ” ì—°ì¤‘ ì¡°ì •ì´ ìˆì„ ìˆ˜ ìˆì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œ ê· í˜•ì¡íŒ ì¶œë°œì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Sure. Lots of pieces there. So 1/1 rates were consistent with expectations. Let's go back to trend. So 2025 trend was in that mid-6s, which I think we talked about on the Q3 call. And then the view of 2026 around mid-4s is really a net trend assumption. And so again, important to think about the fact that we are jumping off of an elevated baseline that included that 94.9% in Q2. And all of the aggressive action that we took in the back half of the year, obviously, coming through Q4 with a 93.0%. So equally important is sort of the assumption around the proof points that we have in terms of bending trend in the back half of the year as well as bankable proof points around actions that we took in Q3 and Q4 that don't take effect until 2026. So that's part of what gives us a view of sort of that mid-4s net trend assumption. And then relative to rates, to your point, we ended the year with that composite of 5.5%. We started the year lower than that. So I believe that we've sort of taken a prudent view of rates in the mid-4s for 2026, and we'll continue to work with the [indiscernible] as we have all along to make sure that they have the most recent trend data. Again, we have the benefit of that sort of trailing 2 years now, which we've been working our way up to. And then also talking to states about places where in the absence of feeling like they can push rate, they can also make program changes. And we've called out a number of those. But if I just think about the back half of 2025, we have proof points around states carving out high-cost drugs. They have clipped ABA outlier providers who are overbilling. We've seen PBM control and formulary control, sort of shift further back to us around CCBHC. So lots of, I think, thoughtful program decisions that are sort of a proxy for addressing trend without having to do it explicitly through rate. So just net-net, we're obviously for a flat HBR year-over-year. And I will say, as I have said before, if that is all we deliver, I will be very disappointed, and I know the team will too.</td><td>**CEO & Director:** ë„¤, ì—¬ëŸ¬ ë¶€ë¶„ì´ ìˆë„¤ìš”. 1/1 ìš”ìœ¨ì€ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì¶”ì„¸ë¡œ ëŒì•„ê°€ë³´ê² ìŠµë‹ˆë‹¤. 2025ë…„ ì¶”ì„¸ëŠ” 6% ì¤‘ë°˜ëŒ€ì˜€ëŠ”ë°, ì´ëŠ” 3ë¶„ê¸° ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ë§ì”€ë“œë ¸ë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  2026ë…„ ì „ë§ì¸ 4% ì¤‘ë°˜ëŒ€ëŠ” ì‹¤ì œë¡œ ìˆœì¶”ì„¸(net trend) ê°€ì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ë†’ì€ ê¸°ì¤€ì„ ì—ì„œ ì¶œë°œí•˜ê³  ìˆë‹¤ëŠ” ì ì„ ìƒê°í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 2ë¶„ê¸°ì˜ 94.9%ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•˜ë°˜ê¸°ì— ìš°ë¦¬ê°€ ì·¨í•œ ëª¨ë“  ê³µê²©ì ì¸ ì¡°ì¹˜ë“¤ì´ ë¶„ëª…íˆ 4ë¶„ê¸°ì— 93.0%ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. <br><br>ë§ˆì°¬ê°€ì§€ë¡œ ì¤‘ìš”í•œ ê²ƒì€ í•˜ë°˜ê¸°ì— ì¶”ì„¸ë¥¼ êº¾ì€ ê²ƒì— ëŒ€í•œ ì¦ê±°ë“¤ê³¼ í•¨ê»˜, 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— ì·¨í•œ ì¡°ì¹˜ë“¤ ì¤‘ 2026ë…„ì—ì•¼ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚  í™•ì‹¤í•œ ì¦ê±°ë“¤ì— ëŒ€í•œ ê°€ì •ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ê°€ ì¤‘ë°˜ 4% ìˆ˜ì¤€ì˜ ìˆœ ì¶”ì„¸ ê°€ì •ì„ ê°–ê²Œ ëœ ë°°ê²½ì˜ ì¼ë¶€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš”ìœ¨ê³¼ ê´€ë ¨í•´ì„œëŠ”, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì €í¬ê°€ ì—°ë§ì— 5.5%ì˜ ë³µí•© ìš”ìœ¨ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ì—°ì´ˆì—ëŠ” ê·¸ë³´ë‹¤ ë‚®ì€ ìˆ˜ì¤€ì—ì„œ ì‹œì‘í–ˆê³ ìš”. ë”°ë¼ì„œ 2026ë…„ì— ëŒ€í•´ ì¤‘ë°˜ 4% ìˆ˜ì¤€ì˜ ìš”ìœ¨ ê´€ì ì„ ì·¨í•œ ê²ƒì€ ì‹ ì¤‘í•œ ì ‘ê·¼ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ê³„ì†í•´ì„œ ì£¼ ì •ë¶€ë“¤ê³¼ í˜‘ë ¥í•˜ì—¬ ê·¸ë“¤ì´ ê°€ì¥ ìµœì‹ ì˜ ì¶”ì„¸ ë°ì´í„°ë¥¼ í™•ë³´í•  ìˆ˜ ìˆë„ë¡ í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì €í¬ëŠ” ì´ì œ ì§€ë‚œ 2ë…„ê°„ì˜ ë°ì´í„°ë¼ëŠ” ì´ì ì„ ê°–ê²Œ ë˜ì—ˆê³ , ì´ë¥¼ í™œìš©í•´ ì™”ìŠµë‹ˆë‹¤. ë˜í•œ ì£¼ ì •ë¶€ë“¤ê³¼ ìš”ìœ¨ ì¸ìƒì´ ì–´ë µë‹¤ê³  íŒë‹¨ë˜ëŠ” ê²½ìš° í”„ë¡œê·¸ë¨ ë³€ê²½ì„ í†µí•´ì„œë„ ëŒ€ì‘í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì— ëŒ€í•´ ë…¼ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‚¬ë¡€ë“¤ì€ ì—¬ëŸ¬ ì°¨ë¡€ ì–¸ê¸‰í•œ ë°” ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2025ë…„ í•˜ë°˜ê¸°ë§Œ ë†“ê³  ë³´ë©´, ìš°ë¦¬ëŠ” ì—¬ëŸ¬ ì‹¤ì¦ ì‚¬ë¡€ë“¤ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ì •ë¶€ë“¤ì´ ê³ ë¹„ìš© ì˜ì•½í’ˆì„ ë³„ë„ë¡œ ë¶„ë¦¬í•˜ê³  ìˆê³ , ê³¼ë‹¤ì²­êµ¬ë¥¼ í•˜ëŠ” ABA ì´ìƒì¹˜ ê³µê¸‰ìë“¤ì„ ì œì¬í–ˆìŠµë‹ˆë‹¤. ë˜í•œ CCBHC ê´€ë ¨í•´ì„œ PBM í†µì œì™€ ì²˜ë°©ì§‘ í†µì œê°€ ë‹¤ì‹œ ìš°ë¦¬ ìª½ìœ¼ë¡œ ì´ì „ë˜ëŠ” ê²ƒë„ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. ì´ì²˜ëŸ¼ ìš”ìœ¨ì„ ëª…ì‹œì ìœ¼ë¡œ ì¡°ì •í•˜ì§€ ì•Šê³ ë„ ì¶”ì„¸ë¥¼ ê´€ë¦¬í•  ìˆ˜ ìˆëŠ” ì‚¬ë ¤ ê¹Šì€ í”„ë¡œê·¸ë¨ ê²°ì •ë“¤ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤. <br><br>ê²°ë¡ ì ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ë¶„ëª…íˆ ì „ë…„ ëŒ€ë¹„ HBR ë™ê²°ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ì „ì—ë„ ë§ì”€ë“œë ¸ë“¯ì´, ë§Œì•½ ê·¸ê²ƒì´ ìš°ë¦¬ê°€ ë‹¬ì„±í•˜ëŠ” ì „ë¶€ë¼ë©´ ì €ëŠ” ë§¤ìš° ì‹¤ë§í•  ê²ƒì´ê³ , íŒ€ë„ ë§ˆì°¬ê°€ì§€ì¼ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Kevin Fischbeck with BoA.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´(BoA)ì˜ ì¼€ë¹ˆ í”¼ì‰¬ë²¡ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Kevin Fischbeck: BofA Securities, Research Division Great. I guess moving to the exchanges. Can you talk a little bit about the confidence and the visibility? Obviously, the exchange members have changed dramatically. You gave a little bit of color there. But I guess in particular, you talked about the metal shift to your shifting. I kind of remember Bronze not being a great plan historically, and now it seems to be growing overall. So I just want to make sure that we're not going to be caught offsides by this metal tier shift that you're going to be seeing next year? And any other additional color you can give about why you feel comfortable in margin improvement on exchanges this year?</td><td>**Kevin Fischbeck:** ì¢‹ìŠµë‹ˆë‹¤. ìµìŠ¤ì²´ì¸ì§€ë¡œ ë„˜ì–´ê°€ì„œìš”. ì‹ ë¢°ë„ì™€ ê°€ì‹œì„±ì— ëŒ€í•´ ì¢€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë¶„ëª…íˆ ìµìŠ¤ì²´ì¸ì§€ ê°€ì…ì êµ¬ì„±ì´ ê·¹ì ìœ¼ë¡œ ë³€í™”í–ˆìŠµë‹ˆë‹¤. ê·¸ ë¶€ë¶„ì— ëŒ€í•´ ì•½ê°„ ì„¤ëª…ì„ í•´ì£¼ì…¨ëŠ”ë°ìš”. íŠ¹íˆ ë©”íƒˆ ë“±ê¸‰ ë³€í™”ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°, ì œ ê¸°ì–µìœ¼ë¡œëŠ” ë¸Œë¡ ì¦ˆê°€ ì—­ì‚¬ì ìœ¼ë¡œ ê·¸ë¦¬ ì¢‹ì€ í”Œëœì´ ì•„ë‹ˆì—ˆë˜ ê²ƒ ê°™ì€ë°, ì§€ê¸ˆì€ ì „ë°˜ì ìœ¼ë¡œ ì„±ì¥í•˜ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë‚´ë…„ì— ë‚˜íƒ€ë‚  ì´ ë©”íƒˆ ë“±ê¸‰ ë³€í™”ë¡œ ì¸í•´ ìš°ë¦¬ê°€ ì˜ˆìƒì¹˜ ëª»í•œ ìƒí™©ì— ì²˜í•˜ì§€ ì•Šì„ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ìµìŠ¤ì²´ì¸ì§€ ë§ˆì§„ ê°œì„ ì— ëŒ€í•´ í™•ì‹ í•˜ì‹œëŠ” ì´ìœ ì— ëŒ€í•´ ì¶”ê°€ë¡œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. Thanks, Kevin. So let's go all the way back to Q3 as we kind of read and reacted to the 2025 weekly data and a much improved visibility over the baseline morbidity that we would be carrying into 2026. And just incredible execution by the team, demonstrating agility and depth of expertise to reprice and reposition the entirety of the book in that short period of time. And taking into account, again, the baseline morbidity trend assumptions, the risk pool impacts of both 2025 and anticipated 2026 program integrity measures as well as the expiration of the enhanced APCs, all of which netted out to that mid-30% pricing increase for 2026. So part of the confidence comes from, I think, the work that we did and sort of the assumptions that we made coming into the year. Then as we stepped into open enrollment, really watching membership progress through kind of effectuation and down into paid membership where we sit here today in early February, we actually have a very good view of sort of that paid membership base. And given our history, a view of how that paid membership matures through the February, March time frame, where there's still a little bit of administrative opportunity and sort of grace period to get worked out, and that's where we get to that 3.5 million member estimate by the end of Q1. So I feel like standing here where we are today, I feel like we have pretty good visibility into how open enrollment played out and then the tail of that will continue to shake out. To your point, the distribution of metal tiers is different this year than in past years. So we're a little over 30% in Bronze, which is up from that 19% to 24% range we talked about in past years. We do see stability in core demographics around gender distribution and average age has not changed. And then to your question about how Bronze has operated historically, the Bronze products operated differently pre-eAPTCs than they did during the eAPTC period. And again, one of the benefits of having been in the market for as long as we have, is that we have all of that data, and we had all of that data back in Q3 when we went through and sort of re-underwrote all of our assumptions relative to 2026. We did that across metal tiers, and we're thoughtful about what the impact might be. And I think what you would see year-over-year is also sort of a reduction in the footprint where we are a low-cost Bronze player. So again, just trying to leverage not just the increased visibility that we had from the data, but just the depth of experience and data we have from sort of end-to-end the tenure of the program to give us a view of where we're sitting today. And also, I would just add, have the benefit of having set 2026 guidance with full visibility into how 2025 and the vast majority of open enrollment played out. So all of that goes into why we feel confident that we will be able to deliver meaningful margin improvement in this business in 2026.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Kevin. ê·¸ëŸ¼ 3ë¶„ê¸°ë¡œ ëŒì•„ê°€ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‹¹ì‹œ ì €í¬ëŠ” 2025ë…„ ì£¼ê°„ ë°ì´í„°ë¥¼ ê²€í† í•˜ê³  ë¶„ì„í•˜ë©´ì„œ 2026ë…„ìœ¼ë¡œ ì´ì–´ì§ˆ ê¸°ì € ìœ ë³‘ë¥ (baseline morbidity)ì— ëŒ€í•œ ê°€ì‹œì„±ì´ í¬ê²Œ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒ€ì´ ì •ë§ ë†€ë¼ìš´ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ì—ˆëŠ”ë°ìš”, ê·¸ ì§§ì€ ê¸°ê°„ ë™ì•ˆ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¬ê°€ê²©í•˜ê³  ì¬ë°°ì¹˜í•˜ëŠ” ë¯¼ì²©ì„±ê³¼ ì „ë¬¸ì„±ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. <br><br>ì´ ê³¼ì •ì—ì„œ ê¸°ì € ìœ ë³‘ë¥  ì¶”ì„¸ ê°€ì •, 2025ë…„ê³¼ 2026ë…„ ì˜ˆìƒë˜ëŠ” í”„ë¡œê·¸ë¨ ë¬´ê²°ì„± ì¡°ì¹˜ë“¤ì´ ìœ„í—˜ í’€(risk pool)ì— ë¯¸ì¹˜ëŠ” ì˜í–¥, ê·¸ë¦¬ê³  ê°•í™”ëœ APC ë§Œë£Œ ë“±ì„ ëª¨ë‘ ê³ ë ¤í–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•œ ê²°ê³¼ê°€ 2026ë…„ 30% ì¤‘ë°˜ëŒ€ì˜ ê°€ê²© ì¸ìƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ì €í¬ê°€ í™•ì‹ ì„ ê°–ëŠ” ì´ìœ  ì¤‘ ì¼ë¶€ëŠ” ì—°ì´ˆì— ì§„í–‰í–ˆë˜ ì‘ì—…ê³¼ ê·¸ë•Œ ì„¸ì› ë˜ ê°€ì •ë“¤ì—ì„œ ë¹„ë¡¯ëœë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤í”ˆ ë“±ë¡ ê¸°ê°„ì— ì ‘ì–´ë“¤ë©´ì„œ íšŒì› ìˆ˜ê°€ ì‹¤ì œ ê°€ì…ìœ¼ë¡œ ì´ì–´ì§€ê³  ìœ ë£Œ íšŒì›ìœ¼ë¡œ ì „í™˜ë˜ëŠ” ê³¼ì •ì„ ì§€ì¼œë´¤ëŠ”ë°ìš”, 2ì›” ì´ˆì¸ í˜„ì¬ ì‹œì ì—ì„œ ìœ ë£Œ íšŒì› ê¸°ë°˜ì— ëŒ€í•œ ë§¤ìš° ëª…í™•í•œ ê°€ì‹œì„±ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ê³¼ê±° ê²½í—˜ì„ ë°”íƒ•ìœ¼ë¡œ 2ì›”ê³¼ 3ì›”ì„ ê±°ì¹˜ë©´ì„œ ìœ ë£Œ íšŒì›ì´ ì–´ë–»ê²Œ ì„±ìˆ™í•´ ë‚˜ê°€ëŠ”ì§€ë„ íŒŒì•…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ê¸°ê°„ ë™ì•ˆì—ëŠ” ì•„ì§ ì•½ê°„ì˜ í–‰ì •ì ì¸ ì²˜ë¦¬ ê¸°íšŒì™€ ìœ ì˜ˆ ê¸°ê°„ì´ ë‚¨ì•„ìˆê±°ë“ ìš”. ì´ëŸ° ê³¼ì •ì„ ê±°ì³ì„œ 1ë¶„ê¸° ë§ê¹Œì§€ 350ë§Œ ëª…ì˜ íšŒì› ìˆ˜ ì¶”ì •ì¹˜ì— ë„ë‹¬í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ ì‹œì ì—ì„œ ë³´ë©´, ì˜¤í”ˆ ë“±ë¡ì´ ì–´ë–»ê²Œ ì§„í–‰ëëŠ”ì§€ì— ëŒ€í•´ ìƒë‹¹íˆ ëª…í™•í•˜ê²Œ íŒŒì•…í•˜ê³  ìˆë‹¤ê³  ìƒê°í•˜ê³ , ê·¸ ì´í›„ì˜ ì”ì—¬ íš¨ê³¼ë“¤ë„ ê³„ì†í•´ì„œ ì •ë¦¬ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ì˜¬í•´ ë©”íƒˆ í‹°ì–´(metal tier, ë³´í—˜ ë“±ê¸‰) ë¶„í¬ê°€ ê³¼ê±°ì™€ ë‹¤ë¦…ë‹ˆë‹¤. ë¸Œë¡ ì¦ˆ(Bronze) ë“±ê¸‰ì´ 30%ë¥¼ ì•½ê°„ ë„˜ëŠ”ë°, ê³¼ê±°ì— ë§ì”€ë“œë ¸ë˜ 19%ì—ì„œ 24% ë²”ìœ„ë³´ë‹¤ ì¦ê°€í•œ ê²ƒì…ë‹ˆë‹¤. ì„±ë³„ ë¶„í¬ ë“± í•µì‹¬ ì¸êµ¬í†µê³„í•™ì  ì§€í‘œëŠ” ì•ˆì •ì ì´ë©°, í‰ê·  ì—°ë ¹ë„ ë³€í™”ê°€ ì—†ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¸Œë¡ ì¦ˆ ìƒí’ˆì˜ ê³¼ê±° ìš´ì˜ ë°©ì‹ì— ëŒ€í•œ ì§ˆë¬¸ê³¼ ê´€ë ¨í•´ì„œëŠ”, ë¸Œë¡ ì¦ˆ ìƒí’ˆì€ eAPTC(ê°•í™”ëœ ì„ ë‚© ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ) ì´ì „ê³¼ eAPTC ê¸°ê°„ ë™ì•ˆ ë‹¤ë¥´ê²Œ ìš´ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì‹œì¥ì— ì˜¤ë«ë™ì•ˆ ì°¸ì—¬í•´ì˜¨ ê²ƒì˜ ì¥ì  ì¤‘ í•˜ë‚˜ëŠ” ì´ ëª¨ë“  ë°ì´í„°ë¥¼ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. 3ë¶„ê¸°ì— 2026ë…„ ê´€ë ¨ ê°€ì •ë“¤ì„ ì¬ê²€í† í•˜ê³  ì¬ì–¸ë”ë¼ì´íŒ…(re-underwrite)í•  ë•Œë„ ì´ ëª¨ë“  ë°ì´í„°ë¥¼ í™œìš©í–ˆìŠµë‹ˆë‹¤. ë©”íƒˆ í‹°ì–´ ì „ë°˜ì— ê±¸ì³ ì´ ì‘ì—…ì„ ìˆ˜í–‰í–ˆê³ , ì ì¬ì  ì˜í–¥ì— ëŒ€í•´ ì‹ ì¤‘í•˜ê²Œ ê²€í† í–ˆìŠµë‹ˆë‹¤. ì „ë…„ ëŒ€ë¹„ ì €ê°€ ë¸Œë¡ ì¦ˆ ìƒí’ˆ ì‹œì¥ì—ì„œì˜ ì…ì§€ê°€ ì¶•ì†Œë˜ëŠ” ëª¨ìŠµë„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ë°ì´í„°ë¥¼ í†µí•´ í™•ë³´í•œ ê°€ì‹œì„±ë¿ë§Œ ì•„ë‹ˆë¼ í”„ë¡œê·¸ë¨ ì „ì²´ ê¸°ê°„ì— ê±¸ì³ ì¶•ì í•œ ê²½í—˜ê³¼ ë°ì´í„°ì˜ ê¹Šì´ë¥¼ í™œìš©í•˜ì—¬ í˜„ì¬ ìš°ë¦¬ì˜ ìœ„ì¹˜ë¥¼ íŒŒì•…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë§ë¶™ì´ìë©´, 2025ë…„ ì‹¤ì ê³¼ ì˜¤í”ˆ ì¸ë¡¤ë¨¼íŠ¸(ê³µê°œ ê°€ì… ê¸°ê°„)ì˜ ëŒ€ë¶€ë¶„ì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ì—ˆëŠ”ì§€ ì™„ì „íˆ íŒŒì•…í•œ ìƒíƒœì—ì„œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì„¤ì •í–ˆë‹¤ëŠ” ì´ì ë„ ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ 2026ë…„ì— ì´ ì‚¬ì—…ì—ì„œ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„ ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today comes from Stephen Baxter of Wells Fargo.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ Wells Fargoì˜ Stephen Baxterë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Stephen Baxter: Wells Fargo Securities, LLC, Research Division I wanted to come back to the Medicaid moving pieces. I guess I'd just love a little bit better of a sense of maybe how much incremental decline in membership. I think the membership months were guided down 5% or 6%, but I think a good deal that would be explained by basically what you saw in 2025. And as you think about the acuity impact, to the extent that you continue to see disenrollment at pace closer to what you saw this past quarter, so down like 1.5%, does that place any weight on the acuity assumptions that you have during the guidance at this point in time?</td><td>**Stephen Baxter:** íšŒì› ìˆ˜ ê°œì›”(membership months)ì´ 5~6% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ìƒë‹¹ ë¶€ë¶„ì€ 2025ë…„ì— ì‹¤ì œë¡œ ë‚˜íƒ€ë‚œ ìˆ˜ì¹˜ë¡œ ì„¤ëª…ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¤‘ì¦ë„(acuity) ì˜í–¥ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ìë©´, ë§Œì•½ ì§€ë‚œ ë¶„ê¸°ì— ë³´ì…¨ë˜ ê²ƒì²˜ëŸ¼ ì•½ 1.5% ê°ì†Œí•˜ëŠ” ìˆ˜ì¤€ì— ê°€ê¹Œìš´ ì†ë„ë¡œ ë“±ë¡ í•´ì§€ê°€ ê³„ì†ëœë‹¤ë©´, í˜„ì¬ ì‹œì ì˜ ê°€ì´ë˜ìŠ¤ì— í¬í•¨ëœ ì¤‘ì¦ë„ ê°€ì •ì— ì–´ë–¤ ë¶€ë‹´ì„ ì£¼ëŠ” ê²ƒì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes, Stephen, I'll hit this at a high level and then ask Drew to add any color. So what we talked about member months, we talked about attrition in Q1. That -- there was an assumption for continued attrition consistent with what we've seen, for example, through 2025 in terms of states tightening the eligibility and normal reverification process coming out of COVID. And then we also have a couple of program changes that we know about, including, for example, the Florida CMS program rolling off 10/1 as well as sort of a probability-weighted bucket of member puts and takes that we track state-by-state. And I think if you were to unpack that, you would find that we're pretty prudent in our assumptions around membership there with an eye to what the additional acuity impact might be and all of that is sort of considered in guidance. But I don't know if there's any other additional pieces you want to call out?</td><td>**CEO & Director:** ë„¤, ë†’ì€ ìˆ˜ì¤€ì—ì„œ ë§ì”€ë“œë¦¬ê³  Drewê°€ ì¶”ê°€ ì„¤ëª…ì„ í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. íšŒì› ê°œì›”ìˆ˜(member months)ì™€ 1ë¶„ê¸° ì´íƒˆë¥ ì— ëŒ€í•´ ë§ì”€ë“œë ¸ëŠ”ë°ìš”. 2025ë…„ê¹Œì§€ ì €í¬ê°€ í™•ì¸í•œ ê²ƒê³¼ ì¼ê´€ë˜ê²Œ ì§€ì†ì ì¸ ì´íƒˆì´ ìˆì„ ê²ƒìœ¼ë¡œ ê°€ì •í–ˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ê° ì£¼ì—ì„œ ìê²© ìš”ê±´ì„ ê°•í™”í•˜ê³  ì½”ë¡œë‚˜ ì´í›„ ì •ìƒì ì¸ ì¬ê²€ì¦ ì ˆì°¨ë¥¼ ì§„í–‰í•˜ëŠ” ê²ƒ ê°™ì€ ìƒí™© ë§ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ì•Œê³  ìˆëŠ” ëª‡ ê°€ì§€ í”„ë¡œê·¸ë¨ ë³€ê²½ì‚¬í•­ë„ ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ í”Œë¡œë¦¬ë‹¤ CMS í”„ë¡œê·¸ë¨ì´ 10ì›” 1ì¼ìë¡œ ì¢…ë£Œë˜ëŠ” ê²ƒ, ê·¸ë¦¬ê³  ì£¼ë³„ë¡œ ì¶”ì í•˜ê³  ìˆëŠ” íšŒì› ì¦ê°ì— ëŒ€í•œ í™•ë¥  ê°€ì¤‘ í•­ëª©ë“¤ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ì‹œë©´, ì €í¬ê°€ íšŒì› ìˆ˜ ê°€ì •ì— ìˆì–´ ìƒë‹¹íˆ ì‹ ì¤‘í•œ ì ‘ê·¼ì„ ì·¨í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œ ìˆ˜ ìˆìœ¼ì‹¤ ê²ë‹ˆë‹¤. ì¶”ê°€ì ì¸ ì¤‘ì¦ë„ ì˜í–¥ì´ ì–´ë–»ê²Œ ë‚˜íƒ€ë‚ ì§€ë¥¼ ì—¼ë‘ì— ë‘ê³  ìˆìœ¼ë©°, ì´ ëª¨ë“  ê²ƒë“¤ì´ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ì¶”ê°€ë¡œ ì–¸ê¸‰í•˜ì‹¤ ë¶€ë¶„ì´ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Chief Financial Officer: Yes, right. You mentioned, Stephen, the 5% to 6% member months reduction through the year. The full year would be higher than that in terms of the membership attrition. And I think about it in 2 buckets, as Sarah indicated, one would be sort of a -- maybe a little over a point per quarter of continued attrition. And we saw that basically throughout 2025, and then the Children's Medical Services business that we expect to roll off 10/1 and then as Sarah mentioned, sort of a pool of other sort of RFP-related probability-weighted membership items. The only other thing to think about is there's very few impacts of OB3 in terms of membership in 2026, but one of those is I think, around 7/1 a subset of the New York essential plan will be rolling off due to sort of an OB3 provision. That's about 140,000 or so members for us. So that's also in the $88 billion midpoint of guidance, the 5% to 6% member months reduction and the -- a little bit higher than that full year absolute membership attrition.</td><td>**Chief Financial Officer:** ë„¤, ë§ìŠµë‹ˆë‹¤. Stephenì´ ì–¸ê¸‰í•˜ì‹  ì—°ì¤‘ 5~6%ì˜ íšŒì› ê°œì›”ìˆ˜(member months) ê°ì†Œ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” íšŒì› ì´íƒˆì´ ê·¸ë³´ë‹¤ ë” ë†’ì„ ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ Sarahê°€ ì„¤ëª…í•œ ëŒ€ë¡œ ë‘ ê°€ì§€ ë²”ì£¼ë¡œ ë‚˜ëˆ ì„œ ìƒê°í•´ë³¼ ìˆ˜ ìˆëŠ”ë°ìš”, ì²« ë²ˆì§¸ëŠ” ë¶„ê¸°ë‹¹ 1% ì •ë„ë¥¼ ì•½ê°„ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ì˜ ì§€ì†ì ì¸ ì´íƒˆì…ë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ë‚´ë‚´ ê¸°ë³¸ì ìœ¼ë¡œ ë‚˜íƒ€ë‚œ í˜„ìƒì´ê³ ìš”, ê·¸ ë‹¤ìŒìœ¼ë¡œ 10ì›” 1ì¼ì— ì¢…ë£Œë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì•„ë™ì˜ë£Œì„œë¹„ìŠ¤(Children's Medical Services) ì‚¬ì—…ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Sarahê°€ ì–¸ê¸‰í•œ ê²ƒì²˜ëŸ¼ ê¸°íƒ€ RFP ê´€ë ¨ í™•ë¥  ê°€ì¤‘ íšŒì› í•­ëª©ë“¤ì´ ìˆìŠµë‹ˆë‹¤. <br><br>í•œ ê°€ì§€ ë” ê³ ë ¤í•˜ì‹¤ ì ì€ 2026ë…„ì—ëŠ” OB3ê°€ íšŒì›ìˆ˜ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì´ ê±°ì˜ ì—†ë‹¤ëŠ” ê²ƒì¸ë°ìš”, ê·¸ ì¤‘ í•˜ë‚˜ê°€ 7ì›” 1ì¼ê²½ ë‰´ìš• í•„ìˆ˜ í”Œëœ(New York essential plan)ì˜ ì¼ë¶€ê°€ OB3 ì¡°í•­ìœ¼ë¡œ ì¸í•´ ì¢…ë£Œë  ì˜ˆì •ì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì €í¬ì—ê²ŒëŠ” ì•½ 14ë§Œ ëª… ì •ë„ì˜ íšŒì›ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì¸ 880ì–µ ë‹¬ëŸ¬ì—ëŠ” íšŒì› ê°œì›” ìˆ˜(member months) 5~6% ê°ì†Œì™€ ì—°ê°„ ì ˆëŒ€ íšŒì› ìˆ˜ ê°ì†Œê°€ ì´ë³´ë‹¤ ì•½ê°„ ë” ë†’ì€ ìˆ˜ì¤€ìœ¼ë¡œ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today comes from Sarah James of Cantor.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ Cantorì˜ Sarah Jamesë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Sarah James: Cantor Fitzgerald & Co., Research Division Can you help us understand the mechanics of the actuarial soundness look-back process? Like how far back are they looking now? How long of a lag does that typically take to come to an agreement on what trends actually were? And as we move forward into continued periods of disruption through work requirements or additional redeterminations. How are you thinking about being able to shorten that period or move forward to rate adjustments in a faster pace?</td><td>**Sarah James:** ë³´í—˜ìˆ˜ë¦¬ì  ê±´ì „ì„± í™˜ì‚°(actuarial soundness look-back) í”„ë¡œì„¸ìŠ¤ì˜ ë©”ì»¤ë‹ˆì¦˜ì„ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? í˜„ì¬ ì–¼ë§ˆë‚˜ ê³¼ê±°ë¡œ ì†Œê¸‰í•´ì„œ ê²€í† í•˜ê³  ìˆë‚˜ìš”? ì‹¤ì œ ì¶”ì„¸ê°€ ë¬´ì—‡ì´ì—ˆëŠ”ì§€ì— ëŒ€í•œ í•©ì˜ì— ë„ë‹¬í•˜ëŠ” ë° í†µìƒì ìœ¼ë¡œ ì–¼ë§ˆë‚˜ ì‹œì°¨ê°€ ë°œìƒí•˜ë‚˜ìš”? ê·¸ë¦¬ê³  ì—…ë¬´ ìš”ê±´ì´ë‚˜ ì¶”ê°€ì ì¸ ì¬ê²°ì •ì„ í†µí•´ ì§€ì†ì ì¸ í˜¼ë€ ê¸°ê°„ìœ¼ë¡œ ì ‘ì–´ë“¤ë©´ì„œ, ì´ ê¸°ê°„ì„ ë‹¨ì¶•í•˜ê±°ë‚˜ ë” ë¹ ë¥¸ ì†ë„ë¡œ ìš”ìœ¨ ì¡°ì •ì„ ì§„í–‰í•  ìˆ˜ ìˆëŠ” ë°©ì•ˆì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. Thanks, Sarah. It's a great question. The short answer is that we are very focused on trying to shorten the period and maximize the amount of sort of most recent data that's being included in the actuarial process, but this is not a new thing, right? That has really been what we have been working on since the back half of 2024 as we started to see that dislocation between rate and acuity from redetermination and then the step-up in trend that we saw in 2025. And so, as we've said, we continue to very proactively engage with the states. We're obviously not alone in doing that. So our peers are also part of that conversation. Bringing forward most recent data direct correlation to the program changes. If I take a step back, I think that perhaps the silver lining of what has been a bit of a painful process to watch these rates lag is the fact that we have now sort of proof points that you can actually have a significant forward-looking trend in ABA unlike anything the actuaries had ever seen before. We do have the proof points of states actually bringing forward more recent data and making in-year adjustments. Again, the Florida CMS contract in Q3 of last year is a great example of that. That was a very quick turnaround time between observed behavior and rate correction. And so all of those lessons learned, we carry into the work that we're going to want to do in 2026 to try to preempt the changes that may come in 2027 and 2028 and make sure that we have appropriate rates as we think about what the impact of work requirements are going to be. It's also why I keep pointing back to the fact that as time rolls forward, our need to push for that more recent data of being included is just happening organically. And so now those acuity shifts in '24, the rate -- sorry, the trend impact in '25 is now basically sitting in the middle of that 2-year look-back period, which is probably the more conservative look back period or standard starting point for the actuarial process. But it is -- it's a dynamic process. It's why it has been really important for us to build and continue to have really strong relationships with our states and to lean in and help them as they're going through that process by bringing forward very specific data. And then the last thing I would say is, just to go back to Justin's question is the idea that in the absence of rates and the states are thinking about what budget pressures they may be facing, it's also a great moment to talk about where there are program refinement opportunities that back into sort of a reasonable cost of care that doesn't just come through the rate. And so we're finding those conversations to be really productive and seeing again some of those bankable proof points in the back half of 2025 that we think will bear fruit in 2026.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Sarah. ì•„ì£¼ ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” ë³´í—˜ìˆ˜ë¦¬ í”„ë¡œì„¸ìŠ¤ì— í¬í•¨ë˜ëŠ” ìµœì‹  ë°ì´í„°ì˜ ì–‘ì„ ìµœëŒ€í™”í•˜ê³  ê·¸ ê¸°ê°„ì„ ë‹¨ì¶•í•˜ëŠ” ë° ë§¤ìš° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ê²ƒì´ ìƒˆë¡œìš´ ì¼ì€ ì•„ë‹™ë‹ˆë‹¤. ì‚¬ì‹¤ 2024ë…„ í•˜ë°˜ê¸°ë¶€í„° ì¬ê²°ì •(redetermination)ìœ¼ë¡œ ì¸í•œ ìš”ìœ¨ê³¼ ì¤‘ì¦ë„ ê°„ì˜ ê´´ë¦¬, ê·¸ë¦¬ê³  2025ë…„ì— ë‚˜íƒ€ë‚œ ì¶”ì„¸ì˜ ê¸‰ì¦ì„ ë³´ê¸° ì‹œì‘í•˜ë©´ì„œ ìš°ë¦¬ê°€ ê³„ì† ì§„í–‰í•´ì˜¨ ì‘ì—…ì…ë‹ˆë‹¤. <br><br>ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ê° ì£¼ì •ë¶€ì™€ ë§¤ìš° ì ê·¹ì ìœ¼ë¡œ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ìš°ë¦¬ë§Œ í•˜ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ë™ì¢…ì—…ê³„ íšŒì‚¬ë“¤ë„ ì´ëŸ¬í•œ ëŒ€í™”ì— í•¨ê»˜ ì°¸ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. í”„ë¡œê·¸ë¨ ë³€ê²½ì‚¬í•­ê³¼ ì§ì ‘ì ìœ¼ë¡œ ì—°ê´€ëœ ìµœì‹  ë°ì´í„°ë¥¼ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•œ ë°œì§ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, ì´ëŸ¬í•œ ìš”ìœ¨ ì§€ì—°ì„ ì§€ì¼œë³´ëŠ” ê²ƒì´ ë‹¤ì†Œ ê³ í†µìŠ¤ëŸ¬ìš´ ê³¼ì •ì´ì—ˆì§€ë§Œ, ê¸ì •ì ì¸ ì¸¡ë©´ë„ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë³´í—˜ê³„ë¦¬ì‚¬ë“¤ì´ ì´ì „ì— ë³¸ ì  ì—†ëŠ” ìˆ˜ì¤€ì˜ ABA ê´€ë ¨ ë¯¸ë˜ ì „ë§ íŠ¸ë Œë“œê°€ ì‹¤ì œë¡œ ì¡´ì¬í•  ìˆ˜ ìˆë‹¤ëŠ” ì¦ê±°ë¥¼ í™•ë³´í•˜ê²Œ ë˜ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì—¬ëŸ¬ ì£¼ì—ì„œ ìµœê·¼ ë°ì´í„°ë¥¼ ë°˜ì˜í•˜ì—¬ ì—°ì¤‘ ìš”ìœ¨ ì¡°ì •ì„ ì‹¤ì‹œí•œ ì‚¬ë¡€ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì‘ë…„ 3ë¶„ê¸° í”Œë¡œë¦¬ë‹¤ CMS ê³„ì•½ì´ ì¢‹ì€ ì˜ˆì…ë‹ˆë‹¤. ê´€ì°°ëœ í–‰íƒœ ë³€í™”ì™€ ìš”ìœ¨ ì¡°ì • ì‚¬ì´ì˜ ì†Œìš” ì‹œê°„ì´ ë§¤ìš° ì§§ì•˜ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë“  êµí›ˆë“¤ì„ ë°”íƒ•ìœ¼ë¡œ, 2027ë…„ê³¼ 2028ë…„ì— ë°œìƒí•  ìˆ˜ ìˆëŠ” ë³€í™”ë“¤ì„ ì„ ì œì ìœ¼ë¡œ ëŒ€ì‘í•˜ê¸° ìœ„í•´ 2026ë…„ì— ìˆ˜í–‰í•  ì‘ì—…ì— ë°˜ì˜í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¼ë¡œ ìš”ê±´(work requirements)ì˜ ì˜í–¥ì„ ê³ ë ¤í•  ë•Œ ì ì ˆí•œ ìš”ìœ¨ì„ í™•ë³´í•  ìˆ˜ ìˆë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ë˜í•œ ì œê°€ ê³„ì† ê°•ì¡°í•˜ëŠ” ë¶€ë¶„ì´ ë°”ë¡œ ì´ê²ƒì¸ë°, ì‹œê°„ì´ íë¥´ë©´ì„œ ë” ìµœê·¼ ë°ì´í„°ë¥¼ í¬í•¨ì‹œì¼œì•¼ í•œë‹¤ëŠ” ìš°ë¦¬ì˜ ìš”êµ¬ê°€ ìì—°ìŠ¤ëŸ½ê²Œ ì‹¤í˜„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ì œ 2024ë…„ì˜ ì¤‘ì¦ë„ ë³€í™”ì™€ 2025ë…„ì˜ ì¶”ì„¸ ì˜í–¥ì´ ê¸°ë³¸ì ìœ¼ë¡œ 2ë…„ í›„í–¥ ê¸°ê°„(2-year look-back period)ì˜ ì¤‘ê°„ì— ìœ„ì¹˜í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë³´í—˜ê³„ë¦¬ í”„ë¡œì„¸ìŠ¤ì˜ í‘œì¤€ ì¶œë°œì ìœ¼ë¡œì„œëŠ” ì•„ë§ˆë„ ë” ë³´ìˆ˜ì ì¸ í›„í–¥ ê¸°ê°„ì¼ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ê²ƒì€ ì—­ë™ì ì¸ í”„ë¡œì„¸ìŠ¤ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ ì£¼ì •ë¶€ë“¤ê³¼ ì •ë§ ê²¬ê³ í•œ ê´€ê³„ë¥¼ êµ¬ì¶•í•˜ê³  ì§€ì†ì ìœ¼ë¡œ ìœ ì§€í•˜ëŠ” ê²ƒì´ ë§¤ìš° ì¤‘ìš”í–ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì´ ì´ëŸ¬í•œ ê³¼ì •ì„ ê±°ì¹˜ëŠ” ë™ì•ˆ ë§¤ìš° êµ¬ì²´ì ì¸ ë°ì´í„°ë¥¼ ì œì‹œí•˜ë©° ì ê·¹ì ìœ¼ë¡œ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ Justinì˜ ì§ˆë¬¸ìœ¼ë¡œ ëŒì•„ê°€ì„œ ë§ì”€ë“œë¦¬ìë©´, ìˆ˜ê°€ ì¸ìƒì´ ì—†ëŠ” ìƒí™©ì—ì„œ ì£¼ì •ë¶€ë“¤ì´ ì˜ˆì‚° ì••ë°•ì„ ê³ ë¯¼í•˜ê³  ìˆì„ ë•Œ, ì´ê²ƒì´ ì˜¤íˆë ¤ í”„ë¡œê·¸ë¨ ê°œì„  ê¸°íšŒì— ëŒ€í•´ ë…¼ì˜í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ì‹œì ì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¨ìˆœíˆ ìˆ˜ê°€ë¥¼ í†µí•´ì„œë§Œì´ ì•„ë‹ˆë¼ í•©ë¦¬ì ì¸ ì˜ë£Œë¹„ìš© ìˆ˜ì¤€ìœ¼ë¡œ ì´ì–´ì§€ëŠ” ê°œì„  ë°©ì•ˆë“¤ ë§ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ëŒ€í™”ë“¤ì´ ì •ë§ ìƒì‚°ì ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, 2025ë…„ í•˜ë°˜ê¸°ì— êµ¬ì²´ì ì¸ ì„±ê³¼ë“¤ì´ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆê³ , ì´ê²ƒì´ 2026ë…„ì— ê²°ì‹¤ì„ ë§ºì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question today comes from Josh Raskin of Nephron.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Nephronì˜ Josh Raskinë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nephron Research LLC: Could you just give a little more specifics on your actual segment margins that are implied in the 2026 guidance? And then maybe remind us what your long-term margin targets are by segment in case anything has changed there. And should I be reading into no PDR in Medicare Advantage, meaning that you may be closer to breakeven in 2026, a little ahead of 2027.</td><td>**Nephron Research LLC:** 2026 ê°€ì´ë˜ìŠ¤ì— ë‚´í¬ëœ ì‹¤ì œ ë¶€ë¬¸ë³„ ë§ˆì§„ì— ëŒ€í•´ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ë¶€ë¬¸ë³„ ì¥ê¸° ë§ˆì§„ ëª©í‘œì¹˜ë„ ë‹¤ì‹œ í•œë²ˆ ìƒê¸°ì‹œì¼œ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. í˜¹ì‹œ ë³€ê²½ëœ ì‚¬í•­ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage)ì—ì„œ PDRì´ ì—†ë‹¤ëŠ” ê²ƒì€ 2027ë…„ë³´ë‹¤ ì¡°ê¸ˆ ì•ë‹¹ê²¨ì ¸ 2026ë…„ì— ì†ìµë¶„ê¸°ì ì— ê°€ê¹Œì›Œì§ˆ ìˆ˜ ìˆë‹¤ëŠ” ì˜ë¯¸ë¡œ í•´ì„í•´ë„ ë ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Yes. So I think, obviously, a lot of stuff has changed across the business. So it's probably premature to talk about long-term margin targets for each business while policy is still shaking out. But the bottom line there is certainly that we do see prior margin improvement in all lines of business and meaningful margin improvement across the enterprise over the next couple of years. But let me turn it over to Drew to walk through the specific margin assumptions by line of business in 2026 guidance and then talk through the PDR.</td><td>**CEO & Director:** ë„¤, ë§ì”€ë“œë¦¬ìë©´ ì‚¬ì—… ì „ë°˜ì— ê±¸ì³ ë§ì€ ë³€í™”ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì •ì±…ì´ ì•„ì§ í™•ì •ë˜ì§€ ì•Šì€ ìƒí™©ì—ì„œ ê° ì‚¬ì—…ë¶€ì˜ ì¥ê¸° ë§ˆì§„ ëª©í‘œë¥¼ ë…¼í•˜ê¸°ì—ëŠ” ì‹œê¸°ìƒì¡°ë¼ê³  ë´…ë‹ˆë‹¤. í•˜ì§€ë§Œ í•µì‹¬ì€ ëª¨ë“  ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ë§ˆì§„ ê°œì„ ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, í–¥í›„ ëª‡ ë…„ê°„ ì „ì‚¬ì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„ ì´ ìˆì„ ê²ƒìœ¼ë¡œ í™•ì‹ í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ëŸ¼ Drewì—ê²Œ ë„˜ê²¨ì„œ 2026ë…„ ê°€ì´ë˜ìŠ¤ì˜ ì‚¬ì—…ë¶€ë³„ êµ¬ì²´ì ì¸ ë§ˆì§„ ê°€ì •ê³¼ PDRì— ëŒ€í•´ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes, sure. I'd express Medicaid margins in terms of a stable HBR year-over-year. The commercial segment, which is largely marketplace, we were at minus one last year. You could do the math on the HBR guidance slide and get to something around 4% pretax for 2026 in marketplace. And then the Medicare segment, as I said in my remarks, PDP around 2% would be our target. We think that's a prudent starting place relative to well into the 3s for 2025. And then Medicare Advantage within that segment, not quite a breakeven yet, but you're right to recognize no PDR in 2026 means that on the margin, it's not losing money, but there are things that aren't incorporated in the accounting of the PDR such that it's still operating at a slight loss on a fully allocated basis for 2026.</td><td>**Chief Financial Officer:** ë„¤, ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ì€ ì „ë…„ ëŒ€ë¹„ ì•ˆì •ì ì¸ HBRë¡œ í‘œí˜„í•˜ê² ìŠµë‹ˆë‹¤. ìƒì—… ë¶€ë¬¸ì€ ì£¼ë¡œ ë§ˆì¼“í”Œë ˆì´ìŠ¤ì¸ë°, ì‘ë…„ì— ë§ˆì´ë„ˆìŠ¤ 1%ì˜€ìŠµë‹ˆë‹¤. HBR ê°€ì´ë˜ìŠ¤ ìŠ¬ë¼ì´ë“œì—ì„œ ê³„ì‚°í•´ë³´ì‹œë©´ 2026ë…„ ë§ˆì¼“í”Œë ˆì´ìŠ¤ì˜ ì„¸ì „ ë§ˆì§„ì´ ì•½ 4% ì •ë„ ë‚˜ì˜¬ ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë©”ë””ì¼€ì–´ ë¶€ë¬¸ì€ ì œê°€ ë°œì–¸ì—ì„œ ë§ì”€ë“œë ¸ë“¯ì´, PDPëŠ” ì•½ 2%ê°€ ëª©í‘œì…ë‹ˆë‹¤. 2025ë…„ì— 3%ëŒ€ ì¤‘ë°˜ì´ì—ˆë˜ ê²ƒê³¼ ë¹„êµí•˜ë©´ ì‹ ì¤‘í•œ ì¶œë°œì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ ë‹¤ìŒ í•´ë‹¹ ë¶€ë¬¸ ë‚´ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ëŠ” ì•„ì§ ì™„ì „í•œ ì†ìµë¶„ê¸°ì ì€ ì•„ë‹ˆì§€ë§Œ, ë§ì”€í•˜ì‹  ëŒ€ë¡œ 2026ë…„ì— PDRì´ ì—†ë‹¤ëŠ” ê²ƒì€ ë§ˆì§„ ì¸¡ë©´ì—ì„œ ì†ì‹¤ì´ ë°œìƒí•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ë‹¤ë§Œ PDR íšŒê³„ì²˜ë¦¬ì— í¬í•¨ë˜ì§€ ì•ŠëŠ” í•­ëª©ë“¤ì´ ìˆì–´ì„œ, 2026ë…„ ê¸°ì¤€ìœ¼ë¡œ ì™„ì „ë°°ë¶„ ë°©ì‹ìœ¼ë¡œ ë³´ë©´ ì—¬ì „íˆ ì•½ê°„ì˜ ì†ì‹¤ì„ ë‚´ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from A.J. Rice at UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ A.J. Riceë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Rice: UBS Investment Bank, Research Division We still are trying and I still get this question a lot, maybe an unfair one to ask you guys, but I'll do it anyway. If you look at your national peers in Medicaid, 2 are still forecasting pretty significant drops in margin in '26 versus '25. One, who was more optimistic has now sort of come in line with you with their comments today. And we all struggle to think about how can the company see such a different outlook. Do you think geographic footprint explains the difference? Or is there anything else there? And specifically, in your case, I wanted to ask about the PBM contract because you haven't said a lot about it. But your vendor, your PBM partner has said that they have renegotiated your contract among a couple of other big ones and that it's a drag to them this year, presumably you're on the receiving end of that and benefiting. And I wondered if that might be accounting for some of the difference or maybe that's helping you in other business lines, but any comment on that as well would be helpful.</td><td>**Albert Rice:** ë©”ë””ì¼€ì´ë“œ ë¶€ë¬¸ì—ì„œ ì €í¬ ì „êµ­ ë‹¨ìœ„ ê²½ìŸì‚¬ 2ê³³ì€ ì—¬ì „íˆ '26ë…„ ë§ˆì§„ì´ '25ë…„ ëŒ€ë¹„ ìƒë‹¹íˆ í•˜ë½í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¢€ ë” ë‚™ê´€ì ì´ì—ˆë˜ í•œ ê³³ì€ ì˜¤ëŠ˜ ë°œí‘œì—ì„œ ì €í¬ì™€ ë¹„ìŠ·í•œ ì…ì¥ìœ¼ë¡œ ì„ íšŒí–ˆê³ ìš”. ê·¸ëŸ°ë° ê° íšŒì‚¬ë“¤ì´ ì™œ ì´ë ‡ê²Œ ë‹¤ë¥¸ ì „ë§ì„ ë‚´ë†“ëŠ”ì§€ ì´í•´í•˜ê¸°ê°€ ì‰½ì§€ ì•ŠìŠµë‹ˆë‹¤. ì§€ì—­ì  ì‚¬ì—… ë²”ìœ„ê°€ ì´ëŸ° ì°¨ì´ë¥¼ ì„¤ëª…í•  ìˆ˜ ìˆì„ê¹Œìš”? ì•„ë‹ˆë©´ ë‹¤ë¥¸ ìš”ì¸ì´ ìˆì„ê¹Œìš”? íŠ¹íˆ ê·€ì‚¬ì˜ ê²½ìš°, PBM ê³„ì•½ì— ëŒ€í•´ ë§ì€ ë§ì”€ì„ ì•ˆ í•˜ì…¨ëŠ”ë° ì´ ë¶€ë¶„ë„ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·€ì‚¬ì˜ ë²¤ë”, ì¦‰ PBM íŒŒíŠ¸ë„ˆì‚¬ê°€ ê·€ì‚¬ë¥¼ í¬í•¨í•œ ëª‡ëª‡ ëŒ€í˜• ê³„ì•½ë“¤ì„ ì¬í˜‘ìƒí–ˆê³  ì˜¬í•´ ê·¸ë“¤ì—ê²ŒëŠ” ë¶€ë‹´ì´ ëœë‹¤ê³  ë°í˜”ìŠµë‹ˆë‹¤. ì•„ë§ˆë„ ê·€ì‚¬ëŠ” ê·¸ ë°˜ëŒ€í¸ì—ì„œ í˜œíƒì„ ë°›ê³  ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì‹¤ì  ì°¨ì´ì˜ ì¼ë¶€ë¥¼ ì„¤ëª…í•˜ëŠ” ê²ƒì¸ì§€, ì•„ë‹ˆë©´ ë‹¤ë¥¸ ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ë„ì›€ì´ ë˜ê³  ìˆëŠ” ê²ƒì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì½”ë©˜íŠ¸ ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. Thanks, A.J. So let me hit Medicaid, and then I'll turn it over to Drew to talk about our bespoke contract with our PBM partner. So sort of going all the way back to where we're starting, which I think is really important. So again, it's important to remember that we are jumping off an elevated baseline. So as you think about trying to foot relativity with peers, just absolute, we are jumping off that elevated baseline in 2025 that included a 94.9% in Q2. We also have, again, proof point sort of rates that matured favorably as we -- in 2025. So that's an important thing to think about relative to that mid-4s rate assumption. And then we have aggressive execution through the back half of the year that played out with that sequential improvement in HBR in Q3 and in Q4, getting to that 93.0% as the jump off as we step into 2026. And so that momentum I think, is really important. And the fact that we laid out sort of the key levers that we were going after and again, executed on those really well in Q3 and Q4, but also took action and influence decisions in Q3 and Q4 aren't effective, for example, until 1/1/26. And so just as a reminder, right, in some of those proof points, rate, obviously, an important one. The favorable maturation of the 2025 composite, the fact that 1/1 came in line with our expectation, the fact that we saw in year rate correction like Florida, the second biggest lever is network. And again, you heard me talk about the ABA example, but really making sure that we focus our network on the highest performing, highest quality providers. The introduction of clinical management programs hitting transitions of care and member engagement program reform. I, talked about a bunch of those ongoing provider engagement, payment integrity and really addressing opportunities where that we're seeing pressure on coding from providers. And then again, a more aggressive stance in fraud, waste and abuse. And you heard us talk about a provider that we termed in New York back in Q3 around ABA, but really leveraging that suspect list to go after bad actors. So a lot of proof points that did actually hit the P&L in the back half to 25% and are teed up for 2026. So that's where I think our view is that we've taken a prudent assumption around rates that the net trend assumption of 4.5% in 2026 takes into account sort of the work that we've done relative to trend vendors and being able to see additional those actions bear additional fruit in 2026. And I will say it again because I will just keep saying it, both internally and externally. If all we do is deliver a 93.7% in Medicaid, I will be very disappointed. But with that, I will let Drew talk about our PBM relationship.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid)ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , ê·¸ ë‹¤ìŒ PBM íŒŒíŠ¸ë„ˆì™€ì˜ ë§ì¶¤í˜• ê³„ì•½ì— ëŒ€í•´ì„œëŠ” Drewì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì²˜ìŒë¶€í„° ì‹œì‘í•´ë³´ë©´, ì´ ë¶€ë¶„ì´ ì •ë§ ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ë†’ì€ ê¸°ì¤€ì„ ì—ì„œ ì¶œë°œí•˜ê³  ìˆë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ë™ì¢…ì—…ì²´ë“¤ê³¼ ìƒëŒ€ì  ë¹„êµë¥¼ í•˜ì‹¤ ë•Œ, ì ˆëŒ€ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” 2025ë…„ì— 2ë¶„ê¸° 94.9%ë¥¼ í¬í•¨í•œ ë†’ì€ ê¸°ì¤€ì„ ì—ì„œ ì¶œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ 2025ë…„ì— ìš”ìœ¨ì´ ìœ ë¦¬í•˜ê²Œ ì„±ìˆ™í–ˆë‹¤ëŠ” ì¦ê±°ë„ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ 4% ì¤‘ë°˜ëŒ€ ìš”ìœ¨ ê°€ì •ê³¼ ê´€ë ¨í•˜ì—¬ ê³ ë ¤í•´ì•¼ í•  ì¤‘ìš”í•œ ì‚¬í•­ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•˜ë°˜ê¸°ì— ê³µê²©ì ì¸ ì‹¤í–‰ì„ í†µí•´ 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— HBRì´ ìˆœì°¨ì ìœ¼ë¡œ ê°œì„ ë˜ì—ˆê³ , 2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ëŠ” ì‹œì ì— 93.0%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë©˜í…€ì´ ì •ë§ ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì§‘ì¤‘í–ˆë˜ í•µì‹¬ ë ˆë²„ë“¤ì„ ëª…í™•íˆ ì œì‹œí–ˆê³ , 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— ì‹¤ì œë¡œ ì´ë¥¼ ë§¤ìš° ì˜ ì‹¤í–‰í–ˆìŠµë‹ˆë‹¤. ë˜í•œ 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— ì·¨í•œ ì¡°ì¹˜ë“¤ê³¼ ì˜í–¥ì„ ë¯¸ì¹œ ì˜ì‚¬ê²°ì •ë“¤ì€ ì˜ˆë¥¼ ë“¤ì–´ 2026ë…„ 1ì›” 1ì¼ê¹Œì§€ëŠ” íš¨ë ¥ì´ ë°œìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. <br><br>ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ë©´, ì´ëŸ¬í•œ ì¦ê±°ë“¤ ì¤‘ì—ì„œ ìš”ìœ¨(rate)ì´ ëª…ë°±íˆ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. 2025ë…„ ì¢…í•© í¬íŠ¸í´ë¦¬ì˜¤ì˜ ìœ ë¦¬í•œ ì„±ìˆ™í™”, 1ì›” 1ì¼ ì‹¤ì ì´ ìš°ë¦¬ ì˜ˆìƒì— ë¶€í•©í–ˆë‹¤ëŠ” ì , í”Œë¡œë¦¬ë‹¤ì™€ ê°™ì€ ì—°ì¤‘ ìš”ìœ¨ ì¡°ì •ì„ í™•ì¸í–ˆë‹¤ëŠ” ì ì´ ìˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ í° ë ˆë²„ëŠ” ë„¤íŠ¸ì›Œí¬ì…ë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ABA ì‚¬ë¡€ë„ ê·¸ë ‡ê³ , ì‹¤ì œë¡œ ìš°ë¦¬ ë„¤íŠ¸ì›Œí¬ë¥¼ ìµœê³  ì„±ê³¼, ìµœê³  í’ˆì§ˆì˜ ì˜ë£Œ ê³µê¸‰ìë“¤ì—ê²Œ ì§‘ì¤‘ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ì„ìƒ ê´€ë¦¬ í”„ë¡œê·¸ë¨ ë„ì…ì„ í†µí•´ ì§„ë£Œ ì „í™˜ ì‹œì ì„ ê´€ë¦¬í•˜ê³ , íšŒì› ì°¸ì—¬ í”„ë¡œê·¸ë¨ì„ ê°œì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ì†ì ì¸ ì˜ë£Œ ê³µê¸‰ì ì°¸ì—¬, ì§€ë¶ˆ ë¬´ê²°ì„±(payment integrity), ê·¸ë¦¬ê³  ì˜ë£Œ ê³µê¸‰ìë“¤ì˜ ì½”ë”© ì••ë°•ì—ì„œ ë°œìƒí•˜ëŠ” ê¸°íšŒë“¤ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ë‹¤ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‚¬ê¸°, ë‚­ë¹„, ë‚¨ìš©ì— ëŒ€í•´ ë”ìš± ì ê·¹ì ì¸ ì…ì¥ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ë‰´ìš•ì—ì„œ ABA ê´€ë ¨ìœ¼ë¡œ ê³„ì•½ì„ í•´ì§€í•œ ì˜ë£Œ ê³µê¸‰ì ê±´ì„ ë§ì”€ë“œë ¸ëŠ”ë°, ì‹¤ì œë¡œ ì˜ì‹¬ ëª©ë¡ì„ í™œìš©í•´ì„œ ì•…ì˜ì  í–‰ìœ„ìë“¤ì„ ì ë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ë§ì€ ì‹¤ì¦ ì‚¬ë¡€ë“¤ì´ ì‹¤ì œë¡œ 2025ë…„ í•˜ë°˜ê¸° ì†ìµê³„ì‚°ì„œì— ë°˜ì˜ë˜ì—ˆê³ , 2026ë…„ì„ ìœ„í•œ ì¤€ë¹„ë„ ì™„ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ê¸ˆë¦¬ì— ëŒ€í•´ ì‹ ì¤‘í•œ ê°€ì •ì„ ì ìš©í–ˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, 2026ë…„ ìˆœ ì¶”ì„¸ ê°€ì •ì¹˜ 4.5%ëŠ” íŠ¸ë Œë“œ ë²¤ë”ë“¤ê³¼ ê´€ë ¨ëœ ì‘ì—…ê³¼ 2026ë…„ì— ì¶”ê°€ì ì¸ ì„±ê³¼ë¥¼ ê±°ë‘˜ ìˆ˜ ìˆëŠ” ì¡°ì¹˜ë“¤ì„ ê³ ë ¤í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‚´ë¶€ì ìœ¼ë¡œë“  ì™¸ë¶€ì ìœ¼ë¡œë“  ê³„ì† ê°•ì¡°í•˜ê² ìŠµë‹ˆë‹¤ë§Œ, ë§Œì•½ ë©”ë””ì¼€ì´ë“œì—ì„œ 93.7%ë§Œ ë‹¬ì„±í•œë‹¤ë©´ ì €ëŠ” ë§¤ìš° ì‹¤ë§í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Drewê°€ PBM ê´€ê³„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes, A.J., thanks for the question. Over the last, really, decade plus, we've had a tailored transparent and flexible contract with like our current PBM, even our predecessor PBM. So we had those provisions before they were cool and before they were legislatively dictated. I think we benefit by having $60 billion of pharmacy spend and not owning our own PBM. In other words, every ounce of the economic benefit of that PBM arrangement and how we collaborate with our partner to go to the market together, whether it's pharma or network or other decisioning around formulary benefit plan designs we've got immense flexibility in how we work with our partner. And that goes into the cost structure of our products and our margin targets. So all of that is captured in our insurance risk business in our 3 segments and pleased with what we talked about last quarter in terms of the continued collaboration with our partner, and we will continue to fight for affordability in health care including other parts of the ecosystem that have margins, including what I saw on CNBC the other day, boasting about a 40% margin in his pharma business. So we will continue to drive affordability on behalf of our low-income and medically complex members, alongside with our PBM partner.</td><td>**Chief Financial Officer:** ë„¤, A.J., ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì§€ë‚œ 10ë…„ ì´ìƒ ë™ì•ˆ ì €í¬ëŠ” í˜„ì¬ PBMì€ ë¬¼ë¡  ì´ì „ PBMê³¼ë„ ë§ì¶¤í˜•ì´ê³  íˆ¬ëª…í•˜ë©° ìœ ì—°í•œ ê³„ì•½ì„ ì²´ê²°í•´ì™”ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°í•­ë“¤ì´ ìœ í–‰í•˜ê¸° ì „ì—, ê·¸ë¦¬ê³  ë²•ì ìœ¼ë¡œ ì˜ë¬´í™”ë˜ê¸° ì „ë¶€í„° ì´ë¯¸ ê°–ì¶”ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” 600ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì•½ì œë¹„ ì§€ì¶œì„ ë³´ìœ í•˜ë©´ì„œë„ ìì²´ PBMì„ ì†Œìœ í•˜ì§€ ì•ŠìŒìœ¼ë¡œì¨ ì´ì ì„ ì–»ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë‹¤ì‹œ ë§í•´, PBM ê³„ì•½ì—ì„œ ë°œìƒí•˜ëŠ” ëª¨ë“  ê²½ì œì  ì´ìµê³¼ íŒŒíŠ¸ë„ˆì™€ì˜ í˜‘ë ¥ì„ í†µí•´ ì œì•½ì‚¬ë“  ë„¤íŠ¸ì›Œí¬ë“  ë˜ëŠ” ì²˜ë°©ì§‘(formulary) ë° ê¸‰ì—¬ í”Œëœ ì„¤ê³„ì™€ ê´€ë ¨ëœ ê¸°íƒ€ ì˜ì‚¬ê²°ì •ì´ë“  í•¨ê»˜ ì‹œì¥ì— ë‚˜ê°ˆ ë•Œ, ì €í¬ëŠ” íŒŒíŠ¸ë„ˆì™€ í˜‘ë ¥í•˜ëŠ” ë°©ì‹ì— ìˆì–´ ì—„ì²­ë‚œ ìœ ì—°ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ ì œí’ˆì˜ ë¹„ìš© êµ¬ì¡°ì™€ ë§ˆì§„ ëª©í‘œì—ë„ ë°˜ì˜ë©ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì´ ìš°ë¦¬ì˜ 3ê°œ ë¶€ë¬¸ ë³´í—˜ ë¦¬ìŠ¤í¬ ì‚¬ì—…ì— ë°˜ì˜ë˜ì–´ ìˆìœ¼ë©°, ì§€ë‚œ ë¶„ê¸°ì— ë§ì”€ë“œë¦° íŒŒíŠ¸ë„ˆì‚¬ì™€ì˜ ì§€ì†ì ì¸ í˜‘ë ¥ì— ëŒ€í•´ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì˜ë£Œ ìƒíƒœê³„ì˜ ë‹¤ë¥¸ ë¶€ë¬¸ë“¤, íŠ¹íˆ ë§ˆì§„ì´ ìˆëŠ” ì˜ì—­ë“¤ì„ í¬í•¨í•˜ì—¬ ì˜ë£Œë¹„ ì ì •í™”ë¥¼ ìœ„í•´ ê³„ì† ë…¸ë ¥í•  ê²ƒì…ë‹ˆë‹¤. ë©°ì¹  ì „ CNBCì—ì„œ ì œì•½ ì‚¬ì—…ì˜ 40% ë§ˆì§„ì„ ìë‘í•˜ëŠ” ê²ƒì„ ë´¤ëŠ”ë°, ì´ëŸ° ë¶€ë¶„ë“¤ë„ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” PBM íŒŒíŠ¸ë„ˆì™€ í•¨ê»˜ ì €ì†Œë“ì¸µ ë° ì˜í•™ì ìœ¼ë¡œ ë³µì¡í•œ ìƒíƒœì˜ íšŒì›ë“¤ì„ ìœ„í•´ ê³„ì†í•´ì„œ ì˜ë£Œë¹„ ì ì •í™”ë¥¼ ì¶”ì§„í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Scott Fidel with Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ìŠ¤ì½§ í”¼ë¸ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Fidel: Goldman Sachs Group, Inc., Research Division Help if you maybe just sort of drill in a little bit more into Part D. And walk us through the book in terms of some of the dynamics through around the LIS versus the non-LIS populations and what you're seeing in the market trends. Obviously, your book of business is heavily weighted towards the LIS. And in particular, just some of the underlying inputs like risk scores and economics in terms of the LIS business post IRA versus the non-LIS. And then how you position the business to grow and be profitable, clearly through '25 and expect to continue to do that in '26?</td><td>**Scott Fidel:** íŒŒíŠ¸ Dì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? LIS ëŒ€ë¹„ ë¹„LIS ê°€ì…ì ì§‘ë‹¨ê³¼ ê´€ë ¨ëœ ì—­í•™ ê´€ê³„, ê·¸ë¦¬ê³  ì‹œì¥ ë™í–¥ì—ì„œ ì–´ë–¤ ì ë“¤ì„ ë³´ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë¶„ëª…íˆ ê·€ì‚¬ì˜ ì‚¬ì—… í¬íŠ¸í´ë¦¬ì˜¤ëŠ” LIS ìª½ì— í¬ê²Œ ì¹˜ì¤‘ë˜ì–´ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ IRA ì´í›„ LIS ì‚¬ì—…ì˜ ìœ„í—˜ì ìˆ˜(risk scores)ì™€ ìˆ˜ìµì„± ê°™ì€ ê¸°ë³¸ ìš”ì†Œë“¤ì„ ë¹„LISì™€ ë¹„êµí•´ì„œ ì„¤ëª…í•´ ì£¼ì‹œê³ ìš”. ê·¸ë¦¬ê³  25ë…„ê¹Œì§€ ì„±ì¥í•˜ê³  ìˆ˜ìµì„±ì„ ìœ ì§€í•˜ê¸° ìœ„í•´, ê·¸ë¦¬ê³  26ë…„ì—ë„ ì´ë¥¼ ì§€ì†í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ë°, ì‚¬ì—…ì„ ì–´ë–»ê²Œ í¬ì§€ì…”ë‹í•˜ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes, really good question and questions, especially around the impact of the IRA in '25, which they were shifting sands. So the good news in '25 is the industry we had that expanded or more protective risk corridor that then reverted in '26 back to the statutory risk corridor that's been in place since the inception of the Part D program. But that gave us some, let's say, breathing room in terms of navigating pretty severe non-low-income specialty trend when the maximum amount of pocket dropped to $2,000. And so we got through that, executed really well. That's in the rearview mirror. And now we and the rest of the industry had that data going into the bids in the summer of '25 as we set them for 2026 with eyes wide open in terms of the impact of the IRA on that non-low-income population that was availing themselves of a much lower maximum amount of pocket. So we can look at our January data. And you're right, we're growing. The revenue growth is largely driven by that yield increase because the direct subsidy increase. But we're still growing membership from about $8.1 million to around $8.7 million across both the low-income population or the auto assigns and the non-low income population. So I feel pretty good about the mix of business we got. We like both populations. You can have earnings on both populations and provide a really great value proposition for the senior giving them access to a great drug program. So that in conjunction with the answer to the last question in terms of cost structure is an important leg of the stool, the underwriting acumen, you're having great actuaries to support and business teams to support that product, which is now a $26 billion product for us with a good margin as well. So we're pretty pleased with that business, our positioning. And maybe most importantly, what we're able to do for seniors to have an affordable product in the open market.</td><td>**Chief Financial Officer:** ì •ë§ ì¢‹ì€ ì§ˆë¬¸ì´ê³ , íŠ¹íˆ 25ë…„ë„ IRA(ì¸í”Œë ˆì´ì…˜ ê°ì¶•ë²•) ì˜í–¥ì— ëŒ€í•œ ì§ˆë¬¸ë“¤ì´ ë§ìœ¼ì…¨ëŠ”ë°, ìƒí™©ì´ ê³„ì† ë³€í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. 25ë…„ë„ì˜ ì¢‹ì€ ì†Œì‹ì€ ì—…ê³„ ì „ì²´ì ìœ¼ë¡œ í™•ëŒ€ë˜ê±°ë‚˜ ë” ë³´í˜¸ì ì¸ ë¦¬ìŠ¤í¬ ì½”ë¦¬ë”(risk corridor, ìœ„í—˜ ë¶„ë‹´ ì œë„)ê°€ ì ìš©ë˜ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” 26ë…„ë„ì— íŒŒíŠ¸D í”„ë¡œê·¸ë¨ ì‹œì‘ ì´í›„ ê³„ì† ì ìš©ë˜ì–´ ì˜¨ ë²•ì • ë¦¬ìŠ¤í¬ ì½”ë¦¬ë”ë¡œ ë‹¤ì‹œ ë³µê·€í•˜ê²Œ ë©ë‹ˆë‹¤. <br><br>ì´ëŸ¬í•œ ì¡°ì¹˜ ë•ë¶„ì— ë³¸ì¸ë¶€ë‹´ê¸ˆ ìƒí•œì•¡ì´ 2,000ë‹¬ëŸ¬ë¡œ í•˜ë½í–ˆì„ ë•Œ ë°œìƒí•œ ìƒë‹¹íˆ ì‹¬ê°í•œ ë¹„ì €ì†Œë“ì¸µ ì „ë¬¸ì˜ì•½í’ˆ íŠ¸ë Œë“œë¥¼ í—¤ì³ë‚˜ê°€ëŠ” ë° ìˆì–´ ì–´ëŠ ì •ë„ ì—¬ìœ  ê³µê°„ì„ í™•ë³´í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¥¼ ì˜ ê·¹ë³µí–ˆê³  ì •ë§ í›Œë¥­í•˜ê²Œ ì‹¤í–‰í–ˆìŠµë‹ˆë‹¤. ì´ì œ ê·¸ ë¶€ë¶„ì€ ì§€ë‚˜ê°„ ì¼ì…ë‹ˆë‹¤. ì´ì œ ì €í¬ì™€ ì—…ê³„ ì „ì²´ê°€ 2025ë…„ ì—¬ë¦„ ì…ì°° ì‹œì ì— í•´ë‹¹ ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ìˆì—ˆê³ , 2026ë…„ ì…ì°°ê°€ë¥¼ ì„¤ì •í•  ë•Œ IRAê°€ ì €ì†Œë“ì¸µì´ ì•„ë‹Œ ì¸êµ¬ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì„ ëª…í™•íˆ ì¸ì‹í•˜ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ í›¨ì”¬ ë‚®ì€ ë³¸ì¸ë¶€ë‹´ê¸ˆ ìƒí•œì•¡ì„ í™œìš©í•˜ê³  ìˆì—ˆì£ . <br><br>1ì›” ë°ì´í„°ë¥¼ ë³´ì‹œë©´, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì €í¬ê°€ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ì¶œ ì„±ì¥ì€ ì£¼ë¡œ ì§ì ‘ ë³´ì¡°ê¸ˆ ì¦ê°€ë¡œ ì¸í•œ ìˆ˜ìµë¥  ìƒìŠ¹ì— ê¸°ì¸í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ íšŒì› ìˆ˜ë„ ì—¬ì „íˆ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €ì†Œë“ì¸µì´ë‚˜ ìë™ ë°°ì • ëŒ€ìƒì, ê·¸ë¦¬ê³  ë¹„ì €ì†Œë“ì¸µ ì¸êµ¬ ëª¨ë‘ë¥¼ í•©ì³ ì•½ 810ë§Œ ëª…ì—ì„œ 870ë§Œ ëª… ìˆ˜ì¤€ìœ¼ë¡œ ëŠ˜ì–´ë‚¬ìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ ì €í¬ê°€ í™•ë³´í•œ ì‚¬ì—… êµ¬ì„±ì— ëŒ€í•´ ìƒë‹¹íˆ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ì¸êµ¬ ì§‘ë‹¨ ëª¨ë‘ ë§¤ë ¥ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë‘ ì§‘ë‹¨ ëª¨ë‘ì—ì„œ ìˆ˜ìµì„ ì°½ì¶œí•  ìˆ˜ ìˆìœ¼ë©°, ì‹œë‹ˆì–´ë“¤ì—ê²Œ í›Œë¥­í•œ ì•½í’ˆ í”„ë¡œê·¸ë¨ì„ ì œê³µí•¨ìœ¼ë¡œì¨ ì •ë§ ë›°ì–´ë‚œ ê°€ì¹˜ ì œì•ˆì„ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•ì„  ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ì—ì„œ ë§ì”€ë“œë¦° ë¹„ìš© êµ¬ì¡°ì™€ í•¨ê»˜ ì¤‘ìš”í•œ ì¶•ì„ ì´ë£¨ê³  ìˆìœ¼ë©°, ì–¸ë”ë¼ì´íŒ… ì—­ëŸ‰, ê·¸ë¦¬ê³  ì´ ìƒí’ˆì„ ë’·ë°›ì¹¨í•˜ëŠ” ìš°ìˆ˜í•œ ë³´í—˜ê³„ë¦¬ì‚¬ë“¤ê³¼ ì‚¬ì—…íŒ€ë“¤ì´ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì´ ìƒí’ˆì€ ìš°ë¦¬ì—ê²Œ 260ì–µ ë‹¬ëŸ¬ ê·œëª¨ì´ë©° ì–‘í˜¸í•œ ë§ˆì§„ë„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ ì‚¬ì—…ê³¼ ìš°ë¦¬ì˜ í¬ì§€ì…”ë‹ì— ìƒë‹¹íˆ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆë„ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€, ì‹œë‹ˆì–´ë“¤ì´ ê³µê°œ ì‹œì¥ì—ì„œ í•©ë¦¬ì ì¸ ê°€ê²©ì˜ ìƒí’ˆì„ ì´ìš©í•  ìˆ˜ ìˆë„ë¡ ìš°ë¦¬ê°€ í•  ìˆ˜ ìˆëŠ” ì¼ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today comes from Lance Wilkes with Bernstein.</td><td>**Operator:** ì˜¤ëŠ˜ ë‹¤ìŒ ì§ˆë¬¸ì€ ë²ˆìŠ¤íƒ€ì¸ì˜ ëœìŠ¤ ìœŒí¬ìŠ¤ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lance Wilkes: Bernstein Institutional Services LLC, Research Division I want to talk a little on Medicaid. And if you could, could you walk through Medicaid trends kind of '25 contrast with '26 in a couple of different ways because there's so many different moving elements. I was interested in your views as to how much risk shift had impacted '25. And if you saw any continued impacts in '26 with that, and whether you're seeing any impacts, either negative or positive from states making benefit design changes? And then I'm kind of assuming that the remainder would be sort of core trend. And so then in core trend, you could kind of describe what's your experience with categories in inpatient, outpatient and/or units and cost inflation? And maybe as a tag on to that, if you could just talk a little bit about what you're seeing as far as competitive dynamics in states given the margin pressures in Medicaid. Are you seeing any issues with small plans not being able to fulfill obligations or any lack of folks stepping back up to try to renew contracts?</td><td>**Lance Wilkes:** ë©”ë””ì¼€ì´ë“œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 25ë…„ê³¼ 26ë…„ì˜ ë©”ë””ì¼€ì´ë“œ ì¶”ì„¸ë¥¼ ì—¬ëŸ¬ ì¸¡ë©´ì—ì„œ ì„¤ëª…í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì›€ì§ì´ëŠ” ìš”ì†Œë“¤ì´ ì •ë§ ë§ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ë¨¼ì € ë¦¬ìŠ¤í¬ ì‹œí”„íŠ¸(risk shift)ê°€ 25ë…„ì— ì–¼ë§ˆë‚˜ ì˜í–¥ì„ ë¯¸ì³¤ëŠ”ì§€ì— ëŒ€í•œ ì €í¬ ê²¬í•´ë¥¼ ë§ì”€ë“œë¦¬ê³ , 26ë…„ì—ë„ ê·¸ ì˜í–¥ì´ ì§€ì†ë˜ëŠ”ì§€ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê° ì£¼ì •ë¶€ì˜ ê¸‰ì—¬ ì„¤ê³„ ë³€ê²½ìœ¼ë¡œ ì¸í•œ ê¸ì •ì ì´ê±°ë‚˜ ë¶€ì •ì ì¸ ì˜í–¥ì´ ìˆëŠ”ì§€ë„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë‚˜ë¨¸ì§€ ë¶€ë¶„ì€ ê¸°ë³¸ì ìœ¼ë¡œ í•µì‹¬ ì¶”ì„¸(core trend)ë¼ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. í•µì‹¬ ì¶”ì„¸ ì¸¡ë©´ì—ì„œëŠ” ì…ì›, ì™¸ë˜ ì§„ë£Œ ë¶€ë¬¸ì˜ ê²½í—˜ê³¼ ì´ìš©ëŸ‰, ê·¸ë¦¬ê³  ë¹„ìš© ì¸í”Œë ˆì´ì…˜ì— ëŒ€í•´ ì„¤ëª…ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œì˜ ë§ˆì§„ ì••ë°•ì„ ê³ ë ¤í•  ë•Œ ì£¼ ì •ë¶€ ì°¨ì›ì—ì„œ ê²½ìŸ êµ¬ë„ê°€ ì–´ë–»ê²Œ ì „ê°œë˜ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì†Œê·œëª¨ ë³´í—˜ì‚¬ë“¤ì´ ì˜ë¬´ ì´í–‰ì— ì–´ë ¤ì›€ì„ ê²ªê±°ë‚˜, ê³„ì•½ ê°±ì‹ ì— ì¬ì°¸ì—¬í•˜ë ¤ëŠ” ì—…ì²´ë“¤ì´ ì¤„ì–´ë“œëŠ” ìƒí™©ì´ ë°œìƒí•˜ê³  ìˆìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>CEO & Director: Yes. Thanks, Lance. I'll hit that at a high level and have Drew chime in as well. So as we said, we did continue to see sort of a low level of continued membership attrition through 2025 as states were getting tighter with their eligibility criteria, which I think naturally put some on trend. Relative to core trends, the drivers are really consistent with what we called out throughout Q2 and rolling forward in terms of behavioral health, home health and high-cost drugs. Those do not materially shift over the course of the last 3 quarters of the year with behavioral health really driving sort of 50% of that excess trend, ABA being sort of a primary underpinning of that, home health and home and community-based services being another and then those high-cost drugs. Relative to impact, those -- particularly those excess trend areas were kind of how we chalk the field in terms of organizing and looking to mitigate that trend. And so lots of proof points in the back half of 2025 in terms of actually being able to intervene and help sort of moderate that trend, which is what contributed at least in part to ending the year at 93.0%. So again, feel good where we stand today in terms of having really solid visibility into the various forms of trends that are influencing the business and being organized around the levers that impact them. Relative to competitive dynamics, we are seeing that continued rate pressure is having an impact on different markets and certainly some of the smaller nonprofit plans. And frankly, that is an important input into states thinking about making sure that they're funding the program sufficiently so that they have a competitive marketplace and that members have the quality of services that they want and they deserve. And I think over time, it's something that we would watch relative to potential membership growth if competitors choose to exit any of those geographies.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Lance. ì œê°€ ì „ë°˜ì ì¸ ë‚´ìš©ì„ ë§ì”€ë“œë¦¬ê³  Drewê°€ ë³´ì¶©í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, 2025ë…„ì—ë„ ë‚®ì€ ìˆ˜ì¤€ì˜ íšŒì› ì´íƒˆì´ ì§€ì†ë˜ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ê° ì£¼ì •ë¶€ê°€ ìê²© ê¸°ì¤€ì„ ê°•í™”í•˜ë©´ì„œ ìì—°ìŠ¤ëŸ½ê²Œ ì¼ë¶€ ì¶”ì„¸ê°€ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. í•µì‹¬ ì¶”ì„¸ì™€ ê´€ë ¨í•´ì„œëŠ”, 2ë¶„ê¸° ë‚´ë‚´ ê·¸ë¦¬ê³  ì•ìœ¼ë¡œë„ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì–¸ê¸‰í–ˆë˜ ìš”ì¸ë“¤ê³¼ ì¼ê´€ë˜ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ë°”ë¡œ í–‰ë™ ê±´ê°•(behavioral health), ì¬ê°€ ê±´ê°•(home health), ê·¸ë¦¬ê³  ê³ ê°€ ì˜ì•½í’ˆì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì€ ì˜¬í•´ ë‚¨ì€ 3ê°œ ë¶„ê¸° ë™ì•ˆ í¬ê²Œ ë³€ë™í•˜ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ë³´ì´ë©°, í–‰ë™ ê±´ê°•ì´ ì´ˆê³¼ ì¶”ì„¸ì˜ ì•½ 50%ë¥¼ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì¤‘ì—ì„œë„ ì‘ìš©í–‰ë™ë¶„ì„(ABA)ì´ ì£¼ìš” ê¸°ë°˜ì´ ë˜ê³  ìˆê³ , ì¬ê°€ ê±´ê°• ë° ì§€ì—­ì‚¬íšŒ ê¸°ë°˜ ì„œë¹„ìŠ¤ê°€ ë˜ ë‹¤ë¥¸ ìš”ì¸ì´ë©°, ê·¸ ë‹¤ìŒì´ ê³ ê°€ ì˜ì•½í’ˆì…ë‹ˆë‹¤. ì˜í–¥ê³¼ ê´€ë ¨í•´ì„œëŠ” íŠ¹íˆ ì´ˆê³¼ ì¶”ì„¸ ì˜ì—­ë“¤ì´ ìš°ë¦¬ê°€ ì´ë¥¼ ì™„í™”í•˜ê¸° ìœ„í•´ ì¡°ì§í™”í•˜ê³  ëŒ€ì‘í•˜ëŠ” ë°©ì‹ì˜ ê¸°ì¤€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. 2025ë…„ í•˜ë°˜ê¸°ì—ëŠ” ì‹¤ì œë¡œ ê°œì…í•˜ì—¬ ê·¸ ì¶”ì„¸ë¥¼ ì™„í™”í•  ìˆ˜ ìˆì—ˆë‹¤ëŠ” ë§ì€ ì¦ê±°ë“¤ì´ ìˆì—ˆê³ , ì´ê²ƒì´ ìµœì†Œí•œ ë¶€ë¶„ì ìœ¼ë¡œëŠ” ì—°ë§ 93.0%ë¼ëŠ” ìˆ˜ì¹˜ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ìš°ë¦¬ëŠ” ì‚¬ì—…ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ë‹¤ì–‘í•œ í˜•íƒœì˜ ì¶”ì„¸ë“¤ì— ëŒ€í•´ ë§¤ìš° í™•ì‹¤í•œ ê°€ì‹œì„±ì„ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ì´ì— ì˜í–¥ì„ ì£¼ëŠ” ë ˆë²„ë“¤ì„ ì¤‘ì‹¬ìœ¼ë¡œ ì¡°ì§í™”ë˜ì–´ ìˆë‹¤ëŠ” ì ì—ì„œ ì¢‹ì€ ìœ„ì¹˜ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê²½ìŸ ì—­í•™ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì§€ì†ì ì¸ ìš”ìœ¨ ì••ë°•ì´ ì—¬ëŸ¬ ì‹œì¥ë“¤ê³¼ íŠ¹íˆ ì¼ë¶€ ì†Œê·œëª¨ ë¹„ì˜ë¦¬ í”Œëœë“¤ì— ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì´ëŠ” ê° ì£¼ ì •ë¶€ê°€ í”„ë¡œê·¸ë¨ì— ì¶©ë¶„í•œ ì¬ì›ì„ í™•ë³´í•˜ì—¬ ê²½ìŸë ¥ ìˆëŠ” ì‹œì¥ì„ ìœ ì§€í•˜ê³ , íšŒì›ë“¤ì´ ì›í•˜ê³  ë§ˆë•…íˆ ë°›ì•„ì•¼ í•  ì–‘ì§ˆì˜ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë° ìˆì–´ ì¤‘ìš”í•œ íŒë‹¨ ê·¼ê±°ê°€ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ê²½ìŸì‚¬ë“¤ì´ í•´ë‹¹ ì§€ì—­ì—ì„œ ì² ìˆ˜í•˜ê¸°ë¡œ ê²°ì •í•  ê²½ìš°, ì´ëŠ” ì ì¬ì ì¸ íšŒì› ì¦ê°€ì™€ ê´€ë ¨í•˜ì—¬ ì €í¬ê°€ ì£¼ì‹œí•´ì•¼ í•  ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Just 2 quick things to add to that. Interesting facts relative to your question, Lance. In patient looks good in Medicaid. And then if you isolate our TANF population, the continuous TANF population, which is like 5 million members. So it's a statistically valid cohort. And you set aside behavioral health, that trend looks fine, looks normal like it would historically. So that enables us to sort of 0 in on, as Sarah said, both those areas that we started talking about and recognizing in Q2 of '25 as well as policy and product and benefit changes with our state partners to really 0 in on what we need to do to pull those levers.</td><td>**Chief Financial Officer:** ë‘ ê°€ì§€ë§Œ ë¹ ë¥´ê²Œ ë§ë¶™ì´ê² ìŠµë‹ˆë‹¤. ì§ˆë¬¸ê³¼ ê´€ë ¨í•´ì„œ í¥ë¯¸ë¡œìš´ ì‚¬ì‹¤ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œì—ì„œ ì…ì›í™˜ì ë¶€ë¬¸ì€ ì–‘í˜¸í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  TANF ì¸êµ¬ì§‘ë‹¨, ì•½ 500ë§Œ ëª…ì˜ íšŒì›ìœ¼ë¡œ êµ¬ì„±ëœ ì§€ì†ì ì¸ TANF ì¸êµ¬ì§‘ë‹¨ì„ ë¶„ë¦¬í•´ì„œ ë³´ë©´, í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ì½”í˜¸íŠ¸ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ í–‰ë™ê±´ê°•(behavioral health)ì„ ì œì™¸í•˜ë©´, íŠ¸ë Œë“œê°€ ì–‘í˜¸í•˜ê³  ê³¼ê±° ìˆ˜ì¤€ì²˜ëŸ¼ ì •ìƒì ìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 25ë…„ 2ë¶„ê¸°ë¶€í„° ë…¼ì˜í•˜ê³  ì¸ì‹í•˜ê¸° ì‹œì‘í–ˆë˜ ì˜ì—­ë“¤ê³¼, ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ì˜ ì •ì±…, ìƒí’ˆ, ê¸‰ì—¬ ë³€ê²½ì‚¬í•­ë“¤ì— ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìš°ë¦¬ê°€ ì–´ë–¤ ë ˆë²„ë¥¼ ë‹¹ê²¨ì•¼ í•˜ëŠ”ì§€ ì •í™•íˆ íŒŒì•…í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question comes from Andrew Mok at Barclays.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë°”í´ë ˆì´ì¦ˆì˜ ì•¤ë“œë¥˜ ëª© ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Mok: Barclays Bank PLC, Research Division When I look at the segment MLR components embedded in guidance, the ACA improvement and Medicaid stability looked consistent with prior commentary, but the guide seems to imply incremental pressure within Medicare Advantage beyond the PDP reset. So first, is that correct? And second, can you help us understand the sources of that pressure and what that means for your target to achieve breakeven in 2027?</td><td>**Andrew Mok:** <response><br><br>ê°€ì´ë˜ìŠ¤ì— í¬í•¨ëœ ì„¸ê·¸ë¨¼íŠ¸ë³„ MLR êµ¬ì„± ìš”ì†Œë¥¼ ë³´ë©´, ACA ê°œì„ ê³¼ ë©”ë””ì¼€ì´ë“œ ì•ˆì •ì„±ì€ ì´ì „ ì½”ë©˜í„°ë¦¬ì™€ ì¼ê´€ë˜ì–´ ë³´ì´ëŠ”ë°, ê°€ì´ë˜ìŠ¤ê°€ PDP ë¦¬ì…‹ì„ ë„˜ì–´ì„œ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage) ë‚´ì—ì„œ ì¶”ê°€ì ì¸ ì••ë°•ì„ ì‹œì‚¬í•˜ëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì²«ì§¸, ì´ê²Œ ë§ëŠ”ì§€ìš”? ë‘˜ì§¸, ê·¸ ì••ë°•ì˜ ì›ì¸ì´ ë¬´ì—‡ì¸ì§€, ê·¸ë¦¬ê³  ì´ê²ƒì´ 2027ë…„ ì†ìµë¶„ê¸°ì  ë‹¬ì„± ëª©í‘œì— ì–´ë–¤ ì˜ë¯¸ì¸ì§€ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br></response></td></tr>
<tr><td>Chief Financial Officer: Yes. I think you'd have to understand bifurcating under Medicare. We absolutely expect progression in Medicare Advantage, meaning improvement in that HBR. PDP yes, there's a piece of going from well into the 3s pretax margin to 2%, and that's HBR related. But also think about the math on the direct subsidy going from $143 to $200 million and as I said in my script, roll that through a P&L and the yield impact where you need 0 incremental admin for that. So you're increasing premium revenue, you're increasing medical cost that has a mathematical impact on the HBR. That's embedded in that 35 basis points segment impact on the consolidated HBR as well. So I think that might be the missing piece Andrew, of what you're trying to achieve.</td><td>**Chief Financial Officer:** ë„¤, ë©”ë””ì¼€ì–´ë¥¼ êµ¬ë¶„í•´ì„œ ì´í•´í•˜ì‹¤ í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage)ì—ì„œëŠ” í™•ì‹¤íˆ ê°œì„ ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¦‰, HBRì´ ë‚˜ì•„ì§ˆ ê²ƒì´ë¼ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. PDPì˜ ê²½ìš°, ì„¸ì „ ë§ˆì§„ì´ 3%ëŒ€ ì¤‘ë°˜ì—ì„œ 2%ë¡œ í•˜ë½í•˜ëŠ” ë¶€ë¶„ì´ ìˆëŠ”ë°, ì´ê²ƒì´ HBRê³¼ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì§ì ‘ ë³´ì¡°ê¸ˆ(direct subsidy)ì´ 1ì–µ 4,300ë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ ë‹¬ëŸ¬ë¡œ ì¦ê°€í•˜ëŠ” ìˆ˜ì¹˜ì  ì˜í–¥ë„ ê³ ë ¤í•˜ì…”ì•¼ í•©ë‹ˆë‹¤. ì œê°€ ì•ì„œ ë§ì”€ë“œë ¸ë“¯ì´, ì´ë¥¼ ì†ìµê³„ì‚°ì„œì— ë°˜ì˜í•˜ë©´ ìˆ˜ìµë¥ (yield)ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ë°, ì—¬ê¸°ì—ëŠ” ì¶”ê°€ì ì¸ ê´€ë¦¬ë¹„ìš©ì´ ì „í˜€ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë³´í—˜ë£Œ ìˆ˜ìµì€ ì¦ê°€í•˜ê³ , ì˜ë£Œë¹„ìš©ë„ ì¦ê°€í•˜ëŠ”ë°, ì´ê²ƒì´ HBRì— ìˆ˜í•™ì ìœ¼ë¡œ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì†Œê°€ ì „ì²´ HBRì— ëŒ€í•œ 35bpì˜ ì„¸ê·¸ë¨¼íŠ¸ ì˜í–¥ì—ë„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì•¤ë“œë¥˜, ì•„ë§ˆë„ ì´ ë¶€ë¶„ì´ ê·€í•˜ê»˜ì„œ íŒŒì•…í•˜ê³ ì í•˜ì…¨ë˜ ëˆ„ë½ëœ ë¶€ë¶„ì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our final question today comes from Dave Windley at Jefferies.</td><td>**Operator:** ì˜¤ëŠ˜ ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ Jefferiesì˜ Dave Windleyë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Windley: Jefferies LLC, Research Division I wanted to come back to exchange. Bronze, I think Bronze margins have been a little more volatile or MLRs have been more volatile in the past. You're seeing trade down as I think a lot of people expected. I'm wondering if you have enough data so far to see whether the utilization patterns of those buy down Bronze members are meeting your expectations? Are they -- is there gross medical cost declining because the individual bears more of the cost in Bronze, things like that? I'm just wondering what that trade down profile looks like.</td><td>**David Windley:** ìµìŠ¤ì²´ì¸ì§€ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤. ë¸Œë¡ ì¦ˆ í”Œëœì˜ ê²½ìš°, ê³¼ê±°ì— ë§ˆì§„ì´ë‚˜ MLRì´ ì¢€ ë” ë³€ë™ì„±ì´ ì»¸ë˜ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ ë¶„ë“¤ì´ ì˜ˆìƒí•˜ì…¨ë“¯ì´ ë‹¤ìš´ê·¸ë ˆì´ë“œ í˜„ìƒì´ ë‚˜íƒ€ë‚˜ê³  ìˆëŠ”ë°ìš”. ì§€ê¸ˆê¹Œì§€ í™•ë³´í•œ ë°ì´í„°ë¡œ ë¸Œë¡ ì¦ˆë¡œ ì „í™˜í•œ ê°€ì…ìë“¤ì˜ ì´ìš© íŒ¨í„´ì´ ì˜ˆìƒê³¼ ë¶€í•©í•˜ëŠ”ì§€ íŒŒì•…ì´ ê°€ëŠ¥í•œì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë¸Œë¡ ì¦ˆ í”Œëœì—ì„œëŠ” ê°€ì…ìê°€ ë” ë§ì€ ë¹„ìš©ì„ ë¶€ë‹´í•˜ê¸° ë•Œë¬¸ì— ì´ ì˜ë£Œë¹„ìš©ì´ ê°ì†Œí•˜ê³  ìˆëŠ”ì§€, ê·¸ëŸ° ë¶€ë¶„ë“¤ ë§ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë‹¤ìš´ê·¸ë ˆì´ë“œ í”„ë¡œí•„ì´ ì–´ë–¤ ëª¨ìŠµì¸ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. Thanks, Dave. So I would say, in general, sort of what we're seeing in terms of trade down again, sort of largely consistent with what we would have expected. We expect that it's probably a market dynamic as well and was contemplated as we thought about overall pricing. And then taking into account not just how the Bronze products have operated over the last 5 years, but what they did pre-COVID and making -- or sorry, pre-eAPTCs and pre-COVID and making sure that, that was part of the calculus. It's obviously very, very early. We have not closed January yet. But I would say, based on a very early look nothing alarming relative to utilization patterns.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ë°ì´ë¸Œ. ì „ë°˜ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ë‹¤ìš´ê·¸ë ˆì´ë“œ í˜„ìƒì€ ëŒ€ì²´ë¡œ ì˜ˆìƒí–ˆë˜ ìˆ˜ì¤€ê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤. ì´ëŠ” ì‹œì¥ ì „ë°˜ì˜ ì—­í•™ ê´€ê³„ë¡œ ë³´ì´ë©°, ì „ì²´ ê°€ê²© ì±…ì •ì„ ê³ ë ¤í•  ë•Œ ì´ë¯¸ ë°˜ì˜í–ˆë˜ ë¶€ë¶„ì…ë‹ˆë‹¤. ì§€ë‚œ 5ë…„ê°„ ë¸Œë¡ ì¦ˆ(Bronze) ìƒí’ˆë“¤ì´ ì–´ë–»ê²Œ ìš´ì˜ë˜ì—ˆëŠ”ì§€ë¿ë§Œ ì•„ë‹ˆë¼, eAPTC(ê°•í™”ëœ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ) ì´ì „ê³¼ ì½”ë¡œë‚˜ ì´ì „ ì‹œê¸°ì˜ ì‹¤ì ë„ í•¨ê»˜ ê²€í† í•˜ì—¬ ì´ë¥¼ ê³„ì‚°ì— í¬í•¨ì‹œì¼°ìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  ì•„ì§ ë§¤ìš° ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. 1ì›”ë„ ì•„ì§ ë§ˆê°í•˜ì§€ ì•Šì•˜ê³ ìš”. í•˜ì§€ë§Œ ì•„ì£¼ ì´ˆê¸° ë‹¨ê³„ì˜ ë°ì´í„°ë¥¼ ë³´ë©´, ì˜ë£Œ ì´ìš© íŒ¨í„´ê³¼ ê´€ë ¨í•´ì„œ ìš°ë ¤í•  ë§Œí•œ ë¶€ë¶„ì€ ì—†ë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes our question-and-answer session. I'd like to turn the conference back over to Sarah London for closing remarks.</td><td>**Operator:** ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ Sarah Londonì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Thanks, Rocco. Thank you all for your time and interest this morning. Despite the challenges of 2025, we entered 2026 with increased visibility and important momentum. I believe that we are well positioned to drive margin improvement in 2026 and over the next few years while ensuring access to high-quality, affordable health care for the members and communities we serve. finally, to my Centene colleagues, I just want to say thank you for your incredible resilience and commitment I am excited to see what we can deliver this year. And in the words of my legendary hometown quarterback, let's go. Back to you, Rocco.</td><td>**CEO & Director:** ê°ì‚¬í•©ë‹ˆë‹¤, Rocco. ì˜¤ëŠ˜ ì•„ì¹¨ ì‹œê°„ ë‚´ì£¼ì‹œê³  ê´€ì‹¬ ê°€ì ¸ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. 2025ë…„ì˜ ì–´ë ¤ì›€ì—ë„ ë¶ˆêµ¬í•˜ê³ , ìš°ë¦¬ëŠ” ê°€ì‹œì„±ì´ ë†’ì•„ì§€ê³  ì¤‘ìš”í•œ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  2026ë…„ì„ ë§ì´í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” íšŒì›ë“¤ê³¼ ì§€ì—­ì‚¬íšŒì— ì–‘ì§ˆì˜ ì €ë ´í•œ ì˜ë£Œ ì„œë¹„ìŠ¤ì— ëŒ€í•œ ì ‘ê·¼ì„±ì„ ë³´ì¥í•˜ë©´ì„œ, 2026ë…„ê³¼ í–¥í›„ ëª‡ ë…„ê°„ ë§ˆì§„ ê°œì„ ì„ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, Centene ë™ë£Œë“¤ì—ê²Œ ì—¬ëŸ¬ë¶„ì˜ ë†€ë¼ìš´ íšŒë³µë ¥ê³¼ í—Œì‹ ì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¬í•´ ìš°ë¦¬ê°€ ë¬´ì—‡ì„ ì´ë¤„ë‚¼ ìˆ˜ ìˆì„ì§€ ê¸°ëŒ€ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œ ê³ í–¥ì˜ ì „ì„¤ì ì¸ ì¿¼í„°ë°±ì˜ ë§ì„ ë¹Œë¦¬ìë©´, í•´ë´…ì‹œë‹¤. Rocco, ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. Everyone, this concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œì— ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë˜ë©°, ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Centene ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>**ì¬ë¬´ ì „ë§ ë° ê°€ì´ë˜ìŠ¤**<br>- 2026ë…„ Medicaid ìš”ìœ¨ ì¸ìƒë¥  4.5% ê°€ì •, 2025ë…„ ë§ 5.5%ì—ì„œ í•˜í–¥ë˜ì—ˆìœ¼ë‚˜ ê²½ì˜ì§„ì€ ë³´ìˆ˜ì  ì ‘ê·¼ì´ë¼ ì„¤ëª…. HBR(ì˜ë£Œë¹„ìœ¨)ì€ ì „ë…„ ëŒ€ë¹„ flat ìœ ì§€ ëª©í‘œì´ë©°, ëª¨ë“  ì‚¬ì—…ë¶€ë¬¸ì—ì„œ ë§ˆì§„ ê°œì„  ì˜ˆìƒ<br>- Medicare Part DëŠ” 2025ë…„ 3%ëŒ€ ë§ˆì§„ì—ì„œ 2026ë…„ 2% ëª©í‘œë¡œ í•˜í–¥ ì¡°ì •. Medicare AdvantageëŠ” ì•„ì§ ì†ìµë¶„ê¸°ì  ë¯¸ë‹¬ì´ë‚˜ ê°œì„  ì¶”ì„¸<br>- ACA(ì˜¤ë°”ë§ˆì¼€ì–´) êµí™˜ì‹œì¥ì€ 2025ë…„ -1%ì—ì„œ 2026ë…„ ì•½ 4% ì„¸ì „ ë§ˆì§„ìœ¼ë¡œ ì˜ë¯¸ìˆëŠ” ê°œì„  ì „ë§. íšŒì›ìˆ˜ëŠ” 350ë§Œëª… ì˜ˆìƒ<br><br>**ê²½ì˜ì§„ í†¤ ë° ì „ëµ**<br>- CEOëŠ” Medicaid HBR 93.7% ë‹¬ì„±ë§Œìœ¼ë¡œëŠ” "ë§¤ìš° ì‹¤ë§ìŠ¤ëŸ¬ìš¸ ê²ƒ"ì´ë¼ë©° ê³µê²©ì  ëª©í‘œ ì‹œì‚¬. 2025ë…„ í•˜ë°˜ê¸° Q4 93.0%ë¡œ ê°œì„ ëœ ëª¨ë©˜í…€ ê°•ì¡°<br>- ì£¼ ì •ë¶€ì™€ì˜ ê±´ì„¤ì  í˜‘ë ¥, ìµœì‹  ë°ì´í„° ë°˜ì˜ ë…¸ë ¥, í”„ë¡œê·¸ë¨ ê°œì„ (ê³ ë¹„ìš© ì•½ë¬¼ ì œì™¸, ABA ì´ìƒì²­êµ¬ í†µì œ ë“±) í†µí•´ ìš”ìœ¨ ì™¸ ë¹„ìš© ê´€ë¦¬ ê°•í™”<br><br>**ë¦¬ìŠ¤í¬ ë° ìš°ë ¤ì‚¬í•­**<br>- Medicaid íšŒì›ìˆ˜ 5~6% ê°ì†Œ ì˜ˆìƒ(ì§€ì†ì ì¸ ìê²© ì¬ì‹¬ì‚¬, í”Œë¡œë¦¬ë‹¤ CMS ê³„</p>
    <hr style="margin:50px 0;">
    
</body></html>